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Summary
Hepatocyte growth factor (HGF) is a novel protein which is believed to have 
an important role in liver regeneration. Initially identified as the most potent 
mitogen for cultured hepatocytes, levels of HGF have since been shown to be 
elevated in serum and liver in animal models of liver disease. Raised levels have 
also been reported in serum from patients with liver disease. The receptor for 
HGF has been identified as the c-met proto-oncogene product. Although much 
has been learned of the structure and function of HGF in vitro, the significance of 
HGF and its receptor in controlling liver growth in health and disease remains to 
be determined.
The work of this thesis represents my attempts to investigate the significance 
of HGF in human liver disease and in an animal model of liver regeneration.
The aims of this work were as follows:
(1) Production of recombinant proteins based on human and rat HGF in 
order to to raise antibodies to native HGF.
(2) Purification of native human HGF in order to produce monoclonal and 
polyclonal antibodies to HGF.
(3) To establish an Enzyme Linked Immunosorbent Assay (ELISA) to 
measure serum HGF in patients with various liver diseases and to correlate these 
levels with disease type and severity.
(4) Immunocytochemical localisation of HGF and its receptor in human 
liver biopsies.
(5) Examination of the expression of HGF mRNA in human liver biopsies 
by in situ hybridisation techniques.
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(6) Modification of the hepatic regenerative response to experimental liver 
injury by administration of neutralising anti-HGF antibody.
Specific cDNA fragments were prepared from mRNA extracted from rat liver 
and human placenta and cloned into suitable expression vectors for protein 
production. The recombinant HGF proteins were expressed in Escherichia coli, 
purified and identification confirmed by SDS-PAGE and N-terminal amino acid 
sequencing.
Native human HGF was purified from fresh human placentas by two stage 
column chromatography involving heparin agarose and hydroxylapatite. Eluted 
fractions containing HGF were identified by ELISA. A purified preparation of 
human placental HGF was produced containing 2 pg/ml HGF.
Rabbit polyclonal antibodies were produced following immunisation with 
recombinant proteins based on human and rat HGF, and with purified human 
placental HGF. These antibodies were characterised by SDS-PAGE. Murine 
antibody response following immunisation with purified human placental HGF 
was confirmed by ELISA. No suitable monoclonal antibody producing hybridoma 
clones were produced.
A number of ELIS As were produced and evaluated as a means of measuring 
HGF. This work culminated in the development of a sensitive, specific ELISA for 
the measurement of HGF in human serum. The reliability of the assay was 
determined and stability of HGF in serum assessed. Using the ELISA serum 
levels of HGF were determined in healthy controls, disease controls and in 
patients with a variety of liver diseases.
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Thirty three healthy controls were assayed for HGF and only two had 
detectable levels of HGF. A group of patients with a diagnosis of acute 
myocardial infarction (n = 11) were used as a disease control group and none had 
detectable levels of HGF. When the healthy control group was compared with 
groups of patients with various liver diseases significant differences in HGF serum 
level were found in a number of cases. Serum HGF concentration was 
statistically significantly higher in patients with acute alcohol induced liver disease, 
chronic alcohol induced liver disease, acute (non alcoholic) hepatitis and chronic 
intrahepatic cholestasis. In contrast there was no difference in serum HGF level 
between healthy controls and patients with chronic hepatitis, extrahepatic biliary 
obstruction, metastatic liver disease, paracetamol overdose or chronic hepatitis C.
When serum HGF level was compared to a number of clinical indices of liver 
disease, several of these demonstrated a relationship with elevated levels of HGF. 
Patients with increased serum levels of HGF were found to have higher serum 
levels of AST, ALT and alkaline phosphatase than those with undetectable levels. 
Similarly, raised HGF levels were associated with prolonged prothrombin time, 
reduced haemoglobin concentration, albumin concentration and platelet count.
A greater proportion of patients with increased serum HGF level were 
jaundiced, had evidence of encephalopathy, hepatomegaly or ascites than those 
with an undetectable HGF level.
No relationship was present between HGF level and clinically evident hepatic 
inflammation (tenderness on examination) serum gamma glutamyl transferase, 
urea, creatinine or white cell count.
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All of the available antibodies to HGF were assessed for use in immunocyto­
chemistry, however, none of the antibodies were suitable for the demonstration of 
HGF in liver sections.
Using in situ hybridisation techniques, attempts were made to examine the 
expression of HGF mRNA in human and rat liver. A probe, pRBC-1, based on 
the rat HGF molecule failed to localise HGF mRNA in human liver tissue. 
However, using rat liver tissue obtained following partial hepatectomy and 
common bile duct ligation the probe demonstrated HGF mRNA in cells which on 
morphological grounds resembled Ito cells. A probe based on the human HGF 
nucleotide sequence was prepared but failed to localise HGF mRNA in normal or 
diseased human liver tissue.
A monoclonal antibody to the extracellular domain of the HGF receptor, c- 
met, was used to examine the expression of the receptor in human liver biopsies.
Histologically normal liver tissue demonstrated the presence of fine hepatocyte 
membranous staining consistent with the presence of membrane bound HGF 
receptor on hepatocytes. In diseased liver of various aetiologies, the level of 
HGF receptor on hepatocyte membrane appears to be reduced.
To investigate the contribution made by HGF to the hepatic regenerative 
response, in vivo inhibition of HGF was attempted in rats subjected to partial 
hepatectomy. Groups of rats were injected with monoclonal antibody to HGF, 
polyclonal antibody to HGF or appropriate control antibody and subjected to two 
thirds partial hepatectomy. Further antibody doses were administered post- 
operatively. The rats were killed at either 24 or 72 hours post-operatively and 
the regenerative response examined by histology and rate of DNA synthesis
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(Bromodeoxyuridine uptake) identified using a standard immunocytochemical 
technique. Liver tissue from all animals showed considerable DNA synthesis.
No difference was found between groups given anti-HGF and those given control 
antibodies.
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cos-1 cells monkey kidney cells
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Cys cysteine
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dH20 distilled water
E. coli Escherichia coli
EDTA ethylene diamine tetra-acetic acid
EGF epidermal growth factor
ELISA enzyme linked immunosorbent assay
ocFGF acidic fibroblast growth factor
F-TCF fibroblast derived tumour cytotoxic factor
GGT gamma glutamyl transferase
GST glutathione-s-transferase
HGF hepatocyte growth factor
HGF/SF hepatocyte growth factor/scatter factor
hpHGF human placental hepatocyte growth factor
HPI hepatocyte proliferation inhibitor
HPLC high performance liquid chromatography
HRP horseradish peroxidase
HSS hepatic stimulatory substance
Ig immunoglobulin
IL interleukin
IMR-90 cells human embryonic lung diploid fibroblasts
IPTG isopropyl-(3-D-thiogalactopyranoside
kb kilobase
KB cells human epidermoid carcinoma cells
kDa kilo Dalton
M Molar concentration
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pCi micro Curie
MDCK Madin Darby canine kidney cells
Mr relative molecular mass
MRC-S cells human embryonic lung fibroblasts
mRNA messenger
MW molecular weight
N normole concentration
NBT/BCIP nitroblue tetrazolium/5-bromo-4-chloro-3-indolyl phosphate
NSS normal swine serum
O.D.280 optical density at 280nm
OPD orthophenylene diamine
PBS phosphate buffered saline
PCR polymerase chain reaction
PDGF platelet derived growth factor
polymorph polymorphonuclear leucocyte
PTH phenylthiohydantoin
PVDF polyvinylidenedifluoride
SDS sodium dodecyl sulphate
SDS-PAGE sodium dodecyl sulphate-polyacrylamide gel electrophoresis
TCA trichloroacetic acid
TGFa transforming growth factor a
TGFp transforming growth factor (3
Tris tris (hydroxymethyl) methylamine
Tyr tyrosine
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CHAPTER 1. Liver Regeneration and Hepatocyte Growth Regulation
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And in ineluctable, painful bonds
he fastened Prometheus
of the subtle mind, for he drove a stanchion
through his middle. Also
He let loose on him the wing-spread eagle
And it was feeding
On his imperishable liver, which by night 
would grow back
To size from what the spread-winged bird 
Had eaten in the day-time
Hesiod (c 750-700BC) Theogeny
1. INTRODUCTION 
1.1 Liver Regeneration
The concept of liver regeneration has long been accepted as scientific fact, but 
original thought on the subject first arose in the ancient Greek myth of 
Prometheus. The benevolent titan, in a bid to improve the lot of mortal man, stole 
fire from the gods in a stalk of fennel and carried it down to earth. Zeus, enraged 
by this act ordered Prometheus to be lashed to a rocky crag in the Caucasus 
mountains. The unfortunate Prometheus' torment was multiplied by an eagle sent 
by Zeus which daily tore on his liver - the organ regrowing by night. The myth 
relates that only after Heracles intervened some 30,000 years later was 
Prometheus freed (1).
The scientific world first considered the idea of hepatic regeneration in 1833 
when Cruveilhier suggested the possibility (2). The earliest experimental work on 
the subject was conducted in Italy in the 1880's but von Podwyssozki is generally 
credited with the first valuable scientific studies. In 1886 he described evidence of 
regeneration in hepatic cells adjacent to the site of excision of small wedges of 
liver in rats, cats, guinea pigs and rabbits (3).
Further studies confirming the phenomenon of hepatic regeneration followed 
and in 1931 Higgins and Anderson published a quantitative assessment of liver 
regeneration in the white rat, demonstrating that following 70% partial 
hepatectomy, restoration of hepatic mass was complete by 14 days (4).
1.2 Organisation of Liver Structure
The liver is composed mainly of epithelial cells, of which parenchymal cells 
constitute 90-95% of cell mass but only 60-65% of cell population. Non- 
parenchymal cells, including the littoral cell population of endothelial cells,
Kupffer cells, fat storing (Ito) cells, pit cells (in the rat), fibroblasts and bile duct 
cells account for the bulk of the remaining cell population (5). This mass of 
epithelial cells is permeated by wide vascular channels known as sinusoids through 
which blood flows from terminal branches of the hepatic arteries and portal vein
r '
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to reach terminal hepatic venules. The channels are separated by a system of 
interconnected walls or plates of hepatocytes which in rats and humans comprise 
only a single cell layer (5). The sinusoids are lined by a population referred to as 
littoral cells comprising Kupffer cells and endothelial cells. Kupffer cells are 
members of the mononuclear phagocytic (reticulo-endothelial) system. The main 
function of these cells is the removal of particulate material and effete red cells 
from portal blood. Endothelial cells form a thin discontinuous cytoplasmic sheet, 
the endothelial defects referred to as fenestrae. The function of these cells is 
believed to include that of a filtration barrier while allowing plasma to come into 
direct contact with hepatocytes. Endothelial cells are also capable of endocytosis 
and may be involved in sequestration of blood borne matter including proteins 
(6,7). Bile secreted by hepatocytes passes into a system of minute canaliculi 
which consist of fine channels passing between adjacent hepatocytes. The walls 
of the canaliculi are formed by the plasma membranes of adjacent hepatocytes. 
Bile flows towards bile collecting vessels in the portal tracts then from the intra- 
hepatic bile collecting system to the right and left hepatic ducts which combine to 
form the common hepatic duct. The cystic duct joins the common hepatic duct to 
form the common bile duct through which bile enters the duodenum.
The functional unit of the liver is the acinus which consists of a region of 
hepatic tissue with its own blood supply (a branch of the portal vein and a hepatic 
artery) and a bile duct (8). Afferent blood streams through sinusoids, between the 
single cell thick hepatocyte plates, to a hepatic vein branch, draining several acini 
(Fig. 1.1).
This leads to the concept of acinar zones 1, 2 or 3 described in relation to the 
afferent supply. These zones surround the axial structures of the acinus like layers 
of a bulb. Zone 1 is closest to the supplying vessels and receives blood of a 
similar composition to that in the afferent vessels. Zone 3 is the most distant from 
the supply vessels of that acinus as well as from those feeding the neighbouring 
acini. In this way, zone 3 cells are situated at the micro-circulatory periphery and
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Figure 1.1 Schematic illustration of a liver acinus
The acinus consists of a region of hepatic tissue with its own blood supply (a 
branch of the portal vein and a hepatic artery) and a bile duct. Acinar zones 1,2 
and 3 are shown. Zone 1 receives blood similar in composition to that in the 
afferent vessels. Zone 3 is situated at the microcirculatory periphery and receives 
blood which has already supplied zones 1 and 2. Hepatocytes are arranged in 
single cell thick plates.
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receive blood which has already supplied zones 1 and 2. These cells are therefore 
more sensitive to injury by ischaemia, congestion and nutritional deficiency. Zone 
2 forms a transitional region the boundaries of which are not fixed. Zones 1 or 3 
may encroach on zone 2 in different microcirculatory conditions, depending on 
fluctuations in arteriolar smooth muscle tone (8) (Fig. 1.2).
1.3 Normal Growth
Following fetal and postnatal liver growth, the level of hepatocyte proliferation 
is extremely low (9). In normal adult liver one replicating hepatocyte is seen per 
10-20,000 cells) (10).
The lifespan of a hepatocyte is very long in mammals - of the order of 200-400 
days (9). In this state the cells are quiescent in terms of proliferation (Go), and 
express diverse liver specific differentiated functions. They are in close contact 
with their neighbours and growth is suppressed. This cell-cell contact has been 
shown to have important implications for hepatocyte proliferation. Studies using 
adult rat hepatocytes in culture have shown that at high cell density tight cell-cell 
contact exists and the cells retain many differentiated functions and do not 
proliferate even in the presence of excess amounts of growth factors (11,12). At 
lower cell density cell-cell contact is lost and cells enter Gj in which liver specific 
functions are suppressed (11). The cells are then sensitive to the effects of 
growth factors, and can be driven from G\ to S-phase (12). Expression of the 
proto-oncogene c-myc, which is known to be related to cell proliferation, is 
increased at low cell density and suppressed at high cell density (13).
This Gq-G] cell cycle transition in hepatocytes has been shown to be regulated 
by a plasma membrane protein named "cell surface modulator" (CSM) (14). 
Addition of this 670kDa protein, extracted from the plasma membrane of liver 
tissue, inhibits hepatocyte responsiveness to mitogens, when cells are cultured at 
low density (14). It is thought that cell-cell contact inhibition mediated by CSM 
may be involved in the regulation of growth and differentiation of hepatocytes in 
liver regeneration. In intact liver, hepatocyte CSM may suppress proliferation and
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Figure 1.2 Schematic illustration of several adjacent liver acini
Acinar zones 1, 2 and 3 surround the axial structures of the acinus like layers of 
a bulb. Zone 3 is the most distant from the supply vessels and receives blood 
from adjacent acini. Zone 2 forms a transitional region the boundaries of which 
are not fixed and which depend on fluctuations in arteriolar smooth muscle tone.
Hepatic vein 
branch
Portal tract
Portal tract
Portal tract
Hepatic vein 
branch
Hepatic vein 
branch
allow expression of differentiated functions. Nakamura et al have suggested that 
when the organ is injured by, for example, surgical resection or hepatitis this cell 
contact may be released allowing progression from Gq-Gj phase in which 
sensitivity to mitogens leads to proliferation which restores tight cell-cell contact 
(15).
This hypothesis is supported by in vivo evidence demonstrating loss of cell-cell 
contact between hepatocytes in regenerating liver (16) and that c-myc gene 
expression is increased soon after partial hepatectomy (17).
1.4 Physiology of Liver Regeneration
A variety of chemical and surgical methods have been employed in the past to 
induce liver regeneration experimentally, the most intensively studied of these is 
partial hepatectomy in the rat. Surgical exicision of a minimum of 9-12% of the 
liver mass is required to initiate the hepatic regenerative response (18). Removal 
of greater amounts of tissue leads to increased levels of hepatocyte DNA 
synthesis up to 75% of liver volume (19). Regeneration following 90% 
hepatectomy has also been described, in which DNA synthesis is delayed but 
similar to that following less extensive resections, provided care is taken to avoid 
hypoglycaemia (19).
The standard procedure, described by Higgins and Anderson, involves removal 
of both anterior liver lobes in the rat (the median and left lateral lobe) which 
constitute two thirds of the liver weight (4). This procedure involves the 
resection of entire intact lobes and restitution is by growth of the remaining lobes 
by hyperplasia and hypertrophy. This process has been known as regeneration in 
the scientific literature although the term is not strictly accurate, since the organ 
responds by compensatory hyperplasia rather than regrowth of excised portions.
1.4.1 Parenchymal Cells
Within thirty minutes of partial hepatectomy morphological changes are 
evident in cells present in acinar zone 1, including dispersion of cytoplasmic 
basophilic bodies. When seen by electron microscopy these changes are reflected
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in the disruption of the endoplasmic reticulum. This appearance gradually spreads 
toward acinar zone 3 over the following 8 hours. There is also 'cloudy swelling' 
of mitochondria (13,20).
After several hours there is an accumulation of lipid, which is maximal by 10 
hours, and a fall in glycogen content. Glycogen is almost undetectable at 10 
hours, after which there is a slow increase and at 72 hours the value is still only a 
third of normal.
An increase in the size of cells, nuclei and nucleoli is evident by 12 hours, and 
is maximal at 12 (or 24) hours when mitosis begins (21).
The endoplasmic reticulum begins to reform by 16-18 hours starting in acinar 
zone 3 and progressing toward zone 1 with restoration of normal structure by 36- 
48 hours (20).
DNA synthesis, as determined by radioautography of radioactive nucleotide 
incorporation, rapidly increases 16-18 hours after partial hepatectomy to a peak at 
20-24 hours followed by a sharp fall. Labelled nuclei predominate initially in the 
periportal areas, then extend toward the terminal hepatic venule and become 
randomly distributed (22).
Cells in zone 1 of the acinus have been reported to undergo several divisions 
while a few in zone 3 may not divide at all.
Mitosis follows DNA synthesis by 6-8 hours and exhibits a similar pattern of 
distribution within the acinus (22). At the time of maximal mitotic activity, 
mitotic cells represent 3-4% of total hepatocyte number.
1.4.2 Non-Parenchymal Cells
Non-parencymal cells as well as those of peritoneal mesothelium forming the 
capsular surface, blood vessel walls, bile ducts and connective tissue lag behind 
hepatocytes in synthesising DNA by about one day. Mitosis is not maximal until 
the end of the second or early on the third day. However, these cells do not 
exhibit the same clear peak of mitosis as parenchymal cells (21,22). Kupffer cells, 
for example, increase gradually, doubling in number over three days (23).
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Connective tissue elements are restored very slowly; periportal fibroblasts 
continue mitotic activity longer than other cell types (collagen formation, 
beginning at 48 hours, remains low even after six weeks) (21).
1.4.3 Sequential Proto-oncogene Expression
The precisely regulated events of hepatocyte replication have been studied in 
ever increasing detail in an attempt to determine the initiating events and 
regulatory mechanisms. Studies of the expression of various cellular proto­
oncogenes during liver regeneration have shown that as early as 15 minutes after 
partial hepatectomy, four fold increases in levels of c-fos mRNA can be detected 
(24). It has also been demonstrated that three main characteristics of such proto­
oncogene expression exist such that it is:
A) Specific
B) Sequential
C) Transient
(A) During liver regeneration there is an increase of mRNAs for c-fos, c-myc, p53
?
and c-ras genes, while c-abl, c-mos and c-src remain unaffected.
(B) A well defined order is evident; fos, myc, p53 then ras h and ras k.
(C) Expression of these genes is transient - lasting only a few hours (fos, myc, 
p53) or longer (ras - 30 hours) during liver regeneration then returning to basal 
levels (9).
1.5 Control of Hepatic Regeneration
The mechanisms involved in the regulation of this process have been, and 
remain, the focus of intense investigation. Two main regulatory mechanisms have 
been proposed involving;
(a) Haemodynamic factors.
(b) Humoral factors.
1.5.1 Haemodynamic Factors
Increased blood flow particularly of portal blood was thought to be of prime 
importance in initiating regeneration following partial hepatectomy and early
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evidence supporting this suggestion was produced by Mann (25,26). However, 
later work demonstrated that regeneration could occur even in the absence of the 
portal blood supply (27,28) and that increasing hepatic blood flow several-fold by 
arterialisation does not lead to a commensurate increase in liver growth (28). 
Moreover, blood flow remains the same in cases of regeneration following carbon 
tetrachloride induced necrosis (27). Finally, increased DNA synthesis in 
heterotopic partial autografts of rat liver following partial hepatectomy confirmed 
that portal blood and increased blood flow are unnecessary for proliferation of 
hepatocytes (29).
1.5.2 Humoral Factors
In 1949 Christensen and Jacobsen described work on the hepatic regenerative 
response in parabiotically united rats (30). Partial hepatectomy was performed on 
one of each pair and at 52 hours the animals were killed and mitosis counted in 
the livers of each parabion. It was found that the number of mitoses was
increased in both animals of a parabiotic pair. Bucher produced similar results by
)
counting mitoses in livers of non-hepatectomised rats following partial 
hepatectomy in animals parabiotically united in pairs or triplets (10).
These experiments were refined by Moolten and Bucher (31) and Sakai (32). 
The later studies, using ^C-thymidine incorporation as an index of DNA 
synthesis, again confirmed the possibility of a humoral mediator of regeneration.
Further work involving the study of the effect of partial hepatectomy on DNA 
synthesis and mitosis in heterotopic partial autografts of rat liver (29) and on 
transplanted hepatocytes (33) showed that DNA synthesis and mitosis is increased 
in the grafted tissue.
These studies provided strong evidence for a humoral mediator of hepatic 
regeneration. The nature of the agent, or agents responsible, has been under 
intense investigation and a number of candidates have been suggested.
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1.6 Hormonal Influences
Work on whole animals with removal of endocrine glands or injection of 
hormones has demonstrated a modifying but not determining role for known 
endocrine factors (20). Of course, such experiments are fraught with difficulties, 
given the complex biochemical interactions present within the intact animal. With 
the advent of isolated primary hepatocyte culture in the 1960s and 1970s the 
possibility of focussing on precise mechanisms controlling hepatocyte growth 
became a reality.
In 1976, Richman et al (34) described conditions in which primary isolated 
hepatocytes could be made to synthesise DNA, and suggested a prominent role 
for epidermal growth factor in concert with insulin and glucagon.
Following this work various manipulations of hepatocyte culture medium were 
performed and it was found that serum obtained from rats 48 hours after partial 
hepatectomy was consistently more effective in stimulating DNA synthesis than 
normal rat serum (35).
1.7 Hepatotropic Agents Hepatocyte Growth Factor (HGF)
The in vitro means of studying hepatocyte functions led to publication of a 
number of reports describing DNA synthesis promoting factors. Morley and 
Kingdom in 1973 (36) reported liver specific stimulation of DNA synthesis by a 
heat stable protein of 26kDa isolated from serum of rats 24 hours after partial 
hepatectomy. This was followed in 1982 by Strain et al (37) who described 
stimulation of DNA synthesis in cultured hepatocytes by a rat platelet associated 
substance. Paul and Piasecki (38) demonstrated the presence in rat platelets of 
hepatocyte growth factor(s) distinct from PDGF. In 1984, three laboratories 
independently reported partial purification of a hepatocyte growth factor or 
hepatopoietin A from rat platelets (39) or serum (40,41). This factor was 
subsequently purified to homogeneity from rat platelets (42) and human plasma 
(43,44), rabbit serum (44), rat liver (45) and human placenta (46). Hepatocyte 
growth factor (HGF) was shown to be a heat and acid labile heterodimeric protein
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which is sensitive to reduction with dithiothreitol, consists of a larger a  chain of 
54-70kDa mass and a smaller (3 chain of 29-35kDa, and which is distinct from 
other growth factors.
1.7.1 Molecular Cloning and Deduced Primary Structure of HGF
In 1989 (47,50) and 1990 (49) cDNA coding for human and rat HGF was 
cloned and the primary structure of HGF deduced. This led to the demonstration 
that rat, rabbit and human HGF are highly homologous molecular species. In 
each case native HGF was purified and the amino acid sequence for parts of the 
protein determined. Degenerate oligonucleotide primers were synthesised on the 
basis of these amino acid sequences and used to screen liver or placental cDNA 
libraries. Northern hybridisation studies demonstrated that the mRNA coding for 
HGF is ~6kb in size. Following this method the nucleotide sequence of the entire 
HGF cDNA was determined. It comprises a 5’ non-coding region of 134 
nucleotides, a single open reading frame of 2,184 nucleotides, and a 3' non-coding 
region of 3,580 nucleotides. The 3' non-coding region contains an A U-rich 
sequence, which is known to be a recognition signal for a processing pathway for 
specific degradation of the mRNA. This A U-rich sequence is commonly 
associated with mRNAs which are expressed transiently (13).
The deduced protein sequence of HGF showed that a polypeptide of 728 
amino acids is encoded by human HGF cDNA in a single open reading frame 
which includes a signal peptide and both the a -  and (3-chains.
Calculated relative molecular masses (Mr) of human HGF have been reported 
as 83.132kDa (47) or 83.126kDa (48) consisting of an a-chain of 440 amino 
acids (Mr; 50.808kDa (48)) and a (3-chain of 234 amino acids (Mr; 25.994) (47) 
or 26.089 (48)). Four asparagine linked glycosylation sites have been identified 
(a-chain positions 294, 402; (3-chain positions 566, 653). Glycosylation at these 
sites may account for the differences in mass of HGF subunits as determined by 
SDS-PAGE and those predicted from the cDNA sequence (in addition to the 
over-estimation of the molecular weight by relaxation of disulphide bonds).
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The protein is produced as a pre-promolecule, the N-terminal of which begins 
with a 54 amino acid pre-pro sequence. The first 29 amino acids are hydrophobic 
as is commonly found in signal sequences. This is followed by the pro-sequence 
of 25 amino acids then the N-terminus of the a-chain. The a  and (3 chains are 
synthesised together from 55-728, the 13-chain starting at 495. The protein is 
produced in this pre-pro form, then undergoes proteolytic processing with 
separation at position 494/495 (Arg-Val). The single chain form of HGF is 
inactive, biological activity only being acquired following conversion to the two 
chain form by extracellular serine-protease (50) referred to as HGF-converting 
enzyme (51). The two chains remain bound, by a disulphide bond between CYS 
487 in a-chain and CYS 604 in (3-chain (Fig. 1.3).
A second type of cDNA coding for a naturally occurring variant of HGF has 
been cloned (52). This c-DNA encodes a form of HGF with a 5 amino acid 
deletion in the first kringle domain. The biological activity of this form of HGF is 
similar to that of full length HGF.
An interesting structural feature of the HGF molecule is the presence of four 
kringle domains. These looped, disulphide bridged regions were named for their 
likeness to a particular type of Danish pastry (53) and are thought to be involved 
in binding regulatory ligands. The a  chain also has a N-terminal hairpin loop 
structure and the (3 chain a serine protease like domain. The N-terminal hairpin 
region, together with the first two kringles are essential for biological activity and 
for binding to the receptor (54,55)
1.7.2 HGF Antagonist
An alternative, truncated form of HGF has also been identified. This naturally 
occurring peptide is encoded by an alternatively processed mRNA generated from 
the human HGF gene (56,57). The alternative transcript (1.5kb (56), 1.3kb (57)) 
is found in human placenta and is identical to the full length form from the 5' end 
for 865 nucleotides, but diverges at the 3' end. It is generated by alternative RNA 
processing events involving the second kringle exon. A cDNA sequence for the
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Figure 1.3 Schematic representation of HGF protein
HGF is produced as a pre-pro molecule which undergoes proteolytic 
processing to form an active 2-chain peptide. The a-chain is characterised by 4 
kringle domains and is joined to the P-chain by a disulphide bond.
Pre-pro HGF
Metww r  i Pro
29 25 |
amino amino 
acids acids
a  chain (440 a.a.)
Ser  1 Val -Arg
P chain
(234 amino acids) 
processing
Mature HGF
Pro ---------------------------------   7 --------------- Arg
sN-terminal /
S
Val----------—^ ----------Ser
a-chain
Pro Ser
B-chain
\J
transcript was isolated and found to contain an open reading frame of 870bp 
predicting a 290 amino acid truncated version of HGF consisting of a signal 
peptide, an NH2  terminal along with the first two kringle domains with a 
calculated size of ~30kDa, excluding the signal peptide. Following production of 
recombinant truncated HGF in COS cells SDS-PAGE analysis confirmed the 
molecular weight of native and recombinant proteins to be 34kDa (57).
This protein has been shown to specifically inhibit the mitogenic effects of the 
full length HGF molecule on B5/589 human mammary epithelial cells and human 
melanocytes, although a 10-20 fold molar excess is required to produce a 50% 
reduction (57) in DNA synthesis.
Crosslinking studies with radio-iodinated terminated HGF and antiserum to the 
carboxyl terminus of the c-met product (HGF receptor) demonstrated competitive 
binding of truncated and full length HGF to the same cell surface receptor 
molecule (52). This also confirms that only the N-terminal region including the 
first two kringle domains is necessary for receptor binding.
It has been suggested that this naturally occurring HGF antagonist may 
modulate the effect of HGF activity in vivo, although this remains to be 
demonstrated.
1.7.3 Homology with Other Proteins
HGF bears little resemblance to other known growth factors but does have 
considerable homology with various 'kringle' bearing proteins including 
plasminogen, prothrombin, tissue plasminogen activator, urokinase type 
plasminogen activator and factor XII (48,58).
The most similar of these is plasminogen (37% homology) (48). The kringle 
domains present in HGF have substantial sequence similarity to kringle domains 1, 
4 and 5 of plasminogen (and to kringle 1 of prothrombin) (58). In addition, the 6- 
chain of HGF has the structure of a pseudo-protease (of the serine protease 
superfamily) and similarities exist with other serum proteins such as kallikrein and 
factor XII (58). However, two (histidine, serine) of the three amino acids of the
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protease active site are replaced in the HGF p-chain by glutamine and tyrosine 
respectively and HGF has no protease activity (58) (similarly, neither plasminogen 
nor plasmin have HGF activity) (13). The presence of such structural similarities 
is consistent with the view that HGF is of relatively recent phylogenetic derivation 
(60). The amino acid sequence homology of human and rat HGF is greater than 
90% (49). This helps to explain the absence of species specificity in terms of 
biological activity. The principle differences that do exist include insertions and 
deletions in the p-subunit sequence such that human HGF pi-chain = 234 and rat 
HGF P-chain = 233 amino acids, also the C-terminus of human p-chain is serine 
whereas in rat this is replaced by leucine (49).
1.7.4 Human HGF Gene
In 1991 Seki et al (59) characterised the gene coding for human HGF, 
demonstrating that it is composed of 18 exons interrupted by 17 introns and is 
about 70kb in length. The first exon contains the 5' untranslated region and the 
signal peptide. The a-chain is coded by the next 10 exons, with each kringle 
domain coded by a pair of exons, as is the case for other proteins containing 
kringle domains. The short spacer region between the a -  and P-chains is coded 
by the 12th exon and the 6-chain is coded by the final six exons (Fig. 1.4).
The organisation of the HGF gene is very similar to that of genes coding for 
plasminogen and other serine proteases involved in blood coagulation and 
fibrinolysis. This is thought to represent further evidence that HGF is 
evolutionally related to these proteins. In 1991, the human HGF gene was 
mapped to the long arm of chromosome 7, band q21.1 (60).
1.7.5 HGF Receptor
Investigation of the means by which HGF exerts its biological effects led to 
attempts to identify receptor(s) for HGF. A high affinity HGF receptor with a 
dissociation constant (Kd) of 20-36pM and an apparent molecular weight of 
220kDa was identified on primary cultured rat hepatocytes and other epithelial 
cells (61,62,63,64).
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Figure 1.4 HGF Gene Organisation
The gene coding for HGF is approximately 40kb in length and is composed of 
18 exons interrupted by 17 introns.
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In 1991 the receptor for HGF was identified as the c-met proto-oncogene 
product (65,66). The met oncogene was identified in 1984 in a human osteogenic 
sarcoma cell line transformed by the chemical carcinogen N-Methyl-N-Nitro-N- 
Nitroguanidine (67). The receptor is a transmembrane protein tyrosine kinase of 
2 subunits; a 50kDa extracellular a-chain and a transmembrane 145kDa p-subunit 
which has a tyrosine kinase domain (68).
The identity of c-met product as the HGF receptor has been confirmed by:
(1) Rapid tyrosine phosphorylation of the c-met product following HGF treatment 
(65,66).
(2) Affinity crosslinking experiments with 125I labelled HGF followed by 
immunoprecipitation using antibodies to the c-met protein (65).
(3) Expression of c-met cDNA in COS cells by transfection leads to expression of 
an HGF receptor of Kd 30pM and is followed by acquisition of mitogenic 
responsiveness to HGF by these cells (69).
The protein product of the c-met proto-oncogene has structural and functional 
features of the tyrosine kinase family of growth factor receptors (68,70).
However, although some 44% homology exists between the kinase domain of c- 
met and the human insulin receptor, no apparent sequence homology exists in the 
ligand binding domain.
The receptor for HGF has been identified in a variety of tissues such as liver, 
lung, kidney, adrenal, pituitary and in various epithelial cells including the lining of 
the gastrointestinal tract and skin (63,71). 
c-metfHGV receptor signal transduction
Binding of HGF to c-metfWGY receptor leads to activation of tyrosine kinase 
resulting in autophosphorylation of the tyrosine residues of the P-subunit (most 
importantly at Tyr1234 and Tyr1235 (72). Following autophosphorylation and 
activation of the receptor interaction occurs with a variety of cytoplasmic proteins 
which contain SH2 {src homology 2) domains, including phosphatidyl(inositol)-3- 
kinase (PI-3 kinase), phospholipase C5 (PLC-5), ras GTPase activating protein
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(ras GAP) and cytoplasmic tyrosine kinases of the c-src family (73,74).
Activation of phospholipase C6 occurs as a result of phosphorylation following 
stimulation with HGF, and induces production of inositol-1,4,5-triphosphate and 
1,2-diacylglycerol followed by calcium mobilisation and activation of protein 
kinase C (75,76). This cascade of phosphorylation and activation ultimately leads 
to altered gene expression and DNA synthesis.
1.7.6 Evidence for HGF as a Mediator of Hepatic Regeneration
Following its discovery and characterisation as the most potent mitogen 
known for cultured hepatocytes, evidence has been accumulating in favour of the 
view that HGF plays a major role in the process of hepatic regeneration following 
injury.
A number of reports have described increased levels of HGF in both liver and 
plasma of rats subjected to partial hepatectomy or carbon tetrachloride induced 
liver injury (77,78). Similarly carbon tetrachloride treatment leads to an elevation 
of circulating HGF in mice (78). In addition, examination of the expression of 
HGF mRNA in liver tissue from rats subjected to a variety of insults such as 
carbon tetrachloride poisoning, D-galactosamine induced hepatitis, partial 
hepatectomy or common bile duct ligation indicates an increase in the level of 
HGF gene transcription (79, 80,81). Increased HGF mRNA expression in liver 
remnant following partial hepatectomy is evident at 12 hours and maximal at 24 
hours i.e. at the same time as initial peak of DNA synthesis. Significantly 
increased plasma HGF levels are however detected as early as 3 hours post 
resection, suggesting that extrahepatic sources of HGF may provide the 
regenerative trigger rather than HGF production within the liver (79).
Such a view is supported by the finding that HGF mRNA expression has been 
shown to be increased in intact kidney, spleen (82) and lung (83) following partial 
hepatectomy in rats. Furthermore, following hepatic injury in rats, marked HGF 
receptor down regulation is seen; interestingly, the down regulation only occurs in 
the organ type injured, i.e. in liver following partial hepatectomy, or in kidney
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following unilateral nephrectomy (63). There is also evidence from in vivo studies 
that HGF has a role in liver regeneration and may ameliorate the effects of 
hepatotoxins. Ishiki et al (84) have reported that intravenous administration of 
recombinant HGF to mice subjected to 30% hepatectomy, carbon tetrachloride or 
a-naphthylisothiocyanate (aANIT) poisoning results in remarkably enhanced liver 
regeneration in vivo. Moreover, the addition of HGF prevented any marked 
increase in serum levels of liver enzymes and bilirubin in mice treated with aANIT 
(84). Similar findings of reduction in aANIT hepatotoxicity when administered 
with recombinant HGF were reported by Roos et al (85).
Studies using transgenic mice which expressed increased levels of HGF under 
the control of albumin regulatory sequences demonstrated that in such animals the 
rate of regeneration after partial hepatectomy could be doubled (86). There have, 
however, been no reports of attempts to inhibit HGF function in vivo. Such a 
study may establish conclusively the significance of the contribution made by HGF 
to the hepatic regenerative response.
1.7.7 Sites of Origin of HGF
In situ hybridisation studies initially identified the hepatic source of HGF as 
Kupffer cells and sinusoidal endothelial cells (87). However, convincing evidence 
has been produced demonstrating that the Ito cell is the main cell type producing 
HGF in the liver (88,89).
HGF mRNA has also been shown, by Northern blot analysis, to be present in 
adult rat kidney, lung, thymus and brain (49) in addition to human placenta (47), 
fetal liver (90) and embryonic lung fibroblast (91).
As described above, HGF activity in the circulation is markedly increased 
within 3 hours of liver injury, suggesting that extrahepatic sources of HGF may be 
involved in the initiation of hepatic regeneration. The level of expression of HGF 
mRNA rapidly increases in the intact lung, spleen and kidney after partial 
hepatectomy or carbon tetrachloride administration.
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In situ hybridisation studies show that the cells expressing HGF mRNA appear 
to be fenestrated endothelial cells in the kidney and endothelial cells in the lung 
(87,62). Localisation of HGF protein in tissues has also been reported in rabbits, 
rats and humans (92,93). Positive staining, using an immunohistochemical 
technique, was found in a variety of tissues and cell types, including acinar cells of 
pancreas, neurons in the brain, c-cells of the thyroid, salivary glands and Brunners 
glands in the rabbit (92). In rat and human most surface epithelia, distal tubules 
and collecting ducts of the kidney; syncytiotrophoblast, extra-villous trophoblast, 
large neurons, megakaryocytes and granulocytes were stained positively (93). 
However, questions arise with regard to the discrepancy found between tissues 
positive for HGF protein by immunocytochemistry in which HGF mRNA cannot 
be detected. Also, contradictory immunocytochemistry results have been 
reported (94) which describe positive staining for HGF in pancreatic islet 'A' cells 
and an absence of acinar staining.
Currently the balance of evidence is in favour of the view that HGF may exert 
hepatotropic effects in an endocrine as well as paracrine fashion.
1.7.8 Injurin
Although HGF appears to be a major effector molecule in liver and kidney 
regeneration, much has yet to be learned of the mechanisms which control HGF 
production. Matsumoto et al (95) have described a protein factor which has the 
capacity to induce expression of the gene for HGF. Rat serum from animals 
subjected to partial hepatectomy or ischaemic injury injected intra-peritoneally 
into intact rats led to a marked increase of HGF mRNA expression in the lung of 
the recipient. The effect was also shown in vitro with MRC-5 cells which 
responded by increased expression of HGF mRNA and increased production of 
HGF. Preliminary purification studies suggest that the agent responsible for these 
effects is a protein of molecular weight 10-20kDa and that its effects are not 
duplicated by known cytokines. Using MRC-5 cells in a functional assay, levels 
of this factor, named ’'injurin*' are seen to rise within 3 hours (i.e. preceding the
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increase in expression of HGF mRNA) of hepatic or renal injury including 
unilateral nephrectomy, mercury chloride (HgCl) or kanamycin administration.
Injurin may therefore represent another link in the chain of events triggered by 
liver (and renal) injury which results in growth and repair in the affected system.
1.7.9 Other Biological Activities of HGF
In addition to its well documented ability to stimulate DNA synthesis in 
isolated cultured rat hepatocytes, HGF has been found to promote DNA synthesis 
in a variety of epithelial cells including rabbit renal tubular epithelial cells (97), 
human epidermal melanocytes (91,97), keratinocytes (98) and other epithelial 
cells (99). However, no growth stimulation of fibroblast/mesenchyme derived 
cells has been described. Another function of HGF is stimulation of cell motility. 
Workers investigating a fibroblast secreted protein which could disperse epithelial 
colonies of a variety of cell types in culture named the protein scatter factor and 
only when sequence data became available was scatter factor found to be identical 
to HGF (100). Examples of cell types which can be made to disperse in culture 
under the influence of HGF/SF include human keratinocytes (98), Madin Darby 
Canine Kidney (MDCK) cells (101), Hep G2 cells, human epidermoid carcinoma 
A431 and mouse keratinocytes PAM 212 (13).
In addition to enhancing cell dispersion, HGF also acts as a 'morphogen'; 
MDCK cells grown in collagen cells can be induced to form branching tubular 
structures under the influence of HGF (101). Similar effects have been 
demonstrated using cell lines derived from hepatic non-parenchymal epithelial 
cells (102). In view of the potent stimulatory effect on cell growth HGF was 
considered as a promoter of hepatocellular carcinoma. However, it is now known 
that HGF actually inhibits a variety of hepatocellular carcinoma cell lines (103). 
Experiments involving such neoplastic cells stably transfected with an albumin- 
HGF expression vector have demonstrated in vitro growth inhibition and when 
these cells are transplanted into mice, the resultant tumours are found to be 
smaller (~10% of expected size) than control lesions (103). Growth inhibition has
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also been seen with B6/Fj mouse melanoma cells and human squamous 
carcinoma cell lines (104).
Interestingly, as in the case of scatter factor/HGF, workers in the field of 
tumour cytotoxic agents identified a tumour cytotoxic factor derived from human 
embryonic lung fibroblast IMR-90 cells which was then shown to be identical to 
HGF (105). Fibroblast derived tumour cytotoxic factor (F-TCF)/HGF has 
cytotoxic activity against sarcoma 180 and cytostatic activity against KB cells 
(105).
Additional processes in which a role for HGF has been proposed include 
embryogenesis (106,107), angiogenesis (108), wound healing (91) and 
inflammation (via neutrophil priming) (109).
1.7.10 Renal Regeneration
HGF has also been implicated in renal regeneration. As described previously, 
HGF is a potent mitogen for a variety of epithelial cells including rabbit renal 
tubular epithelial cells (96). Moreover, HGF mRNA has been detected in a 
number of organs including liver, kidney, lung, heart and brain of rat (49). It is 
known that following unilateral nephrectomy renal compensation occurs by 
hyperplasia and hypertrophy, mainly of proximal tubular epithelial cells in the 
remaining kidney (110). This, together with in vitro and in vivo evidence 
supporting the concept of a humoral mediator in compensatory renal hyperplasia
(111,112) led to the investigation of HGF as a candidate for such a role. Nagaike 
et al (62) have reported that following unilateral nephrectomy, expression of HGF 
mRNA in the intact kidney increased markedly to a maximum at 6 hours and was 
followed by an increase in HGF activity at 12 hours. Similar findings were noted 
in rats treated with carbon tetrachloride. A reduction in HGF receptor number 
was also seen, without change in receptor affinity. Receptor numbers fell as early 
as 2 hours after surgery and between 24 and 48 hours were undetectable. This 
may result from HGF binding to its receptor in vivo followed by internalisation of 
the complex. Since HGF appears to be produced in endothelial cells of the kidney
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(62,112), a paracrine mechanism may exist whereby HGF acts to stimulate 
compensatory growth following injury. Recent work involving administration of 
HGF in a model of acute ischaemic renal injury in rats suggests that HGF 
accelerates recovery from such injury. Acute ischaemic renal injury was induced 
by bilateral renal artery occlusion for 75 minutes and 30 minutes after reperfusion 
a single subcutanous dose of recombinant HGF was administered. Compared 
with controls, rats which had received HGF had improved renal function, reduced 
mortality, greater renal cortex mitogenic activity and reduced histological 
evidence of injury 7 days following reperfusion (113).
Thus HGF has been implicated in stimulation of normal cell growth, inhibition 
of neoplastic cell growth, cell motility and morphogenesis. Multiplicity of 
function has been described in relation to other growth factors, e.g. transforming 
growth factor (3 (TGF13), which is capable inhibition of epithelial cell growth and 
stimulation of mesenchymal cell growth (114). This growth factor has been 
associated with various functions including wound healing and stimulation of 
angiogenesis (9).
1.7.11 HGF and Human Liver Disease
A considerable volume of evidence has been gathered to support the 
hypothesis that HGF has a role in hepatic regeneration. In human liver disease 
regeneration is often a feature, prompting investigation of a possible role for 
HGF. HGF has been purified from the plasma of patients with fulminant hepatic 
failure (43,115) and levels of HGF as determined by bioassay have been found to 
be related to coma grade (116,117). HGF has also been identified in plasma and 
ascites of patients with liver cirrhosis (118).
In 1991 the first report describing a highly specific ELISA protocol for 
HGF in human serum was published (119). Using a sandwich technique ELISA, 
HGF serum levels in patients with fulminant hepatic failure, acute hepatitis, 
chronic hepatitis, cirrhosis and normal controls were determined. Statistically 
significant elevations were seen in patients with fulminant hepatic failure and acute
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hepatitis but not in chronic hepatitis/cirrhosis. The same ELISA system has been 
used to show that levels of HGF in fulminant hepatic failure can be correlated to 
clinical outcome (120) and to demonstrate increased levels of HGF in serum 
following partial hepatectomy for neoplasm (121). Another report using this 
ELISA describes increased serum levels of HGF in both acute and chronic liver 
disease (122). It also suggests that HGF level may serve as an index of severity of 
liver dysfunction in acute and chronic liver disease.
However, the precise contribution made by HGF in liver disease remains to be 
determined. Further measurement of HGF serum levels in different liver diseases 
would be of particular interest (a) in an attempt to clarify whether HGF levels are 
or are not increased in chronic liver disease, (b) in order to explore the possibility 
that HGF measurement may be useful as an index of hepatic dysfunction/ 
regeneration in human liver disease.
1.8 Other Regulators of Hepatic Growth
A number of other substances are known to affect hepatocyte proliferation. 
These may be classified as complete and incomplete hepatic mitogens and growth 
inhibitors.
1.8.1 Complete Hepatocyte Mitogens
These are factors independently capable of stimulating DNA synthesis and 
mitosis in quiescent hepatocyte populations in defined medium, without serum.
The following is a summary of substances known to have such properties: 
Epidermal Growth Factor (EGF)
Epidermal growth factor was the first substance shown to be able to stimulate 
DNA synthesis in hepatocytes (34). Insulin is not required but its addition 
maximises the response to EGF (123). The amino acid proline is very strongly 
implicated in EGF growth promotion, in its absence the labelling index of cultured 
hepatocytes falls to less than 5% (114).
Two receptors for EGF have been defined: 'high' and 'low' affinity. Following 
culture of hepatocytes in vitro the 'high' affinity receptors disappear but low
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affinity receptors persist in sufficient numbers (124) and are believed to be the 
more important group.
EGF is also known to have effects on amino acid transport and protein 
synthesis - TGFB inhibits EGF stimulated mitogenesis but not protein synthesis 
stimulation (125). The role of EGF in partial hepatectomy is unclear; reduced 
numbers of EGF receptors are found by 8 hours with a trough at 40 hours 
following partial hepatectomy. There is also a decline in the EGF dependent 
tyrosine kinase activity of the receptor. However, a number of explanations 
including TGFa (which shares the receptor for EGF) secretion in regenerating 
liver may account for this. In addition, noradrenaline has been shown to cause 
heterologous down regulation of EGF receptors in vitro (114). EGF is not 
produced in the liver (126) and its plasma concentration remains unchanged 
during liver regeneration (126,127).
Transforming Growth Factor Alpha (TGFa)
This protein shares the same receptor as EGF (128) and has -33% sequence 
homology with EGF (129). However, TGFa is a more potent hepatocyte 
mitogen than EGF (130). It is produced by regenerating hepatocytes, a number 
of neoplastic cells (132), in the early fetus and in normal epidermis (132). It is 
also implicated in wound healing (130).
Expression of TGFa mRNA in normal liver is undetectable, but following 
partial hepatectomy an increase is noted at 18 hours with a peak at 24 hours 
(130). This coincides with the decrease in the number of EGF receptors which is 
maximal at 36 hours (133). Serum levels of TGFa are increased within 8 hours of 
partial hepatectomy with a peak of 24 hours (and a later peak at 72 hours) which 
is parallel with DNA synthesis (114).
Acidic Fibroblast Growth Factor (acidic FGF)
Acidic FGF is a heparin binding 16kDa protein capable of stimulating 
hepatocyte DNA synthesis. However, heparin is required for this function, and 
aFGF is less potent than EGF (e.g. 1/3 or 1/5 as effective) (114,13). Acidic FGF
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is secreted by hepatocytes and non parenchymal cells and its mRNA expression 
increased 4 hours after partial hepatectomy reaching a peak at 24 hours (13). 
Hepatopoeitin B
This little known factor was identified by Michalopoulos et al at the time of 
purification of hepatoprotein A/HGF (41). Although a complete mitogen, this 
small (500Da) glycolipid factor is less potent than EGF or HGF and its origin 
remains unknown.
Hepatic Stimulatory Substance (HSS)
Purified from neonatal and regenerating livers HSS is a heparin binding protein 
of 16kDa (114) which has been reported to stimulate hepatocyte mitogenesis in 
vivo (134). HSS is not a complete mitogen for hepatocytes in culture, but does 
augment EGF/insulin (114).
1.8.2 Incomplete Hepatocyte Mitogens
A number of substances have been identified as incomplete hepatocyte 
mitogens. This important group includes factors which, although unable to 
directly stimulate DNA synthesis alone in serum free cultures, can significantly 
enhance the growth promoting properties of other agents.
Noradrenaline
Three important characteristics of this group have been demonstrated in vitro 
for noradrenaline, (a) Inability to independently stimulate DNA synthesis by 
hepatocytes (139). (b) Promotion of the mitogenic effect of HGF (135).
(c) Inhibition of TGFP inhibitory effects on hepatocyte DNA synthesis (136,137). 
This feature has been dramatically illustrated by culture of hepatocytes isolated 
from regenerating liver at 12-16 hours after partial hepatectomy in the presence of 
EGF and TGFp. Merely by adding adrenaline the labelling index can be increased 
from less than 4% to greater than 70% (114).
Reduction of a  \ -adrenergic effect by surgical hepatic denervation or 
administration of Prazosin, an a  \ -adrenergic receptor antagonist, led to a 
reduction in hepatic DNA synthesis during the first 24 hours after partial
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hepatectomy. However, chronic guanethidine injections (3-6 weeks) reduced 
liver catecholamine levels but did not alter the ability of the liver to regenerate 
(138).
Vasopressin, Angiotensin II. Angiotensin III
These hormones also promote EGF induced mitogenesis but to a lesser degree 
than noradrenaline (114). Similarly, they can antagonise the inhibitory effect of 
TGF13, although this effect is less potent than in the case of noradrenaline (137).
Rat strains which are congenitally deficient in vasopressin production 
(Brattleboro strain) demonstrate impaired liver regeneration (120).
Oestrogens
A number of reports implicate oestrogens in liver regeneration (140,141). 
Serum levels of oestrogens increase after partial hepatectomy peaking at 24-48 
hours in man (141) and at 72 hours in rats (140). There is a concomitant increase 
in total hepatic content and nuclear retention of oestrogen receptors (140).
In contrast, following partial hepatectomy there is a fall in serum testosterone 
levels, hepatic androgen receptor activity and in activity of androgen responsive 
proteins (140). Injection of rats with Tamoxifen, an oestrogen receptor 
antagonist, soon after partial hepatectomy has been shown to significantly inhibit 
hepatic DNA synthesis in the regenerating liver (142).
Insulin and Glucagon
Insulin is a necessary constituent of hepatocyte culture media, since in its 
absence the cells degenerate and die (114). Rats subjected to resection of the 
gastrointestinal tract, pancreas, spleen and 70% partial hepatectomy demonstrate 
greatly delayed and attenuated hepatic regeneration. However, when insulin and 
glucagon are administered together the regenerative rate is dramatically restored 
to normal (143). The effects of glucagon appear to be mediated by cAMP since 
they may be duplicated by substitution of cAMP or agents which increase cAMP 
levels (144). In spite of these findings insulin does not stimulate hepatocyte DNA 
synthesis in culture alone or with glucagon (144). In addition, injection of insulin
and glucagon to either normal or eviscerated animals whose livers are intact fails 
to initiate hepatocyte proliferation (143).
1.8.3 Inhibitors of Hepatic DNA Synthesis
The complex processes involved in the phenomenon of controlled cell growth 
as illustrated by hepatic regeneration cannot, of course, be entirely regulated by 
promoters of cell growth. A number of factors have been studied which can 
inhibit mitogenesis. This property has been defined in the context of EGF 
mitogenic effects on primary cultured hepatocytes (114).
Transforming Growth Factor (3 (TGFp)
TGFp is a 25kDa disulphide linked homodimer which has been identified as a 
promoter of mesenchymal cell growth and a potent inhibitor of epithelial cell 
growth (145). This factor is known to exist in two main forms, TGFP] and 
TGFP2 . TGFP] is the more abundant, constituting 80-85% of total recovered 
TGFP in both bovine bone and porcine platelets. In most assays TGFP] and 
TGFp2  are functionally indistinguishable and although it has been suggested that 
TGFP2  may have a unique function this has not yet been demonstrated (145). 
TGFP has been associated with embryogenesis, wound healing and bone 
formation (145) it is known to increase the expression of extracellular proteins 
such as collagen and fibronectin (146) and their cellular receptors. It also reduces 
secretion of protease activators and increases secretion of protease inhibitors 
(147).
TGFP] is a potent inhibitor of primary cultured hepatocyte DNA synthesis 
(148,149). The early phase of regeneration following partial hepatectomy can be 
inhibited by intravenous administration of TGFp j or TGFP2  at the time of, or 
shortly after, hepatic resection (150). However, it should be noted that the 
inhibitory effect of TGFP] and TGFP2  in such studies was released eight days 
after partial hepatectomy. Moreover, complete restoration of liver cell mass was 
achieved by five days even if TGFP \ or TGFP2  was administered repeatedly 
(150). Further evidence that this protein is implicated in the control of hepatic
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regeneration includes the finding that TGFP mRNA expression is increased in 
regenerating liver following partial hepatectomy (151).
TGFpi mRNA expression in non parenchymal cells, especially sinusoidal 
endothelial cells, first becomes detectable by 4-8 hours, remains low until 24 
hours then rises steadily, peaking at 72 hours (48-120 hours). Significant levels of 
expression persist for more than 96 hours (151,152). Thus, the timing of the peak 
of TGFp mRNA expression, occurring after the 24 hour peak of DNA synthesis 
in hepatocytes is appropriate. However, in addition to the delay in peak 
production of the protein, the effect of TGFP may be delayed because of its 
production in a latent form. This latent form is composed of a complex of TGFp \ 
with a high molecular weight binding protein, also referred to as 'masking protein', 
'TGFB-latency associated protein' or 'TGFp binding protein' (153). This binding 
protein is a 180-220 kDa glycoprotein consisting of 2 x 39kDa and a single large 
subunit of 105-120kDa linked by disulphide bonds. The 39kDa protein is 
identical to the N-terminal part of the TGFp precursor (154).
This TGFP i/binding protein complex, linked by non covalent bonds, may be 
dissociated in vitro by treatment with 1M acetic acid, 6 M urea or heat. However, 
it is not yet known how this activation of the complex takes place in vivo (154). 
Interleukins IL-lb and IL-6
IL-lb is also a potent inhibitor of hepatocyte proliferation although less 
effective than TGFp. Similarly, a weak inhibitory effect is seen with IL-6  (155). 
Hepatocyte Proliferation Inhibitor (HPI)
This factor, of MW 17-19kDa, purified from adult rat liver, is an inhibitor of 
proliferation of normal rat liver cells (hepatocytes and other epithelial liver cells). 
Although similarities exist between TGFBj and HPI, differences include dose 
needed for inhibition and failure of antibodies to TGFB to inhibit HPI activity 
(156).
Clearly liver growth and regeneration are complex phenomena and many 
different mechanisms are likely to play a part. The recent discovery of HGF, the
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most potent mitogen for hepatocytes known, has been seen as an exciting event in 
the history of the study of these processes. However, although much has been 
learned of the structure and function of HGF in vitro, the significance of HGF and 
its receptor in continuing liver growth in health and disease remains to be 
determined. It is hoped that a filler understanding of these processes may 
ultimately help to provide a basis for the development of new approaches to the 
treatment of liver disease, in which inadequate or disordered regeneration 
frequently plays a part.
1.9 Aims
The work of this thesis represents my attempts to investigate the significance 
of HGF in human liver disease and in an animal model of liver regeneration.
1. To establish an ELISA to measure serum HGF in patients with various 
liver diseases, and to correlate these levels with disease type and severity.
2. Production of recombinant proteins based on human and rat HGF to raise 
antibodies to native HGF.
3. Purification of native human HGF in order to produce monoclonal and 
polyclonal antibodies to HGF.
4. Immunocytochemical localisation of HGF and its receptor in human liver 
biopsies.
5. Examination of expression of HGF mRNA in human liver biopsies by in 
situ hybridisation techniques.
6 . Modification of the hepatic regenerative response to experimental liver 
injury by administration of neutralising anti-HGF antibody.
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CHAPTER 2. Preparation of Recombinant Bacterial Proteins Based on 
Rat and Human HGF
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2. INTRODUCTION
2.1 Recombinant HGF Proteins
A significant problem encountered in the course of this project has been the 
limited availability of useful antibodies to HGF. A number of antibodies have 
been kindly provided by collaborating research groups, however, at the time of 
this study there were no commercial sources. In addition, none of the antibodies 
provided were able to localise HGF immunocytochemically. Consequently, part 
of this project has involved the production of antibodies intended for use in 
immunocytochemistry as well as ELISA and in vivo HGF inhibition studies.
Although HGF has been purified from human plasma (43,115), ascitic fluid 
(118) and placenta (46), the processes involved are demanding and yield only very 
small quantities of pure protein. Therefore, in addition to purifying native 
placental HGF, synthetic HGF polypeptides have been produced. Using 
recombinant DNA techniques large quantities of pure protein may be 
manufactured. The fundamental steps involved in the generation of such proteins 
include the cloning and amplification of an appropriate gene fragment followed by 
insertion of such clones into cultured prokaryotic or eukaryotic cells. Following 
expression, the protein is purified from the host cell proteins.
2.2 Cloning of Polymerase Chain Reaction (PCR) Products into Vector 
The essence of recombinant DNA technology involves two stages - ( 1) joining
a DNA segment of interest to a DNA molecule which is able to replicate and 
(2) providing a milieu which allows propagation of the joined unit. In this study 
plasmid vectors were used to introduce cDNA sequences and to drive the 
| expression of these sequences in Escherichia coli.
2.3 Transfected Cells
Recombinant proteins may be produced in both prokaryotic (e.g. bacteria) and 
eukaryotic cells (e.g. mammalian, insect). The use of bacteria for gene expression 
and protein synthesis has long been established. The ease with which bacteria 
may be transfected, cultured and selected has been a major part of the reason for
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the enduring popularity of these organisms. Eukaryotic (mammalian and insect) 
cell culture is technically more demanding but significant differences exist between 
the two methods. The cells of the most commonly used bacteria, Escherichia coli 
are unable to carry out N- or O-linked glycosylation, to completely remove the N- 
terminal methionine residue from a number of proteins or to acetylate, 
phosphorylate or palmitate proteins. In addition, E. coli has an internal reducing 
environment, which interferes with disulphydryl bridges such that proteins may 
not be folded properly. Thus the proteins produced may differ immunologically 
and functionally from native proteins. However, notwithstanding these potential 
difficulties, antibodies have previously been successfully produced following 
immunisation with recombinant proteins from E. coli. In this study E. coli were 
used to express recombinant proteins based on rat and human HGF.
2.4 Plasmid Vectors
Plasmids are naturally occurring extrachromosomal circular DNA molecules 
found in most bacterial species and in some eukaryotic species. They have been 
adapted and modified by molecular biologists as tools for DNA manipulation.
Such vectors contain transcriptional promoters which may be used to control 
expression of cloned cDNA and multiple restriction enzyme sites which allow the 
insertion of DNA sequences in frame. Vectors also frequently contain genes 
which code for resistance to certain antibiotics e.g. ampicillin, tetracycline. These 
provide a simple means of identifying host cells which contain either plasmid or 
plasmid with cDNA insert.
The transcriptional promoter region of the vector may be controlled by another 
gene product of the vector in such a way that transcription can be manipulated as 
required. pTAC is an example of this system; normally repressed by the Lac IQ 
gene product, it is induced by isopropyl-13-D-thiogalactopyranoside (IPTG) which 
binds to and inactivates the repressor protein. In this study two plasmid vector 
types were used; the pET and pGEX families.
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2.4.1 pET Protein Expression Vectors
The pET family of plasmids (plasmid for expression by 17 RNA polymerase) 
express target DNA in bacteria under the control of bacteriophage T7 RNA 
polymerase (Figure 2.1). T7 RNA polymerase is not expressed by the plasmid 
and requires to be supplied, usually be transfection of the cell with another vector 
such as bacteriophage CE$ which expresses the enzyme or by use of bacteria 
which contain an integrated copy of the T7 polymerase gene. The plasmids in this 
family all confer antibiotic resistance and possess translation initiation signals 
(Shine Delgamo sequence) for the strongly expressed T7 slO protein (a T7 capsid 
protein). Foreign DNA may be cloned into the BamH I site on the 3' end leading 
to a fusion peptide consisting of the 11 amino-acid N-terminus of the si 0  protein 
with the target protein sequence. In a similar fashion the target protein alone may 
be produced by inserting the target DNA into an Ncol site behind the translation 
initiation codon. This system allows high level expression of target RNA and 
protein in bacterial hosts. In this project the pET plasmid pET-8 c was used with 
BL21 (DE3) bacteria which contain an integrated copy of the T7 polymerase gene 
controlled by the lac UV5 promoter. The addition of Isopropyl-B-D- 
thiogalactopyranoside (IPTG) induces the expression of T7 polymerase. The 
plasmid pET-8 c contains the promoter recognised by T7 polymerase (157,158).
2.4.2 pGEX Protein Expression Vectors
The pGEX protein expression vectors (Promega Ltd, Southampton, UK) are 
designed for high level expression of proteins as fusions with Schistosoma 
japonicum glutathione-S-transferase (159,160,161). These plasmids possess the 
Amp gene which confers resistance to 50pg/ml ampicillin and each has a cloning 
site which allows the cDNA to be inserted in frame with the promoter and stop 
codons. They contain a tac promoter which is normally repressed by the Lac 19 
gene product but which is induced in the presence of IPTG (isopropyl-6 -D- 
thiogalactopyranoside).
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Figure 2.1 Schematic representation of plasmid pET-8c
The plasmid includes a T7 phage promoter that is recognised by the phage T7 
RNA polymerase but not by host E. coli polymerase. In this case T7 RNA 
polymerase is provided by use of BL21 (DE3) bacteria which contain an 
integrated copy of the gene, controlled by the lac UV5 promoter.
Foreign DNA may be inserted into the Bam HI or Nco I sites leading to either 
a fusion peptide consisting of the 11 amino acid N-terminus of the si 0 protein and 
target protein or target protein alone.
The plasmid also carries a gene for ampicillin resistance.
Origin of replication
Represents the T7 terminator 
Represents the insertion site 
Represents the T7 promoter
EcoRV BamHI Nhe]
Ncol 
Bglll
Tj  promoter
Such fusion proteins help to simplify purification of target proteins - in this 
case fusion proteins are removed from bacterial lysates by affinity 
chromatography using glutathione sepharose 4B. Cleavage of the 26kDa 
glutathione S-transferase domain from the fusion protein is by use of a site 
specific protease which recognises an area adjacent to the fusion protein. In the 
case of the pGEX-2T plasmid (illustrated in Fig 2.2) thrombin is used.
2.5 Selection of Peptide Fragments
The DNA sequences of interest coding for fragments of human and rat HGF 
were chosen as candidates for production of recombinant proteins in E. coli on 
the basis of their position on the HGF molecule. This allowed selection of 
(a) areas on the native molecule most likely to be successfully identified by 
antibodies i.e. externally located, (b) areas of differing antigenic properties and 
(c) an area corresponding to that present in full length HGF, but not in its 
antagonist HGF/NK2 . Peptides based on human and rat a  and P chains were 
chosen (Figure 2.3).
Peptide fragments selected for recombinant protein production 
hHGFa266: 266 amino acid peptide based on nucleotides 142-938 of human 
HGF mRNA i.e. amino acids 3 to 269 of human pre- pro- HGF(a chain). 
hHGFB71: 71 amino acid peptide based on nucleotides 1802-2018 of human 
HGF mRNA i.e. amino acids 560 to 631 of human HGF(p chain). 
rHGFa94: 94 amino acid peptide based on nucleotides 215-499 of rat HGF 
mRNA i.e. amino acids 25 to 119 of rat HGF(a chain). 
rHGFf3121: 121 amino acid peptide based on nucleotides 1658-2023 of rat HGF 
mRNA i.e. amino acids 506 to 627 of rat HGF (P chain) (Figs. 2.3, 2.4).
Appropriate specific oligonucleotide primers complementary to the cDNA 
sequence of interest were chosen and synthesised by the p-cyanoethyl 
phosporamidate method on a DNA synthesiser. The fragment was amplified by a 
reverse polymerase chain reaction (PCR). The antisense primer was hybridised to 
a sample of RNA containing HGF mRNA. Addition of reverse transcriptase to
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Figure 2.2 Schematic Representation of the pGEX-2T Vector
This plasmid allows insertion of foreign DNA in frame with the promoter and 
stop codons. The target DNA is expressed as a fusion protein with Schistosoma 
japonicum  glutathione-S-transferase which may be cleaved by the proteolytic 
action of thrombin.
The tac promoter and lac Iq gene allow chemically inducible high level
expression.
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Figure 2.3 Amino Acid Sequence of Recombinant HGF Proteins
Amino acid sequences of rat and human HGF and location of recombinant 
HGF protein sequences. Amino acid numbers are given on the right. Identical 
amino acids are indicated by dashes in the sequence of human HGF.
hHGFa266: 266 amino acid peptide based on nucleotides 142-938 of human 
HGF mRNA i.e. amino acids 3 to 269 of human pre- pro- HGF(a chain). 
hHGFp71: 71 amino acid peptide based on nucleotides 1802-2018 of human 
HGF mRNA i.e. amino acids 560 to 631 of human HGF(P chain). 
rHGFa94: 94 amino acid peptide based on nucleotides 215-499 of rat HGF 
mRNA i.e. amino acids 25 to 119 of rat HGF(a chain).
rHGFp!21: 121 amino acid peptide based on nucleotides 1658-2023 of rat HGF 
mRNA i.e. amino acids 506 to 627 of rat HGF (p chain).
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Figure 2.4 Size and Position of Recombinant HGF Proteins
Illustration of the size and position of recombinant HGF proteins in relation to
full length native human and rat HGF.
hHGFoc266 hHGFp71
rHGF a94 rHGFpl21
the primed mRNA results in synthesis of a DNA/RNA hybrid. Amplification of 
c D N A  was performed by PCR. To prepare double stranded DNA, the 
DNA/RNA hybrid is denatured by heating at 95°C and specific oligo-nucleotide 
primers, complementary to the 5' ends of the sense and antisense strands, added.
As the reaction cools, the primers anneal to the cDNA strands (at 55°C) allowing 
a thermostable DNA polymerase to extend each primer by addition of nucleotides 
at the 3' end (at 72°C). In this case the cDNA strand acts as a template and the 
end result is a double stranded cDNA molecule. This process results, 
theoretically, in doubling the amount of DNA produced in each successive cycle. 
The amplified fragments contained restriction sites that had been incorporated into 
the 5' end of each primer as indicated, to facilitate subsequent cloning. Fragments 
were cloned into pET (Nco-BamHI site) or pGEX-2T (Bam HI site). Insert 
orientation in pGEX-2T was checked by restriction enzyme digestion or by DNA 
sequencing.
Cloning of cDNA fragments was carried out by Dr K Hillan in association with 
Dr C Preston, Senior Scientist, MRC Virology Institute, Glasgow.
Competent E coli cells were prepared and transfected with plasmid then 
selected and restriction digest analysis performed by Mrs T McShane, Department 
of Pathology, Western Infirmary, Glasgow.
2.6 Protein Expression and Purification - Materials and Methods
Materials - see page 141
Methods
2.6.1 Protein Expression
For each of the recombinant proteins the following method was used for IPTG 
induction of plasmid coded protein expression. Scrapings from glycerol stocks of 
DH5 and BL21 (DE3) E. Coli containing plasmids pGEX-2T266 and pET-121 
(stored at -70°C) were mixed with 0.5ml of YT broth and the solution used to 
inoculate culture plates containing medium (with ampicillin 50pg/ml). Following 
incubation at 37°C overnight, a single colony was picked and used to inoculate
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2ml YT broth containing ampicillin 50pg/ml and incubation continued at 37°C for 
2 hours. IPTG was added (1 OOjj.1 of lOOmM IPTG) and culture continued for a 
further 2 hours. Control cultures not treated with IPTG were included. Proteins 
were harvested by repeated cycles of freeze thawing (liquid nitrogen/3 7°C 
incubation) then centrifuge separation at 6000rpm for 10 minutes using a 
"Microcentaur" microfuge (Fisons Scientific Equipment, Leicestershire, UK) from 
culture medium. Lysates from the bacterial cell cultures were analysed by SDS- 
PAGE (sodium dodecyl sulphate-polyacrylamide gel electrophoresis) (162).
2.6.1.1 Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis (SDS- 
PAGE) Analysis of Proteins
Proteins were resolved by electrophoresis on an SDS-polyacrylamide gel using 
"Biorad Miniprotean II" electrophoresis equipment (BioRad Laboratories Ltd, 
Hertfordshire, UK). Resolving and stacking gels were prepared as outlined in 
Appendix 1. After pouring, the resolving gels were overlaid with water saturated 
isobutanol and allowed to set. The isobutanol was poured off and the top of the 
gel rinsed with water. The stacking gel was poured, a toothed comb inserted, and 
allowed to set. Following removal of the comb, the stacking gel and its walls 
were rinsed with water. The gel was placed in a buffer tank with electrode buffer 
(Appendix 2). Protein samples for electrophoresis were mixed with an equal 
volume of loading buffer (Appendix 2). Samples to be reduced were mixed with 
loading buffer containing 5% mercaptoethanol and placed in boiling water for 4 
minutes. Molecular weight markers were prepared for loading in the same 
fashion. Fifteen microlitres of each sample were loaded per well and 
electrophoresis performed at 25mA until the dye front reached the bottom of the 
gel.
2.6.1.2 Coomassie Blue Staining
Gels to be stained were removed from electrophoresis equipment, placed in 
200ml of Coomassie blue stain (Appendix 3) and incubated overnight at room
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temperature. Gels were destained by immersion in destain solution (Appendix 3) 
which was changed several times.
2.6.2 Purification of Protein from SDS-PAGE Gels
Large scale SDS-polyacrylamide gels (20cm x 20cm electrophoresis 
equipment, Scotlab, Coatbridge, UK) were prepared for protein purification. All 
samples, buffers and reagents were as for minigels. Each gel included the 
following samples; molecular weight markers (14,300-71,500 Da (BDH) or 
29,000-205,000 Da (Sigma)), whole bacterial cell lysate of E. coli transfected 
with plasmid but not induced by IPTG and E. coli transfected with plasmid and 
induced by IPTG.
Gels were run at 25mA until dye front reached bottom of gel. The gel was 
removed and vertical strips containing the outer two wells with their 
corresponding resolving gel areas excised. These strips were stained with 
Coomassie blue overnight and the central portion wrapped in polythene film 
('saran' barrier food wrap, Dow Chemical Company) and stored at 4°C. After 
destaining, the side strips were aligned with the central unstained portion of the 
gel and the position of the protein band of interest determined (Figure 2.5). This 
area was then excised from the gel and cut into small fragments (lmm^ or less).
These fragments were placed in 10ml of 0.1% (weight/volume) SDS in water and
HSh^Hb M ' 'li, !.| :w,
the protein allowed to elute overnight at room temperature. The solution was 
removed and concentrated by placing in dialysis tubing and covering the tubing 
with sucrose to remove water by osmosis. The final solution was decanted and 
protein content estimated by measuring absorbance of ultraviolet light at 280nm 
(using OD2 8 0  = mg protein/ml) (Beckman DH-64 spectrophotometer, Beckman 
RIIC Ltd, Glenrothes, UK). Purity was determined by SDS-PAGE analysis.
2.6.3 Purification of hHGFa266 using Glutathione-Sepharose 4B 
Recombinant protein hHGFa266 was produced as a fusion protein with
glutathione-S-transferase (GST) of Schistosoma japonicum. Bacteria containing 
the plasmid coding for hHGFa266 were lysed by repeated freeze/thaw cycles and
Figure 2.5 Purification of recombinant bacterial protein by SDS-PAGE
of bacterial cell lysate.
Coomassie Blue stain and excision of band containing separated protein of interest 
(12% polyacrylamide gel).
Lane 1 Molecular weight markers (kDa)
2 Cell lysate of E. coli transfected with plasmid pGEX2T which does
not contain cDNA coding for hHGFa266.
Lanes 3-13 Cell lysate of£ . coli transfected with plasmid pGEX2T which
contains cDNA coding for hHGFa266.
Protein hHGFa266 can be seen as a band of approximately 56 kDa in lanes 3 
and 13 of the Coomassie Blue stained gel. The central portion of gel (lanes 1- 
12) has been stained after excision of the area corresponding to protein 
hHGFa266.
20
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centrifuged at 6000rpm (‘Microcentaur’ microfuge) for 10 minutes. The 
supernatant and pellet of cell debris and insoluble proteins were analysed by SDS- 
PAGE. Methods to solubilise the recombinant proteins included sonication and 
the use of the following solutions: PBS, PBS containing 1% (volume/volume) 
Tween 20, PBS containing 2% (volume/volume) Triton X-100, 2M urea, 4M urea 
and 8M urea.
A glutathione-sepharose 4B gel was washed in PBS and poured into a 10ml 
syringe to form a chromatography column. Bacterial cell lysate in the solutions 
described was poured through the column. After washing the gel with several 
column volumes of PBS, bound proteins were eluted by washing the column with 
5mM glutathione, pH 8.0. Gel and eluted fractions were analysed by SDS-PAGE 
as described.
N-terminus amino acid sequencing of the recombinant proteins was performed 
as described in chapter 3.
2.7 Results
2.7.1 Cloning of cDNA Fragments Coding for Human and Rat HGF 
Peptides
An 800bp cDNA fragment coding for a peptide based on human a-chain 
(hHGFa266) was produced and cloned into the PGEX 2T vector.
A 365bp cDNA fragment coding for a peptide based on rat HGF 6-chain 
(rHGFpl21) was produced and cloned into pET vector.
Attempts to produce additional cDNA fragments coding for peptides based on 
rat HGFa-chain and human HGF 6-chain were unsuccessful.
2.7.2 Protein Expression
Protein rHGFpi21 (pET-121) was highly expressed by bacterial cells 
transfected with pET-121 plasmid and induced by IPTG, as shown in Figure 2.6. 
The band corresponding to rHGFpi21 is 14kDa in size, consistent with a protein 
comprising 121 amino acids.
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Figure 2.6 SDS-PAGE Analysis of lysate of E  coli transfected with
pET-121
Expression of protein rHGFp 121 (pET-121) by bacterial cells 
transfected with pET-121 plasmid, induced by IPTG SDS-PAGE of bacterial cell 
lysate and molecular weight markers, 12% Polyacrylamide gel, Coomassie Blue 
stain.
Lane 1 Molecular weight markers (kDa)
2 Cell lysate of E. coli expressing rHGFP 121.
Protein rHGFp 121 can be seen as a band of approximately 14 kDa in lane 2.
No such band was seen when a lysate of E. coli containing plasmid without the 
cDNA fragment was subjected to SDS-PAGE and stained.

Similarly, cells transfected with the plasmid coding for hHGFa266 expressed a 
56kDa protein when induced with IPTG (Figure 2.7). This mass is consistent 
with a peptide of 266 amino acids and a fusion protein of 26.5kDa.
2.7.3 Purification of Recombinant Proteins
Figure 2.8 shows protein rHGFB121 following elution and concentration. 
hHGFa266 fusion protein proved to be relatively insoluble and could not be 
purified by affinity to glutathione-sepharose. In addition, the peptide could not be 
cleaved by thrombin. The protein was soluble in 8M urea but this concentration 
prevented binding of the protein to glutathione-sepharose.
The insoluble HGF protein was purified as described above by SDS-PAGE and 
band excision (Figure 2.9).
2.8 Discussion
The aim of this part of the project was to produce synthetic HGF polypeptides 
in order to subsequently generate antibodies to native HGF. Using recombinant 
DNA technology and the known HGF gene sequence we were successful in 
cloning cDNA fragments coding for proteins based on human HGF a-chain and 
rat (3-chain. We were unable to produce cDNA fragments for proteins based on 
rat a-chain or human P-chain. Reasons for this may include a problem of 
integrity of the mRNA used as a template and the presence of mRNA secondary 
structure which interferes with reverse PCR (163).
In the case of both of the cDNA fragments produced protein expression by 
bacterial cells transfected with plasmids containing the cDNA fragment was 
sufficient to assist in identification of the protein and to facilitate purification.
Had the expression of the recombinant protein by the bacterial cells been low, 
even greater difficulty would have been experienced in identifying and purifying 
the target proteins, since both of these processes depended on visible differences 
in protein quantity on SDS-PAGE.
Protein rHGFpi21 which was produced without fusion to a carrier protein 
proved to be more easily purified than protein hHGFa266 which was formed as a
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Figure 2.7 SDS-PAGE analysis of lysate of E. coli transfected with 
pGEX-2T containing cDNA coding for hHGFa266
Expression of protein by bacterial cells transfected with plasmid pGEX-2T
containing cDNA coding for hHGFa266. SDS-PAGE of bacterial cell lysate and
molecular weight markers, 12% Polyacrylamide gel, Coomassie Blue stain.
Lane 1 Molecular weight markers (kDa)
2 Cell lysate of E. coli transfected with plasmid
pGEX2T which does not contain cDNA coding for hHGFot266
3 Cell lysate of E. coli transfected with plasmid pGEX2T which contains 
cDNA coding for hHGFa266
Protein hHGFa266 can be seen as a band of approximately 56 kDa in lane 3. 
This corresponds to hHGFa266 formed as a fusion protein with glutathione-S- 
transferase of Schistosoma japonicum. The protein is not present in lane 2.
kDa
205.0
116.0
97.4
66.0
45.0
29.0
Lane 1 2 3
Figure 2.8 SDS-PAGE analysis of purified rHGFal21 protein
SDS-PAGE analysis of purified recombinant protein rHGFal21 and molecular
weight markers, 10% polyacrylamide gel, Coomassie Blue stain.
Lane 1 Molecular weight markers (kDa)
2 Purified, concentrated rHGFal21 protein
Lane 2 illustrates the purity of the isolated protein, with respect to other bacterial 
proteins of different molecular weight.
kDa
71.5
57.2
42.9
Lane 1 2
Figure 2.9 SDS-PAGE analysis of purified hHGFa266 protein
Purification of recombinant protein hHGFa266. SDS-PAGE analysis of
purified recombinant protein hHGFa266 and molecular weight markers, 10/o 
polyacrylamide gel, Coomassie Blue stain.
Lane 1 Molecular weight markers (kDa)
2 Purified concentrated hHGFa266 protein
Lane 2 demonstrates isolation of the protein of 56kDa corresponding to 
hHGFoc266.
kDa
205.0
97.4 116.0
Lane
fusion protein with Glutathione-S-transferase (GST)
The relative instability of hHGFcc266 and the failure of thrombin to enzymatically 
cleave the GST protein led to difficulty in purification of the target protein. We 
were unable to use the manufacturer’s recommended technique of affinity 
chromatography using Glutathione Sepharose 4B as the concentration of urea 
required to solubilise the protein prevented binding of the protein to Glutathione- 
Sepharose, possibly by denaturing the protein. Satisfactory purification was 
achieved however, leading in the case of rHGFpi21 to a single band on SDS- 
PAGE. The protein hHGFa266, purified in a similar fashion, was associated 
with a small quantity of contaminating proteins on SDS-PAGE.
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CHAPTER 3. Recombinant Protein Sequencing
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3 . INTRODUCTION
To confirm the identity of the recombinant proteins hHGFa266 and 
rHGFpl21 N-terminal amino acid sequencing was performed. This work was 
carried out at the Science and Engineering Research Council Protein Sequencing 
Facility, Marischal College, University of Aberdeen, with the assistance of 
Mr Bryan Dunbar and Professor John Fothergill.
3.1 Protein Sequencing
Proteins are sequenced by degradation from their N-terminus by the Edman 
reaction using phenylisothiocyanate (PITC) (164). The reaction is divided into 
three steps which result in removal of the N-terminal residue leaving the protein 
with a free N-terminus which can undergo another cycle of the reaction. The 
three steps are:
Coupling: in which PITC modifies the N-terminal residue
Cleavage: under anhydrous acidic conditions, removing the N-terminal residue
as an unstable anilinothiozolinone (ATZ) derivative.
Conversion: of the ATZ derivative to a stable phenylthiohydantoin (PTH)- 
amino acid.
Identification of Amino Acids
The PTH-amino acid is injected onto an HPLC and the elution time of a peak 
(absorbance at 269nm) identifies the amino acid. A major problem in protein 
sequencing is "blockage" of the N-terminus commonly by contaminants such as 
cyanate and aldehyde agents. Care is necessary in sample preparation to preserve 
the N-terminus and to avoid chemicals which may interfere with other steps in the 
Edman reaction, these may include buffers and non-ionic detergents.
To separate samples for sequencing, bacterial cell lysate proteins were 
subjected to SDS-PAGE, transferred to “ProBlott” membrane, stained and the 
appropriate band excised. The method of protein purification described in chapter 
2 is unsuitable for the preparation of proteins for sequencing. Polyacrylamide gel 
electrophoresis prior to sequencing requires particular conditions including pre­
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running" the gel and the addition of free-radical scavengers such as glutathione 
and sodium thioglycolate. Proteins were sequenced using an Applied Biosystems 
477A pulsed liquid protein sequencer with a 120A on-line PTH analyser. PTH- 
amino acids are determined on the 120A analyser using reverse phase HPLC at an 
absorbance of 269nm with computer generated chromatographs and results.
Amino acids are identified by comparing the chromatograph of each cycle (1 
residue) with a reference chromatograph.
3.2 Materials and Methods 
Materials - see page 141.
Methods
3.2.1 SDS-PAGE Sequencing: A 12% resolving gel was prepared as described 
in Chapter 2, section 2.6.1.1. The 5% stacking gel was prepared as described in 
Appendix 1 with pH 8.8 buffer. Electrode buffer (Appendix 2) containing lOmM 
glutathione was poured into the top reservoir and an aliquot of loading buffer 
placed in a lane. Electrophoresis at 10mA was performed until the dye front had 
reached the resolving gel. At this stage, the upper buffer was changed to pH 6.8 
electrode buffer (see Appendix 2) containing 0.1 mM sodium thioglycolate and 
reduced samples of bacterial cell lysate hHGFa266 and rHGFpi21, as described 
in chapter 2, loaded. Electrophoresis was carried out at 10mA for 45 minutes 
after which the gels were removed and equilibrated with CAPS (3- 
[cyclohexylamino]-l -propane sulfonic acid) transfer buffer (Appendix 2). 
Separated proteins were then transferred from gel onto 'ProBlott' membrane using 
"Biorad Mini-Protean II" blotting equipment (BioRad Laboratories,
Hertfordshire, UK) and CAPS transfer buffer with a current of 250mA for 1 hour 
an 45 minutes.
After transfer, membranes were stained with amido black (Appendix 3) for 5 
minutes then destained (Appendix 3) by 3 washes of 10 minutes and the band of 
interest excised.
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The excised band was sequenced on the Applied Biosystems 477A automated 
protein sequencer, using the ‘Blott’ reaction cell.
3.3 Results
3.3.1 Recombinant Bacterial Protein rHGFB121, based on rat HGF, p 
Chain.
The cDNA fragment coding for rHGFpl21 codes for a polypeptide of 121 
amino acids. The predicted N-terminal amino acid sequence is as illustrated in 
Figure 3.1. A methionine 'Cap' at the N-terminus of recombinant proteins is 
commonly found, thus the sequence confirms the identity of rHGFpi21.
3.3.2 Recombinant Bacterial Protein hHGFa266, based on Human HGF, a  
Chain
The N-terminus of hHGFa266 consists of the fusion protein glutathione-S- 
transferase followed by the HGF peptide. Sequencing of this protein proved 
difficult and it was not possible to identify a precise sequence (several amino acids 
were suggested for each residue). However, for almost every residue the 
predicted amino acid was present among the suggested amino acids.
Figure 3.2
Although the identity of HGF could not be proved with this method, the 
results suggest the presence of GST fusion protein.
3.4 ‘Vestec’ Laser Desorption Mass Spectrometry
The precise molecular weight of rHGFBl21 was determined with the 
assistance of Mr Ian Davidson, Marischal College, University of Aberdeen. The 
laser desorption massspectrometer, which may be used to investigate subtle 
differences in protein size and structure, can determine the molecular weight of a 
sample to within 0.1%. In this case the molecular weight helped to characterise 
the protein rHGFpi21. The sample of lysed cells, diluted in distilled water was 
placed in the ion chamber of the spectrometer and the proteins ionised by nitrogen 
laser pulses. The ionised particles were accelerated by 25,000 volt plates and 
passed through a 0.7m flight tube. Mass is determined by the time of flight (from
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Figure 3.1 N-terminus Amino Acid Sequence of rHGFp-121
The amino acid sequence is illustrated using the single letter code for amino 
acids, the N-terminus on the left. A methionine residue has been added to the N- 
terminus o f rHGFp-121, a common event when recombinant proteins are 
expressed in bacteria. Following this residue the next twenty amino acids 
correspond exactly with the expected sequence of rat HGF, confirming the 
identity of rHGFp 121.
N-terminus amino acid sequence of rHGFp-121
Predicted {V-G-W-M-V-S-L-K-Y-R-N-K-H-I-C-G-G-S-L-I
Determined {M-V-G-W-M-V-S-L-K-Y-R-N-K-M-I-C-G-G-S-L-I
Figure 3.2 N-terminus amino acid sequence of glutathione-s-transferase 
fusion peptide, hHGFa266
The amino acid sequence is illustrated using the single letter code for amino 
acids, the N-terminus on the left. Where predicted amino acids are present in the 
sequence report, these residues are circled.
Amino acid sequencing for this protein was less satisfactory, and several amino 
acids were suggested for each residue. However, in all but one, the predicted 
amino acid was present among the suggested amino acids.
Note The T-K-L N-terminus may be replaced in E. coli due to cDNA instability
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laser pulse to protein ion detection set at 3.4kV at the end of the flight tube) with 
reference to standard proteins.
Protein rHGFpi21 was found to exist in two forms, with molecular weights of 
13984 m.u. and 14190 m.u. These figures are in agreement with the predicted 
mass of 14kDa and with the appearance of the rHGFpl21 band on SDS-PAGE.
3.5 Discussion
The recombinant bacterial protein rHGFpl21 was found to have the same N- 
terminus amino acid sequence as predicted. A methionine ‘cap’ at the N- 
terminus of recombinant proteins is commonly found, thus the sequence confirms 
the identity of rHGFP 121.
More difficulty was encountered when trying to determine the N-terminus 
amino acid sequence of hHGFa266. This protein consists of the fusion protein 
Glutathione-S-transferase followed by the HGF peptide. The fact that the 
predicted amino acid was present among the suggested amino acids for almost all 
residues is at least suggestive of the presence of GST fusion protein. In addition, 
it has been suggested that the T-K-L N-terminus may be replaced in E. coli by M- 
S due to cDNA instability in this organism (161). One must, however, accept that 
the identity of hHGFa266 could not be proved with this method.
CHAPTER 4. Purification of Native Human Placental HGF (hpHGF)
4. INTRODUCTION
4.1. Placenta: A Source of Native HGF
As described in chapter 2 none of the available antibodies to HGF localised 
HGF immunocytochemically. One possible explanation for this might be antigenic 
differences between native and recombinant HGF, to which all of the available 
antibodies had been raised. It is known that significant differences in protein 
folding and glycosylation may exist between native and recombinant proteins. 
These differences may alter the antigenicity of a molecule (165) or affect its 
recognition by antibody. In an attempt to overcome these difficulties part of this 
project involved purification of native human HGF and the production of 
monoclonal and polyclonal antibodies to this material. Although HGF and its 
mRNA have been localised in a variety of tissues, suitable sources of HGF are 
restricted to plasma (43) and placenta. Since HGF is present in very small 
quantities (ng/ml serum) (119,122) a large volume of plasma would be required to 
isolate sufficient protein for the purposes of antibody production. However, 
human placenta has been identified as a source of significant quantities of HGF 
(46). This source was selected as supplies of fresh placenta were easily secured.
Human placental HGF (hpHGF) can be purified on the basis of its affinity for 
heparin and its hydroxylapatite binding properties, by adapting the methods of 
Hernandez et al (46) and Gohda et al (166). These properties were utilised in 
column chromatography steps with the eluted fractions containing hpHGF, 
identified by ELISA.
4.2 Materials and Methods 
Materials - see page 141 
Methods
4.2.1 Heparin Agarose/Hydroxylapatite Chromatography
Freshly obtained normal human term placenta was cut into 2cm^ cubes and 
homogenised in one litre of cold 1M NaCl (lOOg wet tissue to one litre 1M NaCl) 
using an 'ATOMIX1 homogeniser. The homogenate was diluted to 0.5M NaCl
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with water and clarified by centrifugation at 15000g for 30 minutes at 4°C. The 
supernatant was applied, at a flow rate of 60ml/hr, to a heparin-agarose column 
(bed volume 200ml) equilibrated with PBS containing 0.5M NaCl, pH 7.2. The 
column was washed with 4 litres of PBS containing 0.5M NaCl until the protein 
content of the efferent wash buffer returned to the baseline (protein content was 
estimated by measuring absorbance of ultraviolet light at 280nm OD2 8 O = mg 
protein/ml). The material bound to the immobilised heparin was eluted by 1 litre 
of PBS containing 1,3M NaCl and fractions of 10ml collected. Every third 
fraction from the column was analysed for conductivity (NaCl concentration), 
optical density at 280nm (protein content), pH and HGF content (ELISA (d) as 
described in Chapter 6, section 6.2.5).
Those fractions containing peak amounts of hpHGF were pooled and dialysed 
against 5 litres of PBS. Triton X-100 solution was added to the dialysed 
preparation at a final concentration of 0.013% (volume/volume) and applied to a 
hydroxylapatite column (bed volume 40ml) equilibrated with PBS containing 
0.013% Triton X-100, at a flow rate of 60ml/hr. The column was washed with 
200ml of the same buffer, then with 200ml of 0 .1M sodium phosphate buffer (pH 
7.1) containing 0.15M sodium chloride and 0.013% Triton X-100. Bound 
hpHGF was then eluted with 160ml of 0.45M sodium phosphate buffer (pH 7.1) 
containing 0.15M sodium chloride and 0.013% Triton X-100 at room temperature 
(all other stages carried out at 4°C). Fractions of 2.5ml were collected and every 
third fraction assessed for pH, protein content (O.D. at 280nm), phosphate 
concentration (conductivity) and hpHGF content (ELISA (d)). Those fractions 
containing the greatest amounts of hpHGF with lowest total protein content were 
pooled, dialysed and concentrated by removal of water with sucrose as described 
in Chapter 2, section 2.6.2.
4.2.2 Analysis
Purified hpHGF was analysed by SDS-PAGE (method described in Chapter 2, 
section 2.6.1.1) using Coomassie blue (method described in Chapter 2, section
2.6.1.2) and silver staining techniques and by Western blotting.
Silver stain: Following SDS-PAGE, gels were incubated for 30 minutes in 50% 
methanol/10% acetic acid, followed by 30 minutes in 5% methanol/7.5% acetic 
acid then 30 minutes in 10% glutaraldehyde, using a shaking water bath. The gels 
were next resuspended in 2 litres of distilled water overnight. The water was 
changed several times to remove glutaraldehyde and gels incubated for 30 minutes 
in 150mls dithiothreitol solution (5pg/ml) followed by 30 minutes in 150mls 0.1% 
(weight/volume) silver nitrate. After rinsing with distilled water gels were 
developed with 3% (weight/volume) sodium carbonate containing 500pl filtered 
formaldehyde per litre. Sodium carbonate solution changed after a few minutes to 
prevent excessive precipitation. Reaction stopped by addition of 3M citric acid to 
reduce pH to 7. The gels were finally resuspended in water and viewed using a 
light box.
Western Blotting
Proteins present in samples of fractions collected from hydroxylapatite column 
and samples of concentrated purified hpHGF together with molecular weight 
markers were separated by SDS-PAGE as described in Chapter 2.
The separated proteins were transferred from gel onto PVDF 
(polyvinylidenedifluoride) membrane using ice box cooled "BioRad Mini-Protean 
II" blotting equipment (Bio Rad Laboratories, Hertfordshire, UK) and a carbonate 
buffer (Appendix 2) with a current of 400mA for 1 hour.
Following transfer, PVDF membranes were soaked in 'blocking solution' of 
5% (weight/volume) powdered milk containing 0.1% (volume/volume) Tween 20 
in PBS for 1 hour. Primary antibodies were diluted in PBS containing 0.1% 
(volume/volume) Tween 20 (PBS-Tween) and incubated with membranes 
overnight at room temperature (polyclonal antiserum to HGF Lot No 201; diluted
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1/4000, monoclonal antibody to HGF D9 diluted 1/4, monoclonal antibodies to 
HGF B25, B43 and A3.1.2-2. all diluted 1/5000). Membranes were then washed 
in PBS-Tween ( 3 x 1 0  minutes) and incubated with secondary alkaline 
phosphatase conjugated antibodies diluted 1/1000 in PBS-Tween for one hour at 
room temperature. Membranes were washed in PBS-Tween ( 2x10  minutes) 
and in lOOmM Tris buffer pH 9.5 (1 x 10 minutes). Nitroblue tetrazolium (NBT) 
and 5-bromo-4-chloro-3-indolyl phosphate (BCIP) (Appendix 3) was used as the 
substrate for alkaline phosphatase. The reaction was stopped by washing 
membranes in distilled water.
4.3 Results
4.3.1 Heparin Agarose/Hydroxylapatite Chromatography
The hpHGF (as determined by ELISA (d)) bound to the heparin agarose 
column was eluted by increasing the sodium chloride concentration to 1.3M NaCl. 
The peak of hpHGF concentration occurred after the peak of protein 
concentration eluted from the column, in fractions 25-43 (see Figure 4.1). The 
fractions containing maximal protein quantities (Nos 13-25) are separate. In this 
way HGF can be separated from the bulk of other placental proteins. Similarly, 
hpHGF bound to the hydroxylapatite column was eluted by increasing phosphate 
concentration to 0.45M. Fractions 31-40 contained the greatest amounts of HGF 
and fractions 16-31 contained the greatest quantities of total protein (see Figure
4.2).
4.3.2 Analysis
SDS-PAGE (12% gel) of the final concentrated preparation demonstrated the 
presence of several contaminating bands of unknown identity of molecular weight 
10-20kDa (Figure 4.3(a)). Human placental HGF was not visible with either 
Coomassie blue or silver stain techniques (Figure 4.3(b)).
ELISA (c) (using monoclonal antibody D9, see Chapter 6) was used in 
preliminary studies to identify fractions containing peak hpHGF concentration. 
Figure 4.4 illustrates Western blotting of such fractions, eluted from a
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Figure 4.1 Elution profile of human placental HGF from a heparin 
agarose column
Content of hpHGF is indicated by optical density of HGF ELISA reaction (right 
Y axis). Total protein content is indicated by absorbance of ultraviolet light at 
280 nm, (left Y axis). Sodium chloride concentration, rising from 0.5M to 1.3M 
is indicated by conductivity measurement, (left Y axis X10). Fractions containing 
maximal hpHGF concentration (Nos. 25-43) are separate from fractions 
containing maximal protein concentration (Nos. 13-25).
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Figure 4.2 Elution profile of human placental HGF from a 
hydroxylapatite column
Content of hpHGF is indicated by optical density of HGF ELISA reaction (right Y 
axis). Total protein content is indicated by absorbance of ultraviolet light at 280 
nm (left Y axis). Phosphate concentration, rising from 0.1M to 0.45M, is 
indicated by conductivity in measurement (left Y axis X I00). Fractions 
containing maximal hpHGF concentration (Nos. 31-40) are separate from 
fractions containing maximal protein concentration (Nos. 16-31).
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Figure 4.3(a) SDS-PAGE analysis of purified human placental HGF 
(hpHGF)
Coomassie blue stain using 12% resolving gel and non-reduced samples.
Lane 1 Molecular weight markers
2 Purified hpHGF, 15 ng
No staining is evident in the region of the gel expected to contain hpHGF, i.e. 
adjacent to 80.4kDa.
Contaminating proteins are seen at approximately 10-20kDa.
116.0
96.4
Figure 4.3(b) SDS-PAGE analysis of eluted fractions from a hydroxylapatite 
column containing maximal hpHGF content as determined by
ELISA (c)
Silver stain using a 10% resolving gel and non-reduced samples 
Lane 1 Fraction 31 ELISA O.D. i.e. hpHGF content =0.497
2 Fraction 28 ELISA O.D. =0.592
3 Fraction 25 ELISA O.D. =0.617
4 Fraction 22 ELISA O.D. = 0 601
5 Fraction 19 ELISA O.D. = 0.373
6 Molecular weight markers
No staining is evident in the region of the gel expected to contain hpHGF, i.e. 
adjacent to 80.4kDa.
Contaminating proteins are seen at approximately 40-66 kDa.
1 2 3 4 5 6
Figure 4.4 Western blotting, using polyclonal anti-HGF serum (Lot No. 
201), of eluted fractions from hydroxylapatite column 
containing maximal human placental HGF content as 
determined by ELISA (c)
SDS-PAGE using a 7.5% resolving gel and non reduced samples probed with 
rabbit polyclonal anti-HGF serum (Lot No. 201, 1/4000)
Molecular weight markers
Fraction 19 ELISA O.D. (i.e. hpHGF content) = 0.373
Fraction 22 ELISA O.D. = 0.601
Fraction 25 ELISA O.D. = 0.617
Fraction 28 ELISA O.D. = 0.592
Fraction 31 ELISA O.D. = 0.497
A band is visible adjacent to the molecular weight marker 80.4 kDa, 
corresponding to human placental HGF.
kDa
116.0
96.4
80.4
Lane 1 2 3 4 5 6

hydroxylapatite column, using polyclonal antiserum to human recombinant HGF 
(Lot No 201). A band of ~82kDa corresponding to HGF is seen in those 
fractions which were found to contain peak HGF concentration using ELISA (c). 
The final hpHGF preparation contains 2pg/ml hpHGF (determined by ELISA) 
together with contaminating proteins making up to 3.0 mg/ml.
Western blotting performed using this material and the following antibodies to 
HGF demonstrated an 82kDa band in non-reduced samples with identical 
appearance to human recombinant full length HGF; polyclonal antiserum Lot No 
201, monoclonal antibodies D9, B25, B43, A3.1.2-2. (Figures 4.5, 4.6, 4.7, 4.8, 
4.9).
4.4 Discussion
The heparin agarose/hydroxylapatite chromatography methods used to purify 
human placental HGF were adapted from those of Hernandez et al (46) and 
Gohda et al (166). These methods were selected because they had already been 
shown to be useful in the purification of native HGF and because they could be 
adapted according to available resources.
In each of the chromatography steps, the fraction containing the peak 
concentration of protein were separate from those containing greatest 
concentration of hpHGF. Clearly, however, these methods can only provide 
partial purification of the target protein. Human placental HGF was not present 
in sufficient concentration to be demonstrable in SDS-PAGE, although several 
contaminating proteins were clearly shown. The presence of hpHGF in the 
eluted fractions and final concentrated preparation was confirmed by Western 
blotting in which a number of antibodies to HGF, monoclonal and polyclonal, 
produced similar images of a single band at 82 kDa under non-reducing 
conditions. This form of HGF does not dissociate into separate a  and Pchains 
when subjected to reducing conditions as reported by Hernandez et al (46). The 
final preparation of hpHGF contains 2 pg/ml hpHGF which is sufficient for the 
purposes of raising antibodies in rabbits and mice.
Figure 4.5 Western blotting of a concentrated preparation of human
placental HGF and human recombinant HGF using polyclonal 
anti-HGF serum Lot No. 201
SDS-PAGE using 10% resolving gel and non reduced samples probed with rabbit 
polyclonal anti-HGF serum (Lot No. 201, 1/4000)
Lane 1 Molecular weight markers
2 Human placental HGF (20 ng)
3 Human recombinant HGF (100 ng)
Human placental HGF is visible as a band at 82 kDa, similar to that found in the 
lane containing human recombinant HGF.
kDa
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Figure 4.6 Western blotting using monoclonal antibody D9, of eluted
fractions from hydroxylapatite column containing maximal 
human placental HGF content as determined by ELISA (c)
SDS-PAGE using a 7.5% resolving gel and non-reduced samples, probed with 
monoclonal antibody D9 culture supernatant (1/100)
Lane 1 { Fractions containing peak human placental HGF
2 { concentrations by ELISA
3 { Fractions containing no detectable human placental
4 { HGF
5 {
6 { Molecular weight markers
A band is seen adjacent to the molecular weight marker 80.4 kDa, corresponding 
to human placental HGF.
m l i i
kDa
116.0
96.4
80.4
2 3
♦
Figure 4.7 Western blotting of a concentrated preparation of human 
placental HGF and human recombinant HGF using 
monoclonal antibody B25
SDS-PAGE using a 12% resolving gel and non reduced samples, probed with 
monoclonal antibody to HGF (B25, 1/5000)
Lane 1 Human recombinant HGF (100 ng)
2 Molecular weight markers
3 Human placental HGF (20 ng)
An 82 kDa band is visible, corresponding to HGF, in lanes 1 and 3.
116.0
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Figure 4.8 Western blotting of a concentrated preparation of human 
placental HGF and human recombinant HGF using 
monoclonal antibody B43
SDS-PAGE using a 12% resolving gel and non reduced samples, probed with 
monoclonal antibody to HGF (B43, 1/5000)
Lane 1 Molecular weight markers
2 Human recombinant HGF (100 ng)
3 Human placental HGF (20 ng)
An 82 kDa band is visible, corresponding to HGF in lanes 2 and 3.
fkDa
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Figure 4.9 Western blotting of a concentrated preparation of human 
placental HGF and human recombinant HGF using 
monoclonal antibody A3.1.2-2
SDS-PAGE using a 12% resolving gel and non reduced samples, probed with 
monoclonal antibody to HGF (A3.1.2-2, 1/5000)
Lane 1 Molecular weight markers
2 Human placental HGF (20 ng)
3 Human recombinant HGF (100 ng)
An 82 kDa band is visible, corresponding to HGF, in lanes 2 and 3
kDa
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CHAPTER 5. Production of Polyclonal and Monoclonal Antibodies to
Native and Recombinant Hepatocyte Growth Factor Proteins
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5. INTRODUCTION
5.1 Antibodies; monoclonal and polyclonal
In preparing antibodies to be used as investigative tools a choice is available 
between two very different types of reagent; conventional polyclonal antisera and 
monoclonal antibodies. A polyclonal antiserum contains many different antibody 
specificities to the various epitopes of a structurally complex immunogen. The 
ability to recognise different epitopes present on an antigen facilitates detection of 
that antigen, particularly in situations where the antigen is immobilised and only 
part of its structure is exposed. Examples include immunocytochemistry and 
ELISA. Another advantage includes the relative ease with which they may be 
prepared and their stability in laboratory storage (4°C or minus 20°C). 
Disadvantages relate mainly to the inherent heterogeneity of antibody present. 
Since an antiserum is the product of many responding classes of cells, this 
involves the classes and subclasses (isotypes) of antibody produced, as well as 
their specificity, titre and affinity. In practice this means that each batch of 
antiserum, even from the same animal requires to be assessed for its suitability in 
any particular assay. Unless the antibodies are affinity purified specific antibodies 
of interest account for a maximum of 20-30% of the immunoglobulin present.
Monoclonal antibodies have become increasingly popular since the method for 
their production was developed in 1975 (167). Monoclonal antibodies (MAbs) 
are derived from a single B cell clone which has been immortalised by fusion with 
a myeloma cell line. They are homogeneous in specificity, affinity and isotype. 
Each hybridoma clone produces an antibody which is specific to a single antigenic 
determinant of the immunogen (monospecific). Monoclonal antibodies are 
particularly useful in assays for soluble antigen in which they help overcome 
difficulties of sensitivity and specificity which may accompany the use of 
polyclonal antibody. Their production from cell culture may allow virtually 
unlimited amounts of antibody to be generated.
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5.2 Preparation of Polyclonal Antibodies to Native Human Placental HGF 
and Recombinant Rat and Human HGF Peptides
Polyclonal antibodies are routinely produced in rabbits, sheep and goats. In 
this study rabbits have been used in view of the fact that other workers have 
successfully raised antibodies to HGF in this species (168). Moreover, rabbits are 
relatively easy to care for, robust, long lived and easy to handle, immunise and 
bleed. They give excellent IgG responses to a wide variety of immunogens.
5.3 Materials and Methods 
Materials - see page 141 
Methods
5.3.1 Immunisation of Rabbits
Prior to immunisation 5ml of preimmune blood was taken from the rear 
marginal ear vein of each animal, allowed to clot and serum separated and stored 
at -20°C.
Primary immunisation: Subcutaneous injection of protein was performed. 
hHGFa266 (100-500pg), a 56kDa recombinant bacterial fusion protein based on 
human HGFa-chain, produced as described in Chapter 2. rHGFpl21 (100- 
500pg), a 14kDa recombinant bacterial protein based on rat HGFP chain, 
produced as described in Chapter 2. Native human placental HGF, preparation 
containing full length naturally occurring human placental HGF, as described in 
Chapter 4. Protein preparations were emulsified in PBS/Freunds complete 
adjuvant, to a final volume of 0.5-lml. Two animals were immunised for each 
protein; Nos 340 and 341 - hHGFa266, Nos 38986 and 1700 - rHGFpi21, Nos 
1699 and 1698 - human placental HGF.
Boost injections: Four subcutaneous injections of protein (100-500pg of 
hHGFa266, rHGFB121 or ~l-2pg of hpHGF emulsified in PBS/Freunds 
incomplete adjuvant to a final volume of 0.5ml) at intervals of 2 weeks.
Test bleeds of 5ml blood taken as above prior to each boost injection.
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5.3.2 Western Blotting
Following SDS-PAGE (as described in Chapter 2) of non-reduced samples of 
hHGFa266 (12% gel), rHGFpl21 (15% gel) and human placental HGF (10% 
gel), proteins were blotted onto PVDF membranes using carbonate transfer buffer 
with BioRad Mini Protean II equipment as described in Chapter 3.
After transfer, membranes were incubated with PBS containing 0.1% 
(volume/volume) Tween 20 and 5% (weight/volume) powdered milk for 1 hour at 
room temperature. Membranes were then incubated with preimmune sera, 
antisera from immunised animals or positive control antibodies diluted in PBS 
containing 0.1% (volume/volume) Tween 20 (PBS-Tween) at room temperature 
overnight. Membranes were washed in PBS-Tween ( 3x10  minutes) and 
incubated with secondary antibody (alkaline phosphatase conjugated swine anti­
rabbit immunoglobulins or, in the case of positive control murine monoclonal 
antibodies, in alkaline phosphatase conjugated rabbit anti-mouse 
immunoglobulins) diluted 1/1000 in PBS-Tween at room temperature for 1 hour. 
Membranes were washed 2 x 1 0  minutes in PBS-Tween, then 1x10 minutes in 
lOOmM Tris buffer, pH 9.5 and exposed to nitro-blue tetetrazolium/5-bromo-4- 
chloro-3-indolyl phosphate (NBT/BCIP Appendix 3) and reaction stopped by 
washing with distilled water.
5.4 Results
Immunisation was tolerated well by each of the rabbits used. Adequate 
antibody titres were demonstrated in each animal after four subcutaneous boost 
injections at intervals of 2 weeks.
hHGFa.266: sera from rabbits 340 and 341 were shown to detect the 
immunogen and full length recombinant human HGF in Western blotting studies. 
The antibody also cross-reacted with full length rat recombinant HGF (Fig 5.1).
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Figure 5.1 Western blotting of hHGFa266, recombinant human HGF
and recombinant rat HGF using pre-immune and immune 
serum from rabbit 341
SDS-PAGE using a 10% resolving gel and non reduced samples probed with 
preimmune (a) and immune (b) serum (1/300) from rabbit 341 which had been 
immunised using the recombinant HGF protein hHGFa266.
Lane 1 Molecular weight markers
2 recombinant human HGF (lOOng)
3 recombinant rat HGF (lOOng)
4 partially purified hHGFa266 (lOOng)
Background staining only is seen in the blot using preimmune serum (a). Using 
immune serum (b), bands are visible in lanes 2 and 3 of approximately 82 kDa 
corresponding to HGF. Several bands are visible in Lane 4 of approximate 
molecular weights 55.7-75 kDa. Immune serum thus recognises several proteins 
in the impure preparation of hHGFa266 and both recombinant human and 
recombinant rat HGF.
(a)
kDa
116.0
Lane
kDa
(b)
116.0
96.4
80.4
55.7
43.7
38.8
4
Lane 1 2 3 4
rHGFB121: sera from rabbits 38986 and 1700 were shown to detect both the 
immunogen and full length recombinant rat HGF in Western blotting studies. The 
antibody also crossreacted weakly with human recombinant HGF (Fig 5.2).
Human placental HGF: sera from rabbits 1699 and 1698 were found to detect 
both the immunogen and full length recombinant human HGF in Western blotting 
studies (Fig 5.3).
5.5 Production of Murine Monoclonal Antibodies to Native Human 
Placental HGF
Attempts to generate monoclonal antibodies were carried out in collaboration 
with Dr Ailsa Campbell and Mr Pat Ferry of Glasgow University Department of 
Biochemistry. Mice were immunised according to a standard schedule, killed and 
spleen cells harvested for fusion with myeloma cells. At the same time serum was 
collected for assessment of polyclonal antibody response to the immunisation 
programme. Eight to ten days after plating of cells from fusion, hybridoma 
supernatants were assayed by ELISA for antibodies to human recombinant HGF. 
This was to allow selection of those clones formed following fusion of a cell 
producing antibody to HGF, rather than to any contaminant in the human 
placental HGF preparation. After screening, wells which appeared positive were 
subcloned and assayed again after eight days. Unsuccessful screening was 
followed by continued culture and the assay repeated. Appropriate positive and 
negative controls were included at each stage.
5.6 Materials and Methods 
Materials - see page 141 
Methods
5.6.1 Immunisation of Mice
Day 0; lOOpl (~200ng) hpHGF in Freund's complete adjuvant injected sub- 
cutaneously. Subcutaneous booster injections of lOOpl (~200ng) hpHGF in 
Freund's incomplete adjuvant given on days 10 and 20. On day 30 an intravenous
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Figure 5.2(a) Western blotting of cell lysate of E.coli expressing the
recombinant rat HGF protein rHGFpi21 using pre-immune 
and immune serum from rabbit 38986
SDS-PAGE using a 15% resolving gel and non reduced samples probed with pre­
immune, lane 1, and immune, lane 2 serum (1/200) from rabbit 38986 which had 
been immunised using the recombinant HGF protein rHGFpi21.
Lane 1 Cell lysate of E.coli expressing rHGFpl21 probed with pre-immune 
serum
2 Cell lysate of E.coli expressing rHGFpl21 probed with immune serum
3 Molecular weight markers (pre-stained)
No staining is seen in lane 1. In lane 2 a band of 14 kDa is visible corresponding 
to rHGFpi21.
kDa
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96.4
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1 2 3 Lane
Figure 5.2(b) Western blotting of full length recombinant rat HGF using
pre-immune and immune immunoglobulin from rabbit 38986
SDS-PAGE using a 10% resolving gel and non reduced samples probed with 
immunoglobulin purified from pre-immune, lane 2, and immune, lane 3, serum 
from rabbit 38986 which had been immunised against recombinant HGF protein 
rHGFpl21.
Lane 1 Molecular weight markers
2 Recombinant rat HGF (100 ng) probed with pre-immune 
immunoglobulin (0.232 mg/ml)
3 Recombinant rat HGF (100 ng) probed with immune 
immunoglobulin (0.232 mg/ml)
Background staining only is seen using pre-immune immunoglobulin (lane 2). 
Using immune immunoglobulin a band is visible in lane 3 of approximately 82 kDa 
corresponding to HGF.
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80.4
55.7
43.7
38.8
Lane 1 2 3
Figure 5.2(c) Western blotting of recombinant full length human HGF 
using pre-immune and immune serum from rabbit 38986
SDS-PAGE using a 12% resolving gel and non reduced samples probed with pre­
immune, lane 1, and immune, lane 2, serum (1/100) from rabbit 38986 which had 
been immunised using recombinant HGF protein rHGFpl21.
Lane 1 Recombinant human HGF (100 ng) probed with pre-immune
serum.
2 Recombinant human HGF (100 ng) probed with immune serum
3 Molecular weight markers
No staining is seen in lane 1. In lane 2 a band of approximately 82 kDa is visible 
corresponding to human recombinant HGF.
kDa
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80.4
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Figure 5.3(a) Western blotting of human recombinant HGF using pre­
immune and immune serum from rabbit 1698
SDS-PAGE using a 10% resolving gel and non-reduced samples probed with pre­
immune, lane 1, and immune lane, lane 2, serum (1/1000) from rabbit 1698 which 
had been immunised using purified human placental HGF.
Lane 1 Human recombinant HGF (200 ng)
2 Human recombinant HGF (200 ng)
3 Molecular weight markers
A band of approximately 82 kDa corresponding to human recombinant HGF is 
visible in lane 2 using immune serum. Serum from rabbit 1698 following 
immunisation is thus capable of detecting human recombinant HGF. No signal is 
seen in lane 1 using pre-immune serum.
IkDa
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96.4
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Figure 5.3(b) Western blotting of human placental HGF and human
recombinant HGF using immune serum from rabbit 1698
SDS-PAGE using a 12% resolving gel and non-reduced samples probed with 
immune serum (1/200 and 1/1000) from rabbit 1698 which had been immunised 
using purified human placental HGF.
Lane 1 Human recombinant HGF (250ng)
2 Human placental HGF (20 ng)
serum 1698, 1/200
3 Human recombinant HGF (250 ng)
4 Human placental HGF (20 ng)
serum 1698, 1 /1000
5 Molecular weight markers
In lanes 1 and 3 a band of approximately 82 kDa is visible, corresponding to 
human recombinant HGF. In lanes 2 and 4 a band is also visible at 82 kDa 
corresponding to human placental HGF. Further bands are evident in lanes 2 and 
4 of approximately 10-20 kDa and 50-70 kDa corresponding to contaminating 
proteins in the human placental HGF protein.
Immune serum from rabbit 1698 thus recognises human placental HGF and 
human recombinant HGF
kDa
116.0
96.4
80.4
55.7
43.7
38.8
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injection of 20pl (40ng) hpHGF in PBS was given. Four days later the animal 
was killed and spleen/serum harvested.
5.6.2 Assessment of Mouse Polyclonal Serum Response to Immunisation 
with Human Placental HGF
(1) Wells of microtitre ELISA plates were coated with 50pl/well of human 
placental HGF at a concentration of lOOng/ml or human recombinant HGF at a 
concentration of 2pg/ml in 0 .1M NaHC03 coating buffer (see Appendix 4).
Plates were then incubated at room temperature for one hour.
(2) The ELISA plates were washed six times with PBS containing 0.025% 
(volume/volume) Tween 20 (PBS/Tween 20).
(3) Pre-immune serum and immune serum from a mouse injected with two doses 
of purified human placental HGF were applied at various concentrations (1/100, 
1/200, 1/400, 1/800) in PBS/Tween 20. Monoclonal antibody B25 to human 
recombinant HGF (positive control) diluted 1/5,000 was similarly dispensed. 
Plates were then incubated at room temperature for two hours.
(4) Plates were washed six times with PBS/Tween 20.
(5) Peroxidase conjugated goat anti-mouse immunoglobulin, diluted to 1/500 in 
PBS/Tween 20 was added and the plates incubated at room temperature for one 
hour.
(6) Plates were washed six times with PBS/Tween 20.
(7) Orthophenylene diamine substrate (see Appendix 3) was applied (lOOpl/well) 
and the plates developed in darkness for 10-15 minutes.
(8) Reaction was stopped by addition of 50pl/well 4N H2S04
(9) Plates were read by automatic plate reader (Dynatech MR700, Dynatech 
Laboratories, Guernsey, Channel Islands, UK) at 490nm with a reference 
wavelength of 630nm.
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5.6.3 Spleen Cell/Myeloma Fusion
Following removal the spleen was placed in 10ml RPMI medium in a sterile 
petri dish and cells released by teasing with needles. This cell suspension was 
passed twice through a 21 gauge needle and then through a 25 gauge needle into 
a sterile container.
Preparation of SP20 plasmacytoma cells
SP20 cells in logarithmic growth in RPMI containing 10% fetal calf serum 
were washed and re-suspended in 20ml RPMI containing penicillin and 
streptomycin to give approximately 2-5 x 107 cells in total.
Both spleen cells and SP20 cells were washed with 20ml RPMI 3 times. 
Control cells were taken from each and the cells were mixed and harvested at 
300g as a compact pellet.
Controls from spleen cells and SP20 cells were diluted into HAT medium and 
200pl of each were dispensed into 12 wells of a 96-well culture plate. Both 
spleen and SP20 cell controls were dispensed onto the same plate. Eight other 
plates received medium containing cells following fusion as described below - 
Fusion protocol
The pellet of SP20 and spleen cells was gently mixed with 50% 
(weight/volume) polyethyleneglycol (1.0 ml)), prewarmed to 37°C, over 1-2 
minutes. RPMI (5.0 ml) was then slowly added over 2 minutes to gently dilute 
out the polyethyleneglycol. The mixture of cells was centrifuged at 400 g for 5 
minutes, the cell pellet was resuspended in 96 ml HAT medium and dispensed 
(200 pl/well) into the inner 60 wells of 8 microtitre plates. The plates were next 
incubated at 37°C in a humidified incubator with 5% CO2.
5.6.4 Screening of Hybridomas for Antibodies to Human Recombinant 
HGF
Hybridomas were cultured for eight days prior to screening by ELISA of culture
supernatants.
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1) Wells of nine microtitre ELISA plates were coated with 50pl/well human 
recombinant HGF at a concentration of 2pg/ml in 0 .1M NaHC03 coating buffer 
(see Appendix 4) for 1 hour at room temperature.
2) The ELISA plates were washed 6 times with PBS containing 0.025% Tween 
20 .
3) Culture supernatant (lOOpl) from hybridomas, spleen cells and myeloma cells 
was dispensed into corresponding wells of ELISA plates. Normal and immune 
mouse serum diluted 1/1000 in PBS containing 0.025% Tween 20 and 
monoclonal antibody B25 to HGF (positive control) diluted 1/10,000 (i.e. final 
concentration 167ng/ml) in PBS containing 0.025% Tween 20 were similarly 
dispensed. Plates were then incubated at room temperature for 2 hours. Stages 
(4-9) were as described above in ‘Assessment of mouse polyclonal serum 
response to immunisation with human placental HGF’, section 5.6.2.
5.7 Results
5.7.1 Polyclonal Serum Response of Mice Immunised with Human Placental 
HGF
Sera from immunised mice detected both human recombinant HGF and human 
placental HGF. Figure 5.4 illustrates the difference between immune and pre­
immune serum in the detection of human placental HGF and human recombinant 
HGF. Using wells coated with human placental HGF, pre-immune serum diluted 
1/200 produced an ELISA Optical Density of 0.215. Immune serum gave an 
Optical Density of 0.691. When wells coated with human recombinant HGF were 
used, pre-immune serum diluted 1/200 produced an Optical Density of zero. 
Immune serum diluted 1/200 gave an Optical Density of 0.992.
Figure 5.5 illustrates the level of response produced in a mouse prior to 
sacrifice and spleen cell harvesting. Pre-immune serum diluted 1/1000 produced 
an ELISA Optical Density of 0.091. Immune serum diluted 1/1000 gave an 
Optical Density of 1.939 (maximum O.D. possible; 2.0).
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Figure 5.4 Polyclonal serum response of mice immunised with purified 
human placental HGF
The polyclonal serum response following immunisation was assessed by ELISA 
described.
Immune serum detected both human placental and human recombinant HGF 
producing a significantly greater colour reaction (Optical Density) than pre­
immune serum (from a non-immunised littermate).
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Figure 5.5 Polyclonal serum response of mice immunised with purified 
human placental HGF prior to sacrifice and spleen cell 
harvesting
The polyclonal serum response following immunisation was assessed by ELISA as 
described.
Immune serum detected human recombinant HGF at a dilution of 1/1000 
producing a significantly greater colour reaction (O.D.) than pre-immune serum 
(from a non-immunised littermate). Such a response indicates a satisfactory level 
of immunity prior to spleen cell harvesting.
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5.7.2 Spleen Cell/Myeloma Cell Fusion
Colonies grew in 60-80% of wells on culture plates.
5.7.3 Screening for Antibody to Human Recombinant HGF 
No suitable antibody producing clones were identified.
5.8 Discussion
5.8.1 Polyclonal antibody production
In the case of each immunogen, recombinant proteins hHGFa266, and 
rHGFpi21 and native human placental HGF preparation sufficient antibody 
response was generated to allow Western blotting of the relevant immunogen in 
small quantities. Sera raised against hHGFa266 also detected full length rat 
recombinant HGF. The intensity of staining was greater with rat recombinant 
HGF than with human recombinant HGF. This may be due to subtle differences 
in three dimensional shape of the target protein such that target antibody binding 
sites are more accessible in the rat HGF preparation.
Antiserum raised in response to immunisation with rHGFpi21 clearly 
demonstrated rHGFpl21 in Western blotting whereas preimmune serum did not. 
A cross reaction with human recombinant HGF was also demonstrated but the 
signal intensity was lower, suggesting either weak binding to a similar epitope or 
difficulty accessing antibody binding sites.
Antisera raised following immunisation with human placental HGF produced 
an intense reaction in Western blotting studies using recombinant human HGF 
even at high serum dilution e.g. 1:1000.
In each case pre-immune serum served as a negative control to demonstrate 
the effect of the immunisation process. These studies were useful in 
demonstrating that immunisation had produced a measurable antibody response 
and offered some suggestion as to the sensitivity of the antibody produced. 
Clearly, however, we could not exclude cross reaction with similar proteins i.e. 
the degree of antibody specificity was to be carried out if the antibody raised
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proved capable of demonstrating target protein in immunocytochemistry or 
ELISA.
5.8.2 Monoclonal antibody production
A good polyclonal serum response of mice immunised with human placental 
HGF was obtained when preimmune and immune sera were assessed for reaction 
to human placental HGF and human recombinant HGF in ELISA. Before each 
mouse was killed, high antibody titre was confirmed by ELISA to allow optimal 
timing for production of suitable antibody producing hybridomas.
Spleen cell/myeloma cell fusion was successful with colonies growing in 60- 
80% of culture wells.
No suitable antibody producing clones were identified. Reasons for this 
remain unclear, the mice clearly developed an immune response to the immunogen 
and the sensitivity of the screening assay used is believed to be adequate (detects 
B25 at 1.67mg/ml x 1/10000 i.e. 167ng/ml). It is known that the yield of suitable 
hybridomas from initial screening is found to be of the order of 0-25% (169).
Following unsuccessful attempts with four mice insufficient time remained for 
further approaches to the production of monoclonal antibodies.
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CHAPTER 6. Development of an ELISA for Detection of Hepatocyte 
Growth Factor in Human Serum
6. in t r o d u c t io n
6.1 Enzyme Linked Immunoabsorbent Assay (ELISA)
Since its development in the early 1970s (170,171), Enzyme Linked 
Immunosorbent Assay (ELISA) has become an established tool in a variety of 
fields of biological study. Ideally suited for the detection of minute quantities of 
material present in complex mixtures such as serum, these assays have been 
particularly useful in the detection of growth factors and hormones. One 
particular form of ELISA which is favoured for its combined simplicity, specificity 
and sensitivity is the 'sandwich' or two site antigen capture assay. In the basic 
form of this ELISA an antibody, frequently a monoclonal of high affinity is used 
to coat a solid phase. This is exposed to the test sample, then washed and a 
second, enzyme conjugated antibody is applied which binds to 'captured' antigen. 
After washing away unbound reagent the plate is exposed to substrate and 
developed. With the restriction that the antigen to be detected must have multiple 
or similar but spatially distant antibody binding epitopes such assays are 
potentially extremely sensitive. The use of monoclonal antibodies which confer 
features of specificity and reduced background signal as primary coating antibody 
together with a polyclonal second layer which amplifies the signal, helps to 
increase the sensitivity of these assays. Other means of improving sensitivity 
include the addition of further antibody layers, an avidin-biotin system, and the 
use of luminescence or enzyme cascades. However, clearly the performance 
characteristics of any ELISA are defined by the properties of the antibodies 
utilised.
The major difficulties encountered in the development of novel ELISAs are:
(1) obtaining antibodies of high enough specificity and sensitivity for the antigen 
being studied, (2) obtaining antibodies which have long term stability (in particular 
this applies to monoclonal antibodies), (3) obtaining antibodies which do not bind 
in a non-specific manner, (4) obtaining antigen of known purity and concentration 
for assay standardisation.
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In developing the ELISA for HGF, all of the above points had to be addressed. 
A number of antibodies were obtained for use in an HGF ELISA and their 
specificity and sensitivity assessed by Western blotting and ELISA. The stability 
of the antibodies was determined and cross reactivity to structurally/ 
immunologically similar molecules was examined by ELISA. Purified human 
recombinant full length HGF was obtained at a known concentration for purposes 
of calibration.
In these studies two main forms of ELISA sandwich were used comprising 
two or three antibody layers respectively. In the former, a monoclonal antibody 
was used to coat an ELISA plate, then samples (test or standard recombinant 
human HGF) were applied and incubated with the monoclonal antibody. A 
second antibody layer of purified, biotinylated rabbit IgG to HGF was applied and 
the antibody detected by addition of avidin-HRP (Horse-radish peroxidase) 
conjugates and the substrate orthophenylenediamine. The latter form of ELISA 
comprised a monoclonal coating antibody, then test or standard recombinant 
human HGF samples, detection with whole rabbit polyclonal antiserum to HGF, 
followed by biotinylated purified specific sheep antibody to rabbit 
immunoglobulins. (Cross reacting antibodies to murine immunoglobulins were 
removed prior to use). The detection system was by means of avidin-HRP 
conjugate and orthophenylenediamine (Figure 6.1).
The ELISA assays developed in this study may be summarised as illustrated in 
table 6.1.
6.2 Materials and Methods 
Materials - see page 141.
6.2.1 Western Blotting
Blotting studies were performed as described in Chapter 3. Non-reduced 
samples of purified human recombinant HGF or purified native human placental 
HGF were subjected to SDS-PAGE and transferred to PVDF membrane and non­
specific binding sites blocked by incubation with phosphate buffered saline (PBS)
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Figure 6.1 Schematic representation of HGF ELISA methods
a) Two antibody laver ELISA sandwich: ELISA plate was coated with 
monoclonal anti-HGF trapping antibody, then samples (test sample or standard 
human recombinant HGF) applied. A second antibody layer of purified, 
biotinylated rabbit IgG to HGF was applied and the antibody detected by addition 
of avidin-HRP conjugate and the substrate orthophenylenediamine.
b) Three antibody laver ELISA sandwich: ELISA plate was coated with 
monoclonal anti-HGF trapping antibody, then samples (test sample or standard 
human recombinant HGF) applied. A second antibody layer of whole rabbit 
polyclonal antiserum to HGF was applied, followed by biotinylated purified 
specific sheep antibody to rabbit immunoglobulins. The detection system was by 
means of avidin-HRP conjugate and orthophenylenediamine.
a) Two antibody layer ELISA
Avidin-HRP conjugate
XI ►X
Biotinylated detection/ 
secondary antibody
H G F ----------- y y\ 7
Trapping/coating antibody 
  ELISA plate
b) Three antibody layer ELISA
Avidin-HRP conjugate
X< ►X
Biotinylated_________
tertiary antibody
Detection/secondary antibody
HGF - - - ~ ( j "
Trapping/coating antibody 
  ELISA plate
Table 6.1 Summary of ELISA Constituents and Structure
ELISA
Trapping/
Coating Antibody
Detection/ 
Secondary Antibody
Tertiary
Antibody
Detection
System
(a) A312-1 Purified, biotinylated 
polyclonal rabbit IgG 
to HGF. Lot No. 201
Avidin-HRP 
OPD system
(b) A312-1 Whole serum Lot No. 
201
Biotinylated 
sheep antibody 
to rabbit IgG
Avidin-HRP 
OPD system
(c) D9 Whole serum Lot No. 
201
Biotinylated 
sheep antibody 
to rabbit IgG
Avidin-HRP 
OPD system
(d) ] B25 Whole serum Lot No. 
201
Biotinylated 
sheep antibody 
to rabbit IgG
Avidin-HRP 
OPD system
(e) B43 Whole serum Lot No. 
201
Biotinylated 
sheep antibody 
to rabbit IgG
Avidin-HRP 
OPD system
(f) A312-2 Whole serum Lot No. 
201
Biotinylated 
sheep antibody 
to rabbit IgG
Avidin-HRP 
OPD system
containing 3% (weight/volume) bovine serum albumin and 0.1% (volume/volume) 
Tween 20 at room temperature for 1 hour. The primary antibody under 
examination was diluted to 1/5000 in PBS containing 0.1% (volume/volume) 
Tween 20 (B25, B43, A312-2 and polyclonal rabbit antiserum Lot No 201) or 1/5 
(D9, hybridoma culture supernatant) and incubated, shaking, at room temperature 
overnight (EURO BD60 Shaker, Stovall Life Science Inc. Greensboro, North 
Carolina, USA).
The membranes were then washed ( 3x10  minutes) in PBS containing 0.1% 
(volume/volume) Tween 20 and incubated with the secondary antibody (alkaline 
phosphatase conjugated rabbit anti-mouse immunoglobulins or alkaline 
phosphatase conjugated swine anti-rabbit immunoglobulins) diluted 1/1000 in 
PBS containing 0.1% (volume/volume) Tween 20 at room temperature for 1 
hour. The membranes were washed in PBS containing 0.1% (volume/volume) 
Tween 20 (2 x 10 minutes) and finally in lOOmM Tris buffer pH 9.5 (1 x 10 
minutes).
The signal was developed by bathing the membranes in nitroblue tetrazolium 
(NBT) and 5-bromo-4-chloro-3-indolyl phosphate (BCIP) in lOOmM Tris (pH 
9.5) (Appendix 3). The reaction was stopped by washing the membranes in 
dH20.
6.2.2 Purification and Biotinylation of IgG from Whole Rabbit Serum
(1) Acetic acid (0.1M) was added to serum to reduce pH to 4.5.
(2) Undiluted caprylic acid was added to a final concentration of 5% 
(volume/volume).
(3) The acidified serum and caprylic acid were mixed by vortexing for 5 minutes.
(4) The mixture was centrifuged in 1ml aliquots at 13,000 rpm for 7 minutes 
using a "Microcentaur" microfuge (Fisons, Scientific Equipment), following which 
Pellets were discarded and supernatants retained.
(5) An equal volume of saturated ammonium sulphate was added step wise and 
mixed at room temperature gently for 2 hours.
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(6) The mixture was centrifuged in 1ml aliquots in a "Microcentaur" microfuge at
13,000 rpm for 3 minutes.
(7) Pellets were retained, resuspended in PBS and the resulting solution dialysed 
against 2 changes of 2 litres of PBS for 1 hour.
(8) Protein (immunoglobulin) content of dialysed solution was estimated by 
absorbance of ultraviolet light at 280nm (OD2 8 O = mg protein/ml).
(9) Protein concentration was adjusted to 5mg/ml using PBS.
(10) Biotin (2 mg) was weighed into glass bijoux bottle, then dissolved in 100pi 
dimethyl formamide.
(11) Antibody solution (1 ml i.e. 5 mg) was added to the biotin solution.
(12) Mixed gently by hand and allowed to stand at room temperature with 
occasional gentle mixing for 2 hours.
(13) The solution was dialysed against 2 litres PBS overnight.
6.2.3 Assessment of Untreated Biotinylated Sheep Polyclonal Anti-Rabbit 
Immunoglobulins for Cross Reactivity with Murine Monoclonal IgG 
Antibody
(1) An ELISA plate was coated with murine monoclonal antibody IgG2a CD72 
at a concentration of lOgg/ml in 0 .1M NaHCC>3 , 50pl per well. The plate was 
sealed and incubated at 37°C overnight.
(2) The plate was washed 6 times with PB S containing 0.025%  (volume/volume) 
Tween 2 0 .
(3) Non-specific binding was "blocked" by addition of PBS containing 3% 
(weight/volume) BSA, at lOOpl/well and incubation at 37°C for 2 hours.
(4) The plate was washed 6 times with PBS containing 0.025%  (volume/volume) 
Tween 20.
(5) Untreated biotinylated sheep polyclonal anti-rabbit immunoglobulins in PBS 
containing 0.5% BSA (weight/volume) and 0.5% Tween 20 (volume/volume) was 
added at the following concentrations (see Figure 6.2):
Row 1 : 1 /5 0 0  (neat solution = 1 mg/ml)
Row 2: 1/1000
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Figure 6.2 Plan of ELISA plate used in the assessment of untreated 
biotinylated sheep polyclonal anti-rabbit immunoglobulin for 
cross reactivity with murine monoclonal IgG antibody.
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Diluted antibody solution (100jal) was applied to each well, then the plate was 
sealed and incubated, at 37°C for 2  hours.
(6 ) The plate was washed 6  times in PBS containing 0.025% Tween 20 
(volume/volume).
(7) Avidin-HRP conjugate in PBS containing 0.5% BSA (weight/volume) and 
0.5% Tween 20 (volume/volume) was added at the following concentrations, 100 
pi of solution per well: (see Fig. 6.2).
Columns 1,2 & 3: 1/1000 
Columns 4,5 & 6 : 1/2000 
Columns 7,8 & 9: 1/4000 
Columns 10,11 & 12: 1/8000
The plate was then sealed and incubated at 37°C for 1 hour.
(8) The plate was washed 6  times with PBS containing 0.025% Tween 20.
(9) Orthophenylenediamine substrate solution (see Appendix 4) was added at 
lOOpl/well and the reaction stopped after 3 minutes with 50pl per well of 4N
h2so4.
(10) Absorbance was read by an automatic plate reader at 490nm with a reference 
wavelength of 630nm (Dynatech MR700 microplate reader, Dynatech 
Laboratories, Guernsey, Channel Islands, UK).
6.2.4 Removal of Cross Reacting Antibodies (Anti-Murine IgG) from
Biotinylated Sheep Anti-Rabbit Immunoglobulins by Sepharose 4B- 
CD72 Affinity Chromatography
Murine monoclonal antibody IgG2a CD72 to human B-type lymphocytes was 
conjugated to activated Sepharose 4B-CNBr to form a sepharose-antigen column 
in order to remove cross reacting antibodies to mouse IgG by affinity 
chromatography from biotinylated sheep anti-rabbit immunoglobulins.
(a) rnnjugation of murine monoclonal IgG2a antibody CD72 to sepharose 4R
(1) A volume of 1ml of sepharose 4B-CNBr (activated) beads was poured onto a 
10ml centrifuge test tube (Falcon) and 5ml of 0.001M hydrochloric acid added. 
The rehydrated gel was shaken and washed with 0.001M hydrochloric acid, 
centrifuged and the acid discarded. The process was repeated, the supernatant 
discarded and gel retained.
(2) CD72 murine monoclonal IgG2a antibody was dialysed against 2 litres of 
0 .1M NaHCC>3 plus 0.15M NaCl at room temperature overnight.
(3 ) After removal of an aliquot of CD72 solution for estimation of protein 
concentration the dialysed antibody was added to the sepharose 4B-CNBr gel.
The gel was mixed by gentle rotary inversion at 4°C overnight.
(4) The gel was centrifuged at 10,000 rpm for 10 minutes using a "Microcentaur" 
microfuge at room temperature and supernatant removed. Protein concentration 
in the supernatant was estimated.
(5) Gel was washed once in 0 .1M NaHCCh plus 0 .15M NaCl.
(6 ) Gel was mixed by gentle rotation at 4°C overnight in 0.1M Tris HC1, pH8 .
(7) Gel was washed with 0 .1M acetate pH 4.0 containing 1 0M NaCl.
(8 ) Gel was washed with 0 .1M borate pH 8.0 containing 1 0 M NaCl.
Steps 7 and 8  repeated.
(9) Gel was stored in PBS containing 0.01M EDTA at 5°C.
(b) Removal of swine antibodies to murine monoclonal IgG
(1) The Sepharose 4B-mouse CD72 IgG2a gel was washed in PBS containing 
0.01M EDTA then centrifuged at 10,000 rpm using a "Microcentaur" microfuge 
at room temperature for 10  minutes and the supernatant discarded.
(2 ) Biotinylated sheep anti-rabbit immunoglobulins (1ml, 1 mg/ml) was added to 
the gel and gently mixed by repeated inversion at room temperature for 30 
minutes, then centrifuged at 10,000 rpm using a "Microcentaur" microfuge and 
the supernatant retained for testing and use in ELISA.
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6.2.5 ELISA Protocols
See table 6 .1
EUSAJa) (Monoclonal antibody to HGF A3.1.2-1, purified biotinylated 
polyclonal rabbit IgG (Lot No 201) to HGF, avidin-HRP conjugate/ 
orthophenylenediamine. (See Appendix 4 for buffers, solutions and reagents).
(1) The wells of a 96 well Dynatech microtitre ELISA plate were coated with 
50pl monoclonal antibody to HGF (A312-1) diluted in coating buffer (0.1M 
NaHC(>3 ) to a concentration of lOpg/ml. The plate was then sealed and 
incubated overnight at 37°C.
(2) The plate was washed 6  times with phosphate buffered saline (PBS) 
containing 0.025% (volume/volume) Tween 20.
(3) Non-specific binding sites were "blocked" by addition of lOOpl/well of PBS 
containing 3% bovine serum albumin (BSA) (weight/volume) and incubation for 2 
hours at 37°C.
(4) The plate was washed 6  times with PBS containing 0.025% Tween 20.
(5) Serum samples and standard curve of reference serum diluted in PBS 
containing 0.5% BSA (weight/volume) and 0.5% Tween 20 (volume/volume) 
were applied, lOOpl/well. Serum samples were diluted 1/500. Reference serum 
was diluted 1/40, 1/80, 1/160, 1/320, 1/640, 1/1280, 1/2560, 1/5120, 1/10240 and 
1/20480. The plate was sealed and incubated at 37°C for 2  hours.
(6 ) The plate was washed 6  times with PBS containing 0.025% Tween 20.
(7) Biotinylated IgG purified from rabbit antiserum, (Lot No 2 0 1 ) to human 
recombinant HGF (5mg/ml), diluted 1/400 in PBS containing 0.5% BSA and 
0.5% Tween 20 was applied, lOOpl/well and the plate incubated at 37°C for VA 
hours.
(8 ) The plate was washed 6  times with PBS containing 0.025% Tween 20.
(9) Avidin-HRP conjugate diluted 1/3000 in PBS containing 0.5% BSA and 
0.5% Tween 20 was applied, lOOpl/well. The plate was sealed and incubated at 
37°C for 1 hour.
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(10) The plate was washed 6  times with PBS containing 0.025% Tween 20.
(11) Substrate solution (orthophenylenediamine) (lOOpl/well) was added and 
signal allowed to develop in darkness.
(12) The reaction was stopped by addition of 50pl per well of 4N H2 SO4 .
(13) Absorbence was read at 490nm by automatic plate reader with a reference 
wavelength of 630nm.
ELISAs (b), (c), (d), (e) and (f), were similar in format. In each case a different 
monoclonal trapping antibody was used to coat the plate. However, the same 
secondary antibody (whole anti-HGF rabbit serum Lot No 2 0 1 ), tertiary antibody 
(purified biotinylated sheep anti-rabbit immunoglobulin) and detection system 
(avidin-HRP/orthophenylenediamine) were used in each of these assays. The 
following describes E L ISA  (f), which was eventually chosen as the assay most 
suitable for the measurement of HGF in human serum.
ELISA ffl
(1) The inner 60 wells of a 96 well Dynatech microtitre ELISA plate were coated 
with 50pl per well of A3.1.2-2 monoclonal antibody to human recombinant HGF 
diluted in coating buffer (0 .1M NaHC0 3 ) to a concentration of 5pg/ml sealed and 
incubated overnight at room temperature.
(2 ) The plate was washed 6  times with PBS containing 0.025% (volume/volume) 
Tween 2 0 .
(3) Blocked for 1 hour at room temperature with lOOplAvell of PBS containing 
3% (weight/volume) bovine serum albumin (BSA).
(4) The plate was washed 6  times with PBS containing 0.025% Tween 20.
(5) Serum samples and standard recombinant human HGF diluted in PBS 
containing 0.5% BSA (weight/volume) and 0.5% Tween 20 (volume/volume) 
were dispensed into wells of the plate (lOOpl/well) and the plate incubated at 
room temperature for 2  hours.
(6 ) The plate was washed 6  times with PBS containing 0.025% Tween 2 0 .
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(7) Whole rabbit antiserum, Lot No 201, to HGF diluted to 1/5000 in PBS 
containing 0.5% BSA and 0.5% Tween 20 was dispensed into each well and the 
plate incubated, sealed, at room temperature for 1 hour.
(8) The plate was washed 6  times with PBS containing 0.025% Tween 20.
(9) Biotinylated sheep anti-rabbit immunoglobulins, diluted 1/500 (undiluted 
solution; 1 mg/ml) in PBS containing 0.5% BSA and 0.5% Tween 20 was 
dispensed into each well and plate incubated, sealed, at room temperature for 1 
hour.
(10) The plate was washed 6  times with PBS containing 0.025% Tween 2 0 .
(1 1) HRP-Avidin conjugate diluted 1/8000 in PBS containing 0.5% BSA and 
0.5% Tween 20 was dispensed (lOOpl per well) and the plate incubated at room 
temperature for 1 hour.
(12) The plate was washed 6  times with PBS containing 0.025% Tween 2 0 .
(13) Substrate solution (orthophenylenediamine), (lOOpl per well) was added to 
each well and signal allowed to develop in darkness.
(14) The reaction was stopped by addition of 50pl 4N H2 SO4  to each well.
(15) Absorbence was read at 490nm by automatic plate reader with a reference 
wavelength of 630nm.
Serum samples were diluted 1:4 in PBS containing 0.5% BSA 
(weight/volume) and 0.5% Tween 20 (volume/volume). In those cases where a 
1 4 dilution gave a signal greater than the highest point on the standard curve, the 
serum sample was retested at a higher dilution e.g. 1:10. Standard reference 
solutions of HGF were made up using recombinant human HGF (Genentech Inc, 
California, USA) in the following range:
50ng/ml, 25ng/ml, 12.5ng/ml, 6.25ng/ml, 3.125ng/ml, 1.56ng/ml 
These solutions were stored as aliquots at -70°C until use.
In two of the ELIS As developed (ELIS As (a) and (c)) I was unable to use 
human recombinant HGF to draw standard curves or to calibrate the assay. In 
each of these cases I used two reference serum samples from a patient with liver
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disease. Using this serum as a standard, sera from various patients were assayed 
and ranked in terms of activity in the assay. ELISA (a) method is described under 
gTjSA Protocols; ELISA (a), page 92. The second assay, ELISA (c) was 
performed as follows:
Serum from a patient (E.O.) with acute hepatitis which reacted strongly (ELISA
(c)) was used as a reference. A standard curve was constructed using this serum 
at the following dilutions: 1/15, 1/30, 1/60, 1/120, 1/240, 1/480, 1/960 and 
1/1920. This reference serum was arbitrarily designated as containing 1000 
units/ml serum. Other sera were defined in terms of these units by comparing 
their reaction in ELISA and that of the reference serum.
6.2.6 Levels of HGF in Serum Assayed by Otsuka Assay Laboratories 
ELISA and Comparison with Results Obtained using ELISA (c)
Dr. Fujiwara from the University of Tokyo kindly agreed to measure HGF 
levels in 22 samples using an assay undergoing development by Otsuka Assay 
Laboratories, Takushima, Japan (172).
Sera from 21 patients and one sample of placental homogenate (prior to 
purification of HGF) were assayed.
6.2.7 Assessment of Assays (d), (e) and (f) for Cross Reaction with 
Plasminogen
The wells of an ELISA plate were coated with monoclonal antibodies to HGF 
B25, B43 or A.3.1.2-2. After blocking the walls with BSA, samples of 
plasminogen, human serum or recombinant human HGF were dispensed into the 
wells and allowed to incubate. The assays were then completed as described 
previously. Using standard curves for HGF, cross reaction with plasminogen or 
reaction to HGF within that preparation was calculated.
Plasminogen levels in sera from 10 patients with various serum HGF levels (as 
determined by ELISA (f) were analysed (kindly performed by Dr J Conkie, 
Haematology Department, Royal Infirmary, Glasgow). The following methods
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were used: (1) Amidolytic (streptokinase/plasminogen complex) chromogenic 
assay with plasmin specific substrate S-2251 (Kabi Diagnostica, Sweden) for 
determination of functional activity of plasminogen in sample. (2 ) Single radial 
immunodiffusion with M-Partigen(R) plasminogen immunodiffusion plates 
(Behringwerke AG, Marburg, Germany) for immunological determination of 
plasminogen including biologically inactive material.
The following sections relate to studies carried out using ELISA (f).
6.2.8 Stability of HGF in Serum: Collection of Serum
Blood taken from a patient with acute viral hepatitis was divided into six 
aliquots immediately and treated as follows:
(1) Separation of serum and storage until use at -70°C within 30 minutes.
(2) Storage of blood at room temperature for 24 hours, then separation and 
storage of serum at -70°C until use.
(3) Separation of serum within 30 minutes, storage of serum at room temperature 
for 24 hours, then storage at -70°C until use.
(4) Separation of serum within 30 minutes, storage at 4°C for 24 hours, then 
storage at -70°C until use.
(5) Separation of serum within 30 minutes, storage at 4°C for 1 week, then 
storage at -70°C until use.
(6 ) Storage of whole blood (clotted) at 4°C for 24 hours, then separation and 
storage of serum at -70°C until use.
6.2.9 Assay Precision 
Intra-assav Precision
Serum from a patient known to have an elevated serum HGF level was used. 
The serum was divided into aliquots and stored at -70°C until use. To assess 
intra-assay variation 10 aliquots were thawed and HGF level determined using the 
assay and treating each aliquot as an individual sample.
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Tgtgrassav Precision
In each of 10 assays standards of known human recombinant HGF 
concentration (3.125 ng/ml, 12.5 ng/ml and 25 ng/ml) were used to assess inter­
assay precision at low, medium and high levels respectively.
6.2.10 Collection of Sera
See pages 147,148. Venous blood from patients and volunteers was allowed 
to clot at room temperature and serum obtained by centrifugation. Serum was 
stored in aliquots at -70°C until use. Serum samples were obtained from 33  
healthy individuals (Median age 41 years, range 55) as a normal control group and 
from 11 patients (median age 58 years, range 36) following acute myocardial 
infarction as a disease group. Serum obtained from 221 patients (median age 55 
years, range 78) attending outpatient clinics and from inpatients with liver disease 
was used as a liver disease group (Table 6.2).
Statistical Analysis
Statistical analysis of results was carried out by Dr Gordon Murray and Mrs 
Jan Love, Robertson Centre for Biostatistics, University of Glasgow.
6.3 Results
6.3.1 Western Blotting
In Western blotting studies using monoclonal antibodies B25, B43 and A3.1.2- 
2 to HGF, these antibodies detected an 82kDa band in lanes containing non­
reduced recombinant human HGF. Similarly, the antibodies reacted specifically 
with an 82kDa band in a non-reduced preparation containing native human HGF 
purified from placenta (Figs 6.3, 6.4, 6.5). Antibody D9 did not detect human 
recombinant HGF on Western blotting studies but did detect an 82kDa band in a 
non-reduced preparation containing native human HGF purified from placenta
(Fig 6.6).
Monoclonal antibody A312-1 was not analysed by Western blotting in our 
laboratory but was characterised by Professor T Nakamura and shown to react
97
Table 6.2 Patients and controls used in study of serum HGF levels
Diagnosis Number of 
patients
Male Female
"Control: healthy volunteers 33 11 2 2
fnntrol: acute myocardial infarction 11 7 4
Acute alcohol induced liver injury 19 14 5
Chronic alcohol induced liver injury 43 25 18
Acute hepatitis (non alcoholic) 43 26 17
Chronic active hepatitis 2 0 6 14
Chronic intrahepatic cholestasis 18 5 13
Extrahepatic biliary obstruction 6 2 4
Metastatic carcinoma involving liver 
with primary neoplastic disease 
elsewhere. Includes gastric 
adenocarcinoma ( 1), metastatic 
adenocarcinoma of other 
gastrointestinal tract origin (2 ), 
small cell bronchial carcinoma (3) 
and unknown primary disease (3)
9 5 4
Hepatocellular carcinoma 4 4 0
Paracetamol overdose 5 5 0
Liver transplant recipients 7 1 6
Chronic hepatitis C 10 8 2
Other miscellaneous conditions 
(including transient derangement of 
liver function tests, cause unknown 
(7), fatty liver (4), congenital hepatic 
fibrosis (3), haemochromatosis (3), 
cryptogenic cirrhosis (4), mild 
alcoholic liver disease (2 ), nodular 
regenerative hyperplasia (2 ), drug 
induced transient liver damage (3), 
squamous cell carcinoma of lung 
with nonspecific reactive liver 
changes (2 ), polyarteritis nodosa ( 1), 
non caseating epithelioid 
granulomatous liver disease ( 1), 
symptomatic gallstones without 
jaundice (4), disseminated lymphoma
i i i _
37 2 0 17
Total 265 139 126
Figure 6.3 Western blotting of human recombinant HGF and human 
placental HGF using monoclonal antibody B25
SDS-PAGE using a 12% resolving gel and non reduced samples, probed with 
monoclonal antibody to HGF (B25, 1/5000).
Lane 1 human recombinant HGF (100 ng)
2 Molecular weight markers
3 human placental HGF (20 ng)
An 82 kDa band is visible in lanes 2 and 3 corresponding to HGF
kDa
116.0
96.4
80.4
55.7
43.7
38.8
1 2 3 Lane
Figure 6.4 Western blotting of human recombinant HGF and human
placental HGF using monoclonal antibody B43
SDS-PAGE using a 12% resolving gel and non reduced samples, probed with 
monoclonal antibody to HGF (B43, 1/5000).
Lane 1 Molecular weight markers
2 Human recombinant HGF (100 ng)
3 Human placental HGF (20 ng)
An 82 kDa band is visible in lanes 2 and 3 corresponding to HGF
2 . 3
Figure 6.6 Western blotting using monoclonal antibody D9, of eluted
fractions from a hydroxylapatite column containing maximal 
human placental HGF concentration as determined by ELISA
(c)
SDS-PAGE using a 7.5% resolving gel and non-reduced samples, probed with 
monoclonal antibody D9 culture supernatant (1/100).
Lane 1 { Fractions containing peak human placental HGF
2 { concentrations by ELISA
3 { Fractions containing no detectable human placental
4 { HGF
5 {
6 { Molecular weight markers
A band is seen in lanes 1 and 2 adjacent to the molecular weight marker 80.4 kDa, 
corresponding to human placental HGF.
kDa
1 2 3 4 5 6
116.0
96.4
80.4
Lane
with human recombinant HGF but not rat HGF or other growth factors (TGFa/B, 
EGF, plasmin, insulin, tPA, acidic or basic FGF).
Polyclonal antiserum Lot No 201 to human HGF detected an 82kDa band in 
lanes containing non-reduced human recombinant HGF or a non-reduced 
preparation containing native human HGF purified from placenta (Fig 6.7).
Monoclonal antibodies A3.1.2-2 and B25 and polyclonal antiserum Lot No 
201 to human HGF were tested for activity against human plasminogen. Neither 
of the monoclonal antibodies were shown to detect purified human Glu- 
plasminogen. Polyclonal antiserum Lot No 201 did demonstrate a 96kDa band, 
which approximates to the expected molecular weight of plasminogen (Fig 6.8).
6.3.2 Purification and Biotinylation of IgG from Whole Rabbit Serum 
Immunoglobulin IgG was successfully purified from whole rabbit serum and
biotinylated. Purified, biotinylated antibody retained function as illustrated by 
results of ELISA (a).
6.3.3 Assessment of Untreated Sheep Biotinylated Polyclonal Antibody (to 
Rabbit Immunoglobulins) for Cross Reactivity with Murine IgG 
antibody
Gross cross reaction was evident using the untreated biotinylated sheep anti­
rabbit immunoglobulins. The signal was still greater than 1.0 when the sheep 
antibody was used at 1:4000 dilution with avidin-HRP conjugate dilution of 
1/8000 (Table 6.3).
Cross reaction of sheep anti-rabbit immunoglobulins with murine 
immunoglobulin was dramatically reduced following removal of anti-murine IgG 
antibodies by Sepharose 4B-CD72 affinity chromatography. The signal was 
negligible when the sheep antibody was used at 1:4000, with avidin-HRP 
conjugate dilution of 1/8000 (compare with section preceding) (Table 6.4).
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Figure 6.7 Western blotting of human recombinant HGF and human
placental HGF using polyclonal anti-HGF serum Lot No. 201
SDS-PAGE using a 10% resolving gel and non-reduced samples, probed with 
rabbit polyclonal anti-HGF serum (Lot No. 201, 1/4000).
Lane 1 Molecular weight markers
2 Human placental HGF (20 ng)
3 Human recombinant HGF (100 ng)
A band of 82 kDa is visible in lanes 2 and 3 corresponding to HGF.
_____
Figure 6.8 Western blotting of human plasminogen using polyclonal anti- 
HGF serum Lot No. 201 and monoclonal antibodies B25 and 
A312-2
SDS-PAGE using a 12% resolving gel and non reduced samples.
Lane 1 Molecular weight markers
2 Human plasminogen (200ng) probed with polyclonal anti-HGF 
serum, Lot No. 201 (1/4000)
3 Human plasminogen (200 ng) probed with monoclonal antibody 
B25 (1/5000)
4 Human plasminogen probed with monoclonal antibody A3.1.2-2-
A band of approximately 96 kDa is visible in lane 2 corresponding to plasminogen 
monoclonal antibodies D25 and A 3.1.2-2 do not demonstrate any protein bands 
in lanes 3 and 4.
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6.3.4 ELISA (a)
Using ELISA (a) a strong signal was detected in human serum and it was 
possible to construct a standard curve using various dilutions of a reference serum 
sample from a healthy volunteer.
The biotinylated antibody became degraded before the assay could be tested 
using purified recombinant human HGF. By comparing signal detected using 
other sera, samples could be ranked in terms of "HGF" activity.
If the highest point (1/40 dilution) on the graph is designated as 100 units/ml, 
then whole neat reference serum = 4000 units/ml. Since test samples are applied 
at 1/500 reading these points off the graph gives their value for HGF in relation to 
the reference serum sample (Figure 6.9).
O.D. Units on 
Graph
Serum Level 
(units/ml)
Patient 1 0.547 13.8 6,900
2 0.950 76.0 38,000
3 0.586 16.3 8,150
4 0.496 11.2 5,600
5 0.538 13.3 6,650
6 0.631 19.8 9,400
7 0.533 13.1 6,550
8 0.552 14.1 7,050
9 0.573 15.5 7,750
10 0.472 10.0 5,000
11 0.460 9.6 4,800
12 1.066 Greater than 125 Greater than 62,000
6 3.5 ELISA (b)
ELISA (b) detected recombinant human HGF and a standard curve of signal 
intensity for various concentrations of recombinant human HGF could be drawn. 
Background was negligible - unfortunately insufficient supplies of monoclonal
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Figure 6.9 ELISA (a). Standard curve using various dilutions of a 
reference serum sample
The x-axis also shows assigned units, where dilution of reference serum 1/40 
100 units. The curve is linear in the range 100 units to 1.56 units.
Optical Density of Reaction
Units
1/40 1/80 1/160 1/320 1/640 1/1280 1/2560 1/5120 1/10240 1/20480
Dilution of Reference Serum
antibody A3.2.1-1 remained for the purposes of measuring serum levels to HGF 
(Fig 6.10).
6.3.6 ELISA (c)
ELISA (c) detected recombinant human HGF (Fig 6.11) but it did so weakly 
and inconsistently, leading to apparently very high levels of HGF in serum when 
using recombinant human HGF standard curves. In view of this, a reference 
serum sample was again used as a standard and standard curves drawn using the 
signal obtained with various dilutions of this sample (Fig 6.12). Sera from 
patients with liver disease were then assayed and using the standard curve, a value 
for HGF content was designated. The serum sample used to construct the 
standard curve was arbitrarily designated 1000 u/ml (Table 6.5).
The assay did not detect plasminogen at a concentration of lOgg/ml.
6.3.7 Levels of HGF in Serum Assayed by Otsuka Assay Laboratories 
ELISA and Comparison with Results Obtained using ELISA (c)
Serum HGF levels determined by Dr Kenji Fujiwara ranged from 0.15 to 1.15 
ng/ml. No relationship can be demonstrated between these and the results 
obtained using ELISA (c). In particular, a placental homogenate sample reacted 
strongly in Dr Fujiwara's assay while only faintly detected using ELISA (c).
(Table 6.6)
6.3.8 ELISA (d)
Using ELISA (d) one could detect human recombinant HGF with a sensitivity 
of 1.56 ng/ml. Good standard curves could be obtained using recombinant human 
HGF (Fig 6.13) and positive signal obtained in serum samples. When the assay 
specificity was analysed by testing for cross reaction with Glu-plasminogen at a 
concentration of 10ng/ml, monoclonal antibody B25 bound the plasminogen and 
gave a high optical density (0.700 compared to 0.000 for blank). If this optical 
density is read off a standard curve of recombinant HGF, the reaction corresponds 
to an HGF concentration of lOng/ml.
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Figure 6.10 ELISA (b). Standard curve using various concentrations of 
recombinant human HGF (ng/ml)
Optical Density of Reaction
0.8
0.6
0.4
0.2
0.250.58 14 2
Concentration of Recombinant Human HGF (ng/ml)
Figure 6.11 ELISA (c). Standard curve using various concentrations of 
recombinant human HGF) (ng/ml).
Optical Density of Reaction
0.7
0.6
0.5
0.4
0.3
0.2
100 12.5 6.25 3.125 1.56 0.7850 25
Concentration of Recombinant Human HGF (ng/ml)
Figure 6.12
Optical Density of Reaction
0.8
0.6
0.4
0.2
1/1920
Dilution of Reference Serum
Table 6.5 Serum HGF level determined using ELISA (c) and a reference 
serum sample
Sera from healthy controls and from patients with various liver diseases were 
compared to the reference serum
Patient Initials Diagnosis Serum HGF (units/ml) 
reference serum = 1000 
units/ml
1 DL Acute hepatitis (recovery), 
cause unknown
2699
2 DG Chronic alcoholic liver 
disease
3733
3 JA Normal 2.3
4 RJ Paracetamol overdose 750
5 EO Gallstones - common bile 
duct obstruction
1100
6 MP Chronic renal failure 1291
7 AD Primary biliary cirrhosis 817
8 MD Cryptogenic cirrhosis and 
gallstones
667
9 AH Cryptogenic cirrhosis 12,500
10 LG Chronic alcoholic liver 
disease
42
11 NA Normal 533
12 AG Recovery from alcoholic liver 
disease
98
13 DP Normal 30
14 JM Alcoholic hepatitis 1333
15 JG Gallstones, common bile duct 
obstruction
883
16 AT Haemochromatosis 3333
17 MP Chronic renal failure 1375
18 AN Normal 766
19 JS Acute hepatitis A 57
20 JN Fatty liver 633
21 RC Not known 308
Table 6.6 Comparison of HGF content of sera/placental homogenate 
determined by ELISA (c) and by Dr. Kenji Fujiwara using 
Otsuka Assay Laboratories ELISA
No relationship can be shown between the results obtained using ELISA (c) and 
the Otsuka Assay Laboratories ELISA
Patient Initials HGF content ng/ml 
K. Fujiwara Assay
HGF content, 
standard units, 
in assay (c)
1 DL 0.49 2699
2 DG 0.18 3733
3 JA 0.38 23
4 RJ 0.51 750
5 EO 0.14 1100
6 MP 0.82 1291
7 AD 0.32 817
8 MD 0.47 667
9 AH 0.58 12,500
10 LG 0.47 42
11 MA 0.23 533
12 AG 0.24 98
13 PP 0.27 30
14 JM 0.29 1333
15 JG 0.32 883
16 AT 1.15 3333
17 MP 1.05 1375
18 AN 0.17 766
19 JS 0.33 57
20 JN 0.48 633
21 RC 0.50 308
22 Placental homogenate >10 53
Figure 6.13 ELISA (d). Standard curve using various concentrations of 
recombinant human HGF (ng/ml)
Optical Density of Reaction
0.5
100 12.5 6.25 3.125 1.56 0.7850 25
Concentration of Recombinant Human HGF (ng/ml)
6.3.9 ELISA (e)
Using ELISA (e) human recombinant HGF could be detected with a sensitivity 
of 6.25 ng/ml (Fig 6.14). The assay did not cross react with plasminogen in that 
no signal was detected using 10pg/ml plasminogen. The assay did not however 
detect HGF in human serum samples.
6.3.10 ELISA (f)
With ELISA (f) one could detect as little as 1.56ng/ml of human recombinant 
HGF. A typical standard curve of purified recombinant HGF is illustrated in 
Figure 6.15. The curve was linear in the range 1 56-25ng/ml hrHGF.
6.3.11 ELISA (f) - Analysis of Assay for Cross Reaction with Plasminogen 
When applied at a concentration of lOpg/ml, Glu-plasminogen gave a signal of
optical density of 0.126 (compared to blank, 0.000). This value is below the 
sensitivity of the HGF standard curve and would be considered undetectable.
I further investigated the possibility of a cross reaction between HGF and 
plasminogen in ELISA (f) by comparing levels of HGF and plasminogen in 10 
serum samples. Using a functional and an immunological method for 
measurement of plasminogen, levels were correlated with those obtained for HGF 
(Table 6.7). No significant correlation was observed between HGF and either 
functional or immunological levels of plasminogen using Spearman's rank 
correlation test.
6.3.12 Stability of HGF in Serum
The stability of HGF was assessed in serum from a reference patient with acute 
viral hepatitis. Samples were collected and stored as previously described. HGF 
level was measured by ELISA (f) and Table 6.8 illustrates the results obtained, 
kittle variation was observed in the results obtained using serum collected under 
conditions 1, 4 and 5. Conditions 2 and 3 however, which involve storage at 
room temperature for 24 hours, represent a significant change. Condition 1, 
separation of serum within 30 minutes of venepuncture and storage at -70°C, is 
regarded as the optimal method for preservation of serum proteins.
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Figure 6.14 ELISA (e). Standard curve using various concentrations of 
recombinant human HGF (ng/ml)
Optical Density of Reaction
0.5
100 6.2512.550 25
Concentration of Recombinant Human HGF (ng/ml)
Figure 6.15 ELISA (f). Standard curve using various concentrations of 
recombinant human HGF (ng/ml)
Optical Density of Reaction
0.5
50 1.563.1256.2525 12.5
Concentration of Recombinant Human HGF (ng/ml)
Table 6.7 Comparison of serum levels of plasminogen and HGF 
(determined by ELISA (f))
Sample No. Functional Plasminogen 
Assay (% of normal activity)
Immunological 
Plasminogen Assav
HGF
(ng/ml)
1 80 0.1 <8
2 100 0.125 <8
3 103 0.148 9
4 92 0.136 <8
5 102 0.142 <8
6 105 0.142 <8
7 11 0.029 100
8 109 0.156 21
9 74 0.096 176
10 72 0.096 < 8
No correlation was observed between HGF and plasminogen levels using 
Spearman’s Rank Correlation Test
Table 6.8 Stability of HGF in Serum
[Condition 0 ) (2, (3) (4) (5) (6)
Serum HGF (ng/ml) 9.6 14.8 13.2 9.8 11.2 10.4
Serum was stored under the following conditions and HGF level determined using
ELISA (f)
Conditions
(1) Separation o f  serum and storage until use at -70°C within 30 minutes
(2) Storage of blood at room temperature for 24 hours, then separation and 
storage of serum at -70°C until use
(3) Separation of serum within 30 minutes, storage at room temperature for 
24 hours, then storage at -70°C until use
(4) Separation of serum within 30 minutes, storage at 4°C for 24 hours, then 
Storage at -70°C until use
(5) Separation of serum within 30 minutes, storage at 4°C for 1 week, then 
storage at -70°C until use
(6) Storage of whole blood (clotted) at 4°C for 24 hours, then separation and 
storage of serum at -70°C until use
HGF level was significantly greater in serum stored under conditions (2) and (3)
6.3.13 Assay Precision
frlff-assav precision using ELISA (f)
The results obtained using ELISA (f) and 10 aliquots of a known serum 
sample assayed during one run of the ELISA are shown in table 6.9.
The intra-assay coefficient of variation was 4.85% (mean value 108.85ng/ml, 
range 12ng/ml).
Tnterassav Precision using ELISA (f)
The results obtained using standards of known human recombinant HGF 
concentration at low (3.125ng/ml), medium (12.5ng/ml) and high (25ng/ml) levels 
in 10 assays were as shown in table 6.10.
The interassay coefficient of variation at low (3.125ng/ml), medium 
(12.5ng/ml) and high (25ng/ml) HGF levels were 8.2% (mean value 3.2ng/ml, 
range 0.7ng/ml), 9.7% (mean value 13.3ng/ml, range 4.5ng/ml) and 10.0% (mean 
value 24.7ng/ml, range 9.0ng/ml) respectively.
The sensitivity of the assay was 2ng/ml and the maximum serum concentration 
was 1/4, thus the minimum detectable concentration of HGF in serum was 8ng/ml.
6.3.14 Measurement of Serum HGF Levels in Health and Disease using 
ELISA (f)
Thirty-three healthy controls were assayed for HGF by ELISA (f), only two 
had detectable levels of HGF. A group of patients with a diagnosis of acute myo- 
ardial infarction (n = 11) were used as a disease control group and none had 
detectable levels of HGF. Figure 6.16. As only two normals had detectable levels 
normal levels could not be constructed against which patients could be compared. 
However, when the healthy control group was compared with groups of patients 
with various liver diseases, significant differences in HGF serum level were found 
ln a number of cases. Serum HGF concentration was statistically significantly
102
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Table 6.10 Interassay precision using ELISA (f)
—------- ng/ml ng/ml ng/ml
standard 3.125 12.5 25
a wav Number 1 3.125 13.5 25
------ L 2 3.7 12.5 24
3 3.0 12.5 26
' 4 3.125 16.5 27
5 3.125 12.5 25
6 3.1 12.5 26
7 3.0 13.5 18
8 3.125 13.5 25
9 3.7 12.0 25.5
10 3.1 13.8 25
Results obtained using standard of known human recombinant HGF at low, 
medium and high levels in 10 runs of ELISA (f)
Figure 6.16 Serum Level of HGF in Liver Disease and Controls
This figure illustrates the range of HGF levels in controls and patients with 
various liver diseases
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higher in patients with acute alcohol induced liver disease (n=19, pcO.OOT)*, 
chronic alcohol induced liver disease (n=43, p=<0.001+), acute (non-alcoholic) 
hepatitis (n=43, p=<0.001+), chronic intrahepatic cholestasis (n=18, p<0.01+). In 
contrast, there was no difference in serum HGF level between healthy controls 
and patients with chronic hepatitis (n=20, p=0.19++) extrahepatic biliary 
obstruction (n=6, p=0.46+), metastatic liver disease (n=9, p=0.68++), paracetamol 
overdose (u=5i p=0.31++)) or chronic hepatitis C (n=10, p=0.65++) (Figure 6.16). 
When serum HGF level was compared to a number of clinical indices of liver 
disease, several of these demonstrated a relationship with elevated levels of HGF. 
Patients with increased serum levels of HGF were found to have higher levels of 
AST (p=<0.001°), ALT (p=0.002°) and alkaline phosphatase (p=0.0002°) than 
those with undetectable levels. Similarly, raised serum HGF levels were 
associated with prolonged prothrombin time (P=<0.0001°) reduced haemoglobin 
concentration (p=0.0062°), albumin concentration (p=<0.0001°) and platelet 
count (p=0.027°).
A greater proportion of patients with increased serum HGF level had jaundice 
(p=<0.001°), encephalopathy (p=0.0015*), hepatomegaly (p=0.045+) or ascites 
(p=<0.01°), than those with an undetectable HGF level.
No relationship was present between HGF level and clinically evident hepatic 
inflammation (tenderness on examination), serum gamma glutamyl transferase, 
urea, creatinine or white cell count. Table 6.11 
6 4 Discussion
This work has addressed the development of a specific and sensitive ELISA to
* + = V2 ++ _
A -  Fisher’s exact test ° = Mann-Whitney * = 2-tailed Fisher’s exact test
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measure serum levels of HGF. ELISA has been established as a powerful tool in 
the investigation of biological systems, allowing specific detection of proteins and 
their measurement within complex mixtures such as serum. However, major 
problems are often encountered in the development of such assays in ensuring 
assay specificity and sensitivity.
HGF is a potent growth factor, and to date work has mainly been concentrated 
on its hepatocyte mitogenic activity, however, the descriptions of raised levels of 
HGF in a number of liver disease types including fulminant hepatic failure, acute 
hepatitis, liver cirrhosis and hepatocellular carcinoma (119,122) have raised 
interest in its use in the assessment of liver disease. To this end a sensitive and 
specific ELISA was developed for HGF. Both monoclonal and polyclonal 
antibodies were evaluated for use in the ELISA.
All of the antibodies assessed for possible use in ELISA were analysed by 
Western blotting studies in order to confirm activity against HGF and to 
investigate activity against the related protein plasminogen. (Monoclonal 
antibody A312-1 was characterised by Professor T. Nakamura and shown to react 
with recombinant HGF but not with rat HGF or other growth factors or plasmin). 
All of the tested antibodies which had been raised against recombinant human 
HGF (A312-2, B25, B43 and polyclonal antiserum Lot No 201), detected an 
82 kDa band in non reduced samples of human recombinant HGF or purified 
native human placental HGF. Monoclonal antibody D9 which had been raised 
against a synthetic 11-amino acid peptide based on rat a-chain did not detect 
recombinant human HGF in Western blotting, but did detect an 82 kDa band in 
non reduced native human placental HGF. These results suggest that antibodies
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A3 12-2, B25, B43 and polyclonal serum Lot No 201 are capable of detecting 
both native and recombinant forms of full length, non reduced HGF. Monoclonal 
antibody D9 however seems capable of detecting native placental HGF, but not 
recombinant human HGF, a finding which has implications for the use of 
recombinant HGF in an assay based on this antibody. This point is significant, 
since it would not be possible to calibrate an ELISA based on this antibody using 
recombinant HGF.
When antibodies A312-2, B25 and polyclonal antiserum Lot No 201 to human 
recombinant HGF were assessed for activity against plasminogen by Western 
blotting, only the polyclonal antiserum demonstrated a band of approximately the 
expected weight of plasminogen. These results suggest specificity of A312-2 and 
B25 for human HGF, native or recombinant and cross reactivity of polyclonal 
antiserum Lot No 201 for human plasminogen. Although ideally one would hope 
for no antibody cross-reaction with proteins other than target protein, the ELISA 
developed utilises a sandwich technique in which the first, monoclonal, antibody 
layer confers specificity to the assay, allowing the use of secondary antibody 
which may have some cross reacting features. The use of secondary polyclonal 
antibody helps to amplify the assay signal. In assays (b), (c), (d), (e) and (f) this 
principle is taken a step further with the addition of a third, biotinylated, 
polyclonal antibody which is used to detect the secondary antibody. This anti­
body is detected by means of avidin peroxidase conjugates with the application of 
orthophenylene diamine substrate which produces an orange/brown signal in the 
presence of peroxidase. The adverse effect of the use of additional antibody 
layers is the problem of cross reaction with protein in the assay other than the
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target protein. In these studies biotinylated polyclonal sheep anti-rabbit 
immunoglobulin was used and found to strongly cross react with murine IgG 
monoclonal antibody. The cross reacting anti-mouse immunoglobulin activity was 
successfully removed by affinity chromatography using murine monoclonal IgG 
antibody bound to CNBr-activated Sepharose 4B; a dramatic reduction in 
background signal was achieved.
Several assays, using different antibody combinations, were used to develop 
the most sensitive and specific ELISA for the measurement of serum HGF.
ELISA la): Although ELISA (a) was capable of developing a strong signal using 
human serum degradation of the purified biotinylated rabbit anti-HGF 
immunoglobulin prevented calibration of the assay and measurement of serum 
HGF levels. The antibody instability may be related to the purification and 
biotinylation of the polyclonal anti-HGF antibody. It is of interest that the few 
sera with the greatest activity as detected by ELISA (a) were also found to react 
strongly in ELISA (f) (greater than 62,000 units and 38,000 units in ELISA (a); 
124 ng/ml and 11 ng/ml respectively, in ELISA (f)).
ELISA (b): The standard curve of recombinant human HGF illustrates that the 
assay could detect HGF. Unfortunately insufficient monoclonal antibody was 
available to measure serum levels of HGF. The process of establishing the assay 
and reagent conditions involved consumption of considerable antibody stock. 
ELISAjcl; this assay involved monoclonal antibody D9 which on Western 
blotting studies demonstrated an 82 kDa band in a non reduced preparation of 
native human placental HGF, but did not detect human recombinant HGF. 
Although the assay could detect recombinant human HGF it did so weakly and
inconsistently. The use of recombinant human HGF standards with the ELISA 
led to apparently very high levels of HGF in serum. It was believed that the 
problem involved differences in recognition of native and recombinant human 
HGF by monoclonal antibody D9, a view supported by the Western blotting 
studies. In an attempt to overcome this difficulty serum from a patient with acute 
hepatitis which reacted strongly in the assay (ELISA (c)) was used as a reference 
and arbitrarily designated as containing 1000 units per millilitre of serum. Other 
sera were defined in terms of these units by comparing their reaction in ELISA (c) 
and that of the reference serum. A range of levels was obtained (Table 6.5). The 
highest level was seen in a patient with cryptogenic cirrhosis with end stage liver 
disease who was later to be considered for liver transplant surgery. Liver biopsy 
from this patient demonstrated established macronodular cirrhosis. Serum 
obtained from another patient, who had recently sustained minor hepatic injury 
following paracetamol overdose was found to have a modest level of HGF. Such 
findings required confirmation, in particular the assay required to be calibrated 
against purified HGF. I sought to achieve this by sending a number of serum 
samples to Dr. Kenji Fujiwara, of the University of Tokyo (Dr. Kenji Fujiwara et 
al reported measurement of serum HGF levels using an ELISA kit undergoing 
development by Otsuka Assay Laboratories, Tokushima, Japan (172)).
It was hoped that if the HGF content of the reference serum and a number of 
patient s sera could be determined, one might derive HGF levels for the other 
tested samples. No relationship could be demonstrated between results obtained 
using ELISA (c) and those produced by Dr. Fujiwara. While this finding was 
considered significant, a more important difference was found in the result
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obtained using human placental homogenate, which is used as a starting material 
for the purification of HGF as described in Chapter 4. The material was strongly 
positive in Dr. Fujiwara’s assay, while only weakly detected in ELISA (c). In 
view of this fact, together with the poor sensitivity of ELISA (c) for human 
recombinant HGF and the inability of the monoclonal antibody D9 to detect 
recombinant human HGF on Western blotting analysis, ELISA (c) was deemed 
unsuitable for precise quantitative assessment of HGF levels in serum.
FITS A Id): The assay developed using monoclonal antibody B25 illustrates the 
difficulty in achieving specificity in an ELISA even when the assay is based on a 
monoclonal antibody. This assay demonstrates cross reaction with plasminogen, 
the plasma protein bearing closest resemblance to HGF (amino acid sequence 
homology of 37%). It is also important to note that the cross reactivity was not 
evident on Western blotting studies using B25 and purified native human Glu- 
plasminogen. The degree of cross reaction was such that the assay could not be 
used to measure serum HGF levels.
ELISA (eV This assay was also unsuitable for measurement of HGF levels. 
Although no cross reaction was evident with plasminogen and suitable standard 
curves could be drawn using human recombinant HGF, the assay failed to 
produce a signal when serum samples or native human placental HGF were tested. 
An explanation for this finding may be that subtle differences in structure between 
native and recombinant human HGF prevent recognition of the former by 
monoclonal antibody B43.
This assay which is based on monoclonal antibody A312-2 has been 
shown to detect both native and recombinant human HGF. Clearly one major aim
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in the development of an ELISA for HGF was the achievement of a sufficient 
degree of sensitivity. Previously reported levels of HGF are very low with 
quoted values comparable to those observed for the interleukins (119,122), hence 
a high level of sensitivity in the ELISA was required. The use of a sandwich 
assay with an additional layer of polyclonal antibody and an avidin/biotin 
peroxidase detection system greatly enhanced the assay sensitivity. The detection 
limit was 0.2 ng of HGF per well, taking into account the serum dilution used for 
the assay this is equivalent to 8 ng/ml.
Another important factor when establishing a new ELISA is confirmation of 
assay specificity. As has been described, cross reaction with structurally similar 
proteins may occur in an ELISA. No significant cross reaction was seen in assay 
(f) with purified native human Glu-plasminogen at 10 pg/ml. The inability of the 
assay to detect plasminogen was confirmed by a lack of correlation between HGF 
levels as measured in the assay and plasminogen levels as measured by 
conventional biochemical techniques (Table 6.7).
We sought to determine whether the conditions under which serum is collected 
and stored would affect the value for HGF concentration in serum using the 
ELISA. Table 6.8 illustrates that some storage dependent variation does occur. 
Condition (1) in which serum was separated and frozen within 30 minutes was the 
optimal method for preservation of serum proteins. There was little difference 
between the figure for HGF concentration under this condition and that produced 
when serum was separated and stored at 4°C before freezing or where whole 
lood was allowed to clot and stored at 4° prior to separation and freezing. The 
SUlts *n Table 6.8 suggest that under storage at room temperature serum
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undergoes changes that result in detection of increased levels of HGF. Possible 
reasons for this include alteration in molecular structure, such that more epitopes 
are readily detected by antibodies in the ELISA. In view of these findings, only 
sera which had been collected under the following conditions were used when 
comparing HGF serum levels in patients with liver disease and controls:
(1) Separation of serum and storage until use at -70°C, within 30 minutes of 
venepuncture. (2) Separation of serum within 30 minutes, storage at 4°C for 24 
hours then storage at -70°C until use. (3) Storage of blood at 4°C for 24 hours 
then separation and storage of serum at -70°C until use.
Under these conditions, the assay had an intra-assay coefficient of variation of 
4.85% and inter-assay coefficients of variation at low (3.125 ng/ml), medium 
(12.5 ng/ml) and high (25 ng/ml) levels of human recombinant HGF of 8.2%,
9.7% and 10.0% respectively. These figures are consistent with a high degree of 
intra- and interassay precision and fall within acceptable limits for assay 
performance (173). In view of the results of testing for assay specificity, 
sensitivity and precision, I believe there was sufficient evidence to conclude that 
ELISA (f) is capable of reliably detecting HGF in human serum. I did not, 
therefore, seek to compare serum HGF levels obtained by Dr Kenji Fujiwara with 
figures obtained using ELISA (f).
Three groups of serum samples were studied to establish whether serum levels 
of HGF as measured by ELISA have potential clinical value. Thirty three normal 
mdividuals (median age 41 years, range 55) were used as a negative control 
Sroup. Only two normal individuals had detectable HGF levels, and these 
observed levels were low. A patient group in whom no liver damage was
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anticipated; patients recovering from uncomplicated myocardial infarction (n=l 1, 
median age 58 years, range 3 6 ) had no detectable HGF levels. However, 
comparison of serum HGF levels in normals and in patients with a variety of liver 
iseases (n=221, median age 55 years, range 7 8 )  demonstrates an increased HGF 
serum level in patients with liver damage and in particular disease states where 
onsiderable hepatic regeneration would be predicted.
A number of groups of patients with liver disease were observed to have 
significantly higher levels of serum HGF than controls viz. acute (p=<0.001) and 
chronic (p=<0.001) alcohol induced liver disease, acute (non-alcoholic) hepatitis 
(p=<0.001) and chronic intrahepatic cholestasis (p=<0.01). Other groups of 
atients were identified which did not have significantly increased levels of HGF. 
These include patients with chronic hepatitis, extrahepatic biliary obstruction, 
metastatic liver disease, paracetamol overdose and chronic hepatitis C. Our 
findings are similar to those previously reported by other groups, although there 
are a number of differences (119,122,172,174). All of these reports describe low
serum HGF levels in controls, with raised levels in various groups of patients with 
liver disease. Tsubouchi et al (119) noted HGF levels in serum from patients with
r ^ sease- Hioki et al (122) recorded high levels of serum HGF in patients
; fulminant hepatitis, acute hepatitis, chronic hepatitis and cirrhosis to be higher 
than controls. However, only the increase in serum HGF of patients with 
fulminant hepatitis and acute hepatitis was statistically significant. Tomiya et al 
(172) found raised levels of HGF in nineteen percent of 112 patients with chronic
vith acute hepatitis, fulminant hepatitis, liver cirrhosis and hepatocellular 
arcinoma. Our findings differ in that HGF levels were not increased in chronic
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hepatitis or hepatocellular carcinoma. We did not find increased HGF levels in 
patients following paracetamol overdose. Possible reasons for these findings may 
include differences in population groups and perhaps differences in disease 
aetiology e.g. chronic alcohol excess and viral hepatitis. In addition several of the 
groups described involve small patient numbers. All of the patients in the small 
group in whom we measured HGF level following paracetamol overdose made a 
rapid recovery. None experienced major hepatic injury. Shiota et al (174) have 
recently reported similar results following measurement of serum HGF in patients 
with liver disease using an immunoradio-metric assay (IRMA). However, their 
results differ from those described here in that they found increased serum levels 
of HGF in patients with chronic hepatitis and hepatocellular carcinoma. These 
groups describe lower figures for HGF in serum than those reported here.
Reasons for such differences may be related to the mechanism of HGF detection 
with antibodies detecting different epitopes upon the HGF molecule. Thus, it is 
difficult to compare exact values obtained with different assays.
Serum HGF may be elevated as a result of increased production (80) or 
reduced clearance. The liver is the major organ for clearance of exogenously 
administered HGF (175,176,177) and clearance of HGF decreases in rats 
following carbon tetrachloride induced liver injury (176) or partial hepatectomy 
(178). Tsubouchi et al have suggested that serum HGF may be useful in 
predicting outcome in patients with fulminant hepatic failure (120).
It has also been suggested that HGF serum level may be an index of the 
severity of liver disease (122,172,174). These reports have also proposed that 
HGF e^ve s^ may be related to conventional indices of liver disease. We have
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found that patients with increased serum levels of HGF were likely to have higher 
levels of AST, ALT and alkaline phosphatase. Raised serum HGF levels were 
also associated with prolonged prothrombin time, reduced haemoglobin 
concentration, albumin concentration and platelet count. A greater proportion of 
patients with increased HGF levels had jaundice, encephalopathy, hepatomegaly 
or ascites. These findings would be consistent with the suggestion that increased 
HGF levels are to be found in patients with more advanced liver disease. As 
discussed above, mechanisms for this increase in HGF level may include increased 
production in an attempt to repair the hepatic damage or reduced clearance by the 
injured liver.
This study has highlighted some of the difficulties encountered in the 
development of an ELISA for measurement of minute quantities of target material 
in complex biological fluids such as serum. The work has also extended the 
variety of liver diseases in which serum HGF has been measured and reinforces 
the concept that HGF is related to severity of liver disease and may be useful as an 
index of degree of hepatic dysfunction.
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CHAPTER 7. Expression of Hepatocyte Growth Factor and Hepatocyte 
Growth Factor mRNA in Human Liver Biopsies
■INTRODUCTION
7 1 Immunocytochemistry and in situ Hybridisation for HGF and HGF 
mRNA
HGF has been localised in non-parenchymal liver cells immunocytochemically 
in man and rats (93) and its mRNA detected by in situ hybridisation in normal rats 
158) and following hepatic injury (81). In order to examine the role of HGF in 
human liver disease I sought to investigate whether changes in expression of HGF 
iiRNA and its protein product in the liver could be related to disease type or 
J;verity. All available antibodies to HGF, except A3.1.2-1, were assessed for 
■jitability in immunocytochemistry for HGF using a variety of techniques 
■eluding indirect alkaline phosphatase, indirect immunoperoxidase and alkaline 
Siosphatase-anti-alkaline phosphatase (APAAP), in fresh frozen and formalin 
ed paraffin embedded tissue.
To examine the expression of HGF mRNA non-isotopic in situ hybridisation 
ftchniques have been employed. Initially a digoxigenin labelled riboprobe based 
on rat HGF was assessed in view of sequence homology of greater than 90% 
between rat and human HGF. In addition a human specific digoxigenin labelled 
oprobe was synthesised and tested.
12 Immunocytochemistry - Localisation of HGF in Human Liver Tissue
Materials - see page 141
Methods
12.1 Frozen Tissue
Sections of 5 pm thickness were cut from blocks, placed on poly-L-lysine 
coated slides and allowed to dry for 1 hour at room temperature. Sections were 
then fixed in acetone for 10 minutes and allowed to air dry.
A solution of Tris buffered saline, containing 20% (volume/volume) normal 
s^ine serum, was applied for 10 minutes to reduce non-specific binding of 
Hitibody. Primary antibody was then applied.
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.2.2 Paraffin Section
Liver biopsies were fixed in 10% buffered formalin and processed for paraffin 
inbedding. Sections of 3 pm thickness were cut onto poly-L-lysine coated slides 
Hid dried for 1 hour at 60°C. Sections were dewaxed in xylene for 10 minutes, 
washed with three changes in absolute alcohol, followed by two washes in 
methanol. After being rinsed in methanol the sections were hydrated in distilled 
Jrater. In some experiments sections were trypsinised (Tris buffered saline 
Containing 0.1% weight/volume and 0.1% calcium chloride) for 10 minutes.
Slides were then washed in phosphate buffered saline and 'blocked' by addition of 
phosphate buffered saline containing 20% (volume/volume) normal swine serum 
ftr 10 minutes.
2.3 Indirect Alkaline Phosphatase Detection Method 
This method was used with each of the available antibodies. Various dilutions 
o antibody were used, starting from a minimum of 1 in 5. Each antibody was 
il cubated for both 1 hour at room temperature and overnight at 4°C. Monoclonal 
antibodies were diluted in phosphate buffered saline containing 2% (weight/ 
I)lume) bovine serum albumin (2% BSA/PBS) and polyclonal antibodies in 
phosphate buffered saline containing 4% (volume/volume) normal swine serum 
|J% NSS/PBS). Sections were washed 3 x 1 0  minutes in phosphate buffered 
line and secondary antibody applied (alkaline phosphatase conjugated rabbit 
ti-mouse immunoglobulins diluted 1:25 in 2% BS A/PBS or alkaline 
phosphatase conjugated swine antibody to rabbit immunoglobulins diluted 1:75 in 
4/o NSS/PBS). After incubation for 1 hour at room temperature sections were 
washed 3x 1 0  minutes in phosphate buffered saline and exposed to substrate 
(NBT/BCIP or fast red, Appendix 3) for 5-10 minutes. Sections were mounted 
under glycerol gelatin and examined under the light microscope.
7 2.4 Alkaline Phosphatase Anti-Alkaline Phosphatase Detection Method 
(APAAP)
This method was used with monoclonal antibodies.
Secondary antibodies: rabbit anti-mouse immunoglobulins diluted 1:30 in 2%
BSA/PBS was applied to sections and incubated for 1 hour at room temperature.
Sections washed 3 x 1 0  minutes with phosphate buffered saline and murine
monoclonal alkaline phosphatase-anti-alkaline phosphatase complexes, diluted
1:50 in 2% BSA/PBS, added. After incubation for 1 hour at room temperature,
slides were washed 3 x 1 0  minutes with phosphate buffered saline and exposed to
substrate, mounted and examined as described above in the Indirect Alkaline
Phosphatase Detection Method.
7.2.5 Indirect Immunoperoxidase Detection Method
This technique was used with all polyclonal antibodies. Each primary 
antibody, diluted in phosphate buffered saline containing 20% (volume/volume) 
normal swine serum, was incubated for both 1 hour at room temperature and 
overnight at 4°C. Various dilutions of antibody were used, starting from a 
minimum of 1:5.
Sections were washed 3 x 1 0  minutes in phosphate buffered saline and 
secondary antibody applied; peroxidase conjugated swine anti-rabbit 
immunoglobulin, diluted 1:50 in 4% NSS/PBS. After incubation for 1 hour at 
room temperature slides were washed 3 x 1 0  minutes in phosphate buffered 
saline.
Signal was developed by incubation of sections in 3' diamino-benzidine 
tetrachloride (DAB) solution. DAB is converted by peroxidase to an insoluble 
brown precipitate. The slides were washed in water and counterstained with
haematoxylin, dehydrated through graded alcohols, cleared in xylene and mounted 
with Hystomount.
7.2.6 Preparation of Polymorphonuclear Leucocyte (Polymorph) Neutrophil 
Proteins
Venous blood (20ml) was taken from a healthy volunteer into a heparinised 
tube. A volume of 5ml of this blood was layered on top of 3 .5ml “Polymorph 
prep” (Nycomed A S. (UK) Ltd, Birmingham, UK) and centrifuged at 500g for 
15 minutes. This step leads to separation into layers of plasma, monocytes, 
polymorphs and erythrocytes. The layer containing neutrophil polymorphs was 
removed and mixed with an equal volume of 0.45% NaCl and 0.9% NaCl added 
to bring the volume up to 15ml. This preparation was then centrifuged at 400g 
for 10 minutes. The pelleted cells were resuspended and made up to 15ml volume 
with PBS and centrifuged for a further 10 minutes at 400g. The pellet was re­
suspended and mixed with 0.5ml d t^ O  until red cells lysed. Double concentrate 
PBS (0.5ml) was added and volume made up to 15ml with PBS. The sample was 
centrifuged again at 400g for 10 minutes. The cellular pellet was resuspended in a 
total volume l-2ml of PBS and cells sonicated for 10 seconds to disrupt the cells 
and solubilise the cellular proteins (Branson Sonifier 250, Dane Ultrasonics,
Hayes, Middlesex, UK).
7.2.7 Western Blotting of Polymorph Proteins
Non-reduced samples of polymorph neutrophil cell lysate, (8.8 pg/lane) 
recombinant human HGF (each 200ng/lane) and purified native human placental 
HGF (20ng/lane) were subjected to SDS-PAGE on a 10% gel and blotted onto 
PVDF membrane as described in chapters 2 and 3. Following transfer, 
membranes were "blocked" by incubation with phosphate buffered saline 
containing 3% (weight/volume) bovine serum albumin and probed with:
a) Pre-immune serum from rabbit 1699, diluted 1/1000
b) Immune serum from rabbit 1699, diluted 1/1000
c) Rabbit anti-HGF serum, Lot No. 201 diluted 1/4000
d) Mouse monoclonal antibody to human recombinant HGF, B25, diluted 
1/5000
These primary antibodies were detected using alkaline phosphatase conjugated 
swine anti-rabbit immunoglobulins or alkaline phosphatase conjugated rabbit anti­
mouse immunoglobulins and NBT/BCIP (Western blotting as described in 
Chapter 4).
7.2.8 Absorbance of Antibody with Antigen
Rabbit antiserum 1699 was diluted to 1/400 in Tris buffered saline and 400pl 
incubated with either 5.75|ig of polymorph proteins or 20 pg of recombinant 
human HGF (Genentech) at room temperature overnight.
Immunocytochemistry using the antiserum was then performed as described 
above using the indirect immunoperoxidase detection method.
7.3 Results
7.3.1 HGF Immunocytochemistry
The following antibodies failed to demonstrate HGF in frozen human liver 
biopsies.
Monoclonal: A321-2
B25
B43
D9
Polyclonal: Lot No 201
640/641 (rabbit antisera to HGF4, as described in section 4.
Polyclonal rabbit antiserum 38986 failed to demonstrate HGF in frozen rat 
liver following carbon tetrachloride administration.
Polyclonal rabbit antiserum 1699 localised polymorph neutrophil leucocytes 
and some non-parenchymal cells in fresh frozen and formalin fixed, paraffin 
embedded tissues with no staining of parenchymal cells (Figure 7.1). No staining 
Was evident using preimmune serum.
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Figure 7.1 Human liver from a patient with clinical evidence of chronic 
alcohol induced liver disease stained with polyclonal rabbit 
antiserum 1699
Primary antibody used at a dilution of 1/400. Secondary antibody; Peroxidase 
conjugated affinity purified swine anti-rabbit immunoglobulins. Substrate; 
diaminobenzidine tetrachloride (DAB) solution. Haematoxylin counterstain 
Polymorph neutrophil leucocytes are positively stained as shown.

When antiserum which had been preabsorbed with polymorph proteins was 
used, virtually all cellular staining was abolished (Figure 7.2). Incubation of 
antiserum with bovine serum albumin (as a control) did not affect staining (Figure 
7.3). Preabsorption of antiserum with human recombinant HGF similarly did not 
affect staining (Figure 7.4).
7.3.2 Western Blotting of Polymorph Proteins
Immune serum, but not pre-immune serum, from rabbit 1699 detected several 
protein bands in the polymorph neutrophil lysate and detected human recombinant 
and native human placental HGF. Polyclonal antiserum Lot No. 201 and 
monoclonal antibody B25 both detected human recombinant HGF, but failed to 
detect any protein band in polymorph neutrophil lysate (Figure 7.5).
7.4 Discussion
Immunolocalisation of HGF in tissue sections has proved difficult to achieve. 
Although some work has been published on this subject, differing results have 
been obtained by independent groups. Wolf et al (93) reported localisation of 
HGF in a wide variety of human and rat tissues. In human liver bile duct 
epithelium and endothelial cells of central veins and portal vessels, moderate 
staining for HGF was obtained. Sakaguchi et al (178) found HGF staining in 
polymorphonuclear leucocytes and biliary epithelial cells but not in the endothelial 
cells of hepatic or portal veins. In this study, none of the antibodies that detected 
human recombinant HGF in Western blotting or ELISA demonstrated HGF 
immunohistochemically.
Fresh frozen tissue was used in an attempt to avoid some of the known 
difficulties associated with immunocytochemistry in fixed tissues. Fixation alters 
tissue antigenicity by, for example, crosslinking proteins. Although important for 
morphological preservation, crosslinking may reduce the availability of antigen 
within tissue; epitopes may be denatured, antigen conformation altered or 
accessibility to immunoreagents reduced (180).
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Figure 7.2 Human liver from a patient with clinical evidence of chronic 
alcohol induced liver disease stained with polyclonal rabbit 
antiserum 1699, which had been pre-absorbed with 
polymorph proteins
Formalin fixed, paraffin embedded liver tissue. Primary antibody used at a 
dilution of 1/400. Secondary antibody; peroxidase conjugated affinity purified 
swine anti-rabbit immunoglobulins. Substrate; diaminobenzidine tetrachloride 
(DAB) solution. Haematoxylin counterstain.
Virtually all cellular staining has been abolished following incubation of antiserum 
1699 with polymorph proteins.

Figure 7.3 Human liver from a patient with clinical evidence of chronic 
alcohol induced liver disease stained with polyclonal rabbit 
antiserum 1699, which had been incubated with bovine serum 
albumin
Formalin fixed, paraffin embedded liver tissue. Primary antibody used at a 
dilution of 1/400. Secondary antibody; peroxidase conjugated affinity purified 
swine anti-rabbit immunoglobulins. Substrate; diaminobenzidine tetrachloride 
(DAB) solution. Haematoxylin counterstain.
Incubation of antiserum with bovine serum albumin does not affect staining.

Figure 7.4 Human liver from a patient with chronic alcohol induced liver 
disease stained with polyclonal rabbit antiserum 1699, which 
had been incubated with human recombinant HGF
Formalin fixed, paraffin embedded liver tissue. Primary antibody used at a
dilution o f 1/400. Secondary antibody; peroxidase conjugated affinity purified
swine anti-rabbit immunoglobulins. Substrate; diaminobenzidine tetrachloride
(DAB) solution. Haematoxylin counterstain.
Incubation of antiserum with human recombinant HGF does not affect staining

Figure 7.5 Western blotting of human recombinant HGF and polymorph 
proteins using pre-immune and immune serum from rabbit 
1699, rabbit anti-HGF serum Lot No. 201 and monoclonal 
antibody B25
Lane 1 Human placental HGF (20 ng/Lane)
2 Human recombinant HGF (200 ng/Lane)
3 Polymorph neutrophil cell lysate (8.8 pg/Lane)
4 Human recombinant HGF
5 Polymorph neutrophil cell lysate
6 Human recombinant HGF
7 Polymorph neutrophil cell lysate
8 Human recombinant HGF
9 Polymorph neutrophil cell lysate
10 Molecular weight markers
Lanes 1,4 & 5 probed with immune serum from rabbit 1699 diluted 1/1000 
Lanes 2 & 3 probed with pre-immune serum from rabbit 1699, diluted 1/1000 
Lanes 6 & 7 probed with rabbit anti-HGF serum Lot No. 201, diluted 1/4000 
Lanes 8 & 9 probed with mouse monoclonal antibody to human recombinant 
HGF B25 diluted 1/5000
Immune serum only from rabbit 1699 detected several protein bands in the 
polymorph neutrophil cell lysate and detected human recombinant and native 
human placental HGF. Rabbit anti-HGF serum Lot No. 201 and mouse 
monoclonal antibody B25 detected human recombinant HGF but did not 
demonstrate any protein bands in polymorph neutrophil lysate.
96.4 
■  80.4
55.7
Lane 1 2  3 4 5 6 7 8 9 10
Similarly, the alkaline phosphatase-anti-alkaline phosphatase (APAAP) method 
was adopted in view of the known improvements in sensitivity which may be 
achieved with the technique. Mason has reported APAAP to be four or five times 
more sensitive than conventional two and three stage indirect immunoperoxidase 
methods (181).
Antiserum 1699, raised against human placental HGF, initially appeared to 
detect HGF in non-parenchymal cells of liver and in neutrophils. To test the 
hypothesis that polymorphs contained HGF, Western blotting studies of 
polymorph proteins with a number of antibodies to HGF were performed. All 
failed to demonstrate HGF among the polymorph proteins. Absorption studies 
using antiserum 1699 and polymorph lysate, bovine serum albumin or human 
recombinant HGF have shown that the antiserum was detecting polymorph 
proteins but not HGF.
A likely explanation for this finding is that the preparation used to immunise 
rabbit 1699 was not pure (see Chapter 3). This work underlines the importance 
of clearly validating the specificity of staining produced in immunohistochemical 
studies. Notwithstanding the work by Sakaguchi et al (179) which describes 
immunolocalisation of HGF in polymorphonuclear leucocytes within liver, our 
results indicate that immunocytochemical staining in our study is due to reaction 
with polymorph proteins, not HGF.
7.5 HGF mRNA in situ Hybridisation Studies
In situ hybridisation methods allow the examination of specific nucleic acid 
sequences in biological preparations in which the structure of the material present 
is preserved intact. The preparation may consist of tissue sections, cells or 
chromosomes. When combined with immunocytochemistry, in situ hybridisation 
offers the possibility of investigating gene activity, in terms of DNA, mRNA and 
protein expression and relating this to histological findings of the tissue in
question.
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The technique of in situ hybridisation was first developed in 1969 (182,183) 
and initially could only be performed by radioisotopic labelling of complementary 
nucleic acid sequences and detection with autoradiography. More recently 
considerable advances have been made in the field of probe detection by non­
isotopic methods. Such methods are for several reasons considered to represent 
significant improvements in the area of in situ hybridisation technology.
(1) Detection of hybrids can be achieved in a shorter time than is required for 
autoradiography, (2) Cellular resolution is improved compared to that achieved 
using radiolabelled systems, (3) The biohazards and expense associated with 
radioisotope work are avoided, (4) Non-radioactive probes have a long shelf life.
Two disadvantages have been identified with the use of non-radioactive 
probes:
(1) sensitivity of the probe may be less than that of a radiolabelled probe. 
However, this problem has in many cases been overcome following refinement of 
non-radioactive labelling and detection methods, (2) standardisation of the 
procedure of non-isotopic in situ hybridisation and of the intensity of the reaction 
product is difficult to obtain, preventing quantitative analysis.
In general one may consider two types of non-radioactive hybridisation 
method - direct and indirect. In the direct approach the reporter (detectable) 
molecule is attached directly to the nucleic acid probe and detection of probe is 
possible immediately after hybridisation. Examples of this approach include 
terminal fluorochrome RNA probe labelling (184) and direct enzyme labelling of 
nucleic acids (185). In the indirect techniques probes contain a reporter molecule 
which is subsequently detected by affinity cytochemistry. Examples of this 
method include biotin labelling (186) and, more recently, the digoxigenin system 
(187).
When embarking on the study of a particular nucleic acid species by in situ 
hybridisation one may choose from three main types of probe; cDNA probes,
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cRNA probes and synthetic oligonucleotide probes. The first type produced were 
cDNA probes and for many years represented the only kind available. However, 
cRNA probes provide a number of advantages over cDNA probes.
(1) cRNA probes are single stranded and therefore are not affected by 
problems of self annealing in solution.
(2) Hybrid stability is greater; allowing post-hybridisation washing to be more 
stringent.
(3) Unhybridised probe may be destroyed by addition of RNase which does 
not affect cRNA hybrids, leading to reduced background signal.
In addition to these methods one may now choose the option of using 
synthetic oligonucleotide probes which have been successfully used to localise 
mRNA by in situ hybridisation (188). However, the synthetic oligonucleotides 
cannot readily be labelled to the same degree of specific activity possible with 
cRNA probes. In addition, hybrids involving cRNA probes are more stable and 
allow more thorough post hybridisation removal of unhybridised probe. For these 
reasons cRNA probes are preferred over synthetic oligonucleotide probes in the 
study of low abundance mRNAs.
In this study two riboprobes were prepared - pRBC-1, based on rat HGF 
cDNA sequence, and hHGFa266, based on human HGF nucleotide sequence. In 
situ hybridisation to HGF mRNA was attempted using these two probes in rat and 
human tissue.
7.6 Materials and Methods 
Materials - see page 141.
Methods
7.6.1 Probe Preparation
Probes were prepared by Mr R. Ferrier and Dr K. Hillan, Department of 
Pathology, Western Infirmary, Glasgow.
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To transcribe anti-sense probes plasmid DNA was linearised with Xhol then 
incubated with a transcription buffer containing T3 RNA polymerase and 
digoxigenin labelled UTP: sense probes were produced by linearising plasmid 
DNA with PstI and transcribing with T7 polymerase. The resultant probe was 
purified then identified by blotting onto Hybond C-membrane and probing with 
alkaline phosphatase conjugated sheep antibodies to digoxigenin with NBT/BCIP 
substrate. 
hHGFa266
In a similar fashion, plasmid DNA was linearised using Hind III cDNA 
fragment hHGFa266 was cloned into pGEM II (Promega) and specific antisense 
single stranded RNA probes transcribed using T7 polymerase in the presence of 
digoxigenin-II-UTP (Boehringer-Mannheim).
7.6.2 Partial Alkaline Hydrolysis of cRNA Riboprobe to Produce a Cocktail 
of 100-150 Base Probes
After testing of full length probes, both were subjected to partial alkaline 
hydrolysis treatment (Mr R. Ferrier, Department of Pathology, Western Infirmary, 
Glasgow).
Regulation of RNA Probe Length by Alkaline Hydrolysis 
Carbonate buffer: 60mM Na2CO3/40mM NaHCC>3 , pH 10.2 .
Neutralisation buffer: 200mM acetate: 1% (volume/volume) acetic acid, pH 6.
(1) RNA (lpg) was hydrolysed by adding an equal volume of DEPC 
(Diethylpyrocarbonate) treated water and 2 volumes of carbonate buffer. The 
solution was incubated at 60°C for 10 minutes.
(2) An equal volume of neutralisation buffer was added to stop hydrolysis.
(3) RNA ethanol was precipitated with sodium acetate.
(4) The precipitate was centrifuged and the pellet washed in 70% spirit.
(5) The probe was reconstituted in DEPC-treated water.
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7.6.3 HGF mRNA Detection - In situ Hybridisation
(1) Sections of 3 pm thickness were cut onto 3-aminopropyl tri-ethyoxysilane 
(APES) coated slides. The sections were dewaxed in xylene and hydrated 
through alcohols to diethylpyrocarbonate treated phosphate buffered saline 
(PBS/DEPC).
(2) Sections were incubated in 0.2M HC1 for 20 minutes at room temperature 
and washed in PBS/DEPC.
(3) Sections were incubated in 0.3% (volume/volume) Triton X-100 for 15 
minutes at room temperature and washed in PBS/DEPC.
(4) Proteinase K digestion was carried out for 15 minutes at 37°C (lOOpg/ml in 
PBS/DEPC).
(5) Sections were fixed in 4% (weight/volume) paraformaldehyde for 5 minutes 
and washed in PBS/DEPC.
(6) Sections were bathed in prehybridisation buffer for 2 hours at 37°C (2 x 
SSC/50% formamide).
(7) The probe, diluted in hybridisation buffer, was denatured by heating at 70°C 
for 2 minutes, then quenched on ice and applied to section, coverslip mounted and 
hybridised overnight at 42°C.
(8) Coverslips were removed in 2 x SSC and sections washed twice in 2 x SSC 
for 30 minutes at room temperature.
(9) Sections were washed in 0.1% SSC for 30 minutes at room temperature, then 
for 30 minutes at 45°C and finally in digoxigenin buffer 1 for 5 minutes at room 
temperature.
(10) Sections were incubated with alkaline phosphatase conjugated anti- 
digoxigenin antiserum for 2 hours at room temperature (1:2000 in digoxigenin 
buffer 1 plus 20% normal swine serum).
(11) Sections were washed twice in digoxigenin buffer 1 for 15 minutes at room
temperature.
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(12) Washed in digoxigenin buffer 3 for 5 minutes at room temperature.
Finally, the sections were:
(13) Incubated in NBT/BCIP (Appendix 3) at room temperature overnight.
(14) Washed in water.
(15) Counterstained with haematoxylin and mounted with glycerol gelatin.
7.7 Results
The alkaline hydrolysed pRBC-1 probe based on rat HGF molecule sequence 
failed to localise HGF mRNA in human liver tissue. Using rat liver obtained 
following partial hepatectomy and common bile duct ligation the probe 
demonstrated HGF mRNA in cells which, on morphological grounds, resembled 
Ito cells (81) (Figures 7.6, 7.7).
The alkaline hydrolysed hHGFa266 probe based on human HGF nucleotide 
sequence failed to localise HGF mRNA in normal or diseased human liver tissue.
7.8 Discussion
The pRBC-1 probe based on rat HGF nucleotide sequence was used in an 
attempt to localise human HGF mRNA since there is known to be 90% homology 
between human and rat HGF sequence (49). It is possible that the small 
differences which exist in sequence between the two species are responsible for 
the failure of the probe to detect human HGF mRNA.
The HGFa266 probe was produced in an attempt to overcome this problem by 
generating a probe based on the human HGF sequence. Possible reasons for the 
failure of this probe and pRBC-1 may include the large size of the probes. 
pRBC-1 is 1200 bases long and hHGFa266 is 796 bases long. However, 
following alkaline hydrolysis in which the probes were reduced to 100-150 bases 
the probes still failed to detect human HGF mRNA. The use of the digoxigenin 
system may also be a factor since this is a large molecule and may affect nucleic 
acid hydridisation by steric hindrance.
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Figure 7.6 Expression of HGFmRNA demonstrated by in situ
hybridisation using pRBC-1 probe in rat liver, day 1 following 
common bile duct ligation.
Formalin fixed, paraffin embedded rat liver tissue. Probe pRBC-1 detected using
alkaline phosphatase conjugated antidigoxigenin antiserum and NBT/BCIP
substrate.
Positive staining is present in cells corresponding to Ito cells.

Figure 7.7 Expression of HGF mRNA demonstrated by in situ
hybridisation using pRBC-1 probe in rat liver, day 1 following 
partial hepatectomy.
Glutaraldehyde fixed, paraffin embedded rat liver tissue. Probe pRBC-1 detected
using alkaline phosphatase conjugated antidigoxigenin antiserum and NBT/BCIP
substrate.
Positive staining is present in cells corresponding to Ito cells.

CHAPTER 8. Examination of the Expression of Hepatocyte Growth 
Factor Receptor (c-met) in Diseased Human Liver by 
Immunocytochemistry
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8. INTRODUCTION
8 1 HGF Receptor (c-met) Immunocytochemistry
The cell surface receptor for HGF was identified in 1991 as the product of the 
proto-oncogene c-met (65,66). The proto-oncogene codes for a hetero-dimeric 
protein consisting of two dilsulphide bonded chains, an a-chain of 50kDa and a 6- 
chain of 145kDa. The a  and 13 chains are both exposed at the cell surface and the 
13-chain spans the cell membrane. The protein is widely distributed in various 
tissues (71) and cell types (189) and is a member of the family of protein tyrosine 
kinases. The tyrosine kinase part of the receptor is present on the intracellular 
part of the 6-chain (70).
One way in which to determine the role of HGF in liver disease is to examine 
expression of its receptor. In 1991 Prat et al described a murine monoclonal 
antibody to the extracellular domain of c-met (71). The antibody was obtained 
following immunisation with living cells from the human gastric carcinoma cell 
line GTL-16 in which the gene is amplified and over-expressed (68). The 
antibody, DO-24, had been used to examine expression of the met protein in 
frozen sections of various tissues including liver and gastrointestinal tract. Using 
this antibody on frozen sections of normal liver and on biopsies from patients with 
various liver diseases the expression of HGF receptor was examined by immuno- 
histochemistry.
8*2 Materials and Methods
Materials - for all materials including fresh frozen normal and diseased human 
liver tissue see page 141.
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Methods
8.2.1 Immunocytochemistry
Sections of 5 pm thickness were cut onto poly-L-lysine coated slides, allowed 
to air dry at room temperature for 1 hour and fixed in cold acetone for 10 
minutes.
After washing sections in phosphate buffered saline (2 x 1 minute) non-specific 
binding sites were blocked by incubation with phosphate buffered saline 
containing 2% bovine serum albumin (weight/volume) (2% BSA/PBS). Blocking 
solution was poured off and DO-24 monoclonal antibody (culture supernatant) or 
control antibody (culture supernatant) applied neat to sections and incubated at 
room temperature for 1 hour.
Sections washed 3 x 1 0  minutes in phosphate buffered saline.
Rabbit polyclonal antibodies to murine immunoglobulins diluted 1:30 in 2% 
BSA/PBS applied to sections and incubated at room temperature for 1 hour.
Slides were washed, 3 x 1 0  minutes, in phosphate buffered saline, incubated 
with murine monoclonal alkaline phosphatase - anti-alkaline phosphatase 
complexes diluted 1:50 in 2% BSA/PBS for 1 hour, washed 3 x 10 minutes in 
phosphate buffered saline and incubated with substrate (Fast red, see appendix 3). 
Sections were lightly stained with haematoxylin and mounted under glycerol 
gelatin.
8.3 Results
Staining was present in the sections with DO-24 antibody but of low intensity, 
and associated with a considerable degree of non-specific background staining.
No staining was evident using control antibody. Histologically normal liver tissue
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demonstrated the presence of fine hepatocyte membranous staining consistent 
with the presence of membrane bound HGF receptor on hepatocytes. Biopsies in 
which histological, particularly architectural, abnormalities were present 
demonstrated absence or reduced intensity of staining (Figures 8.1,8.2,8.3)
8.4 Discussion
The effects of HGF are believed to be mediated by its cell surface receptor, the 
c-met proto-oncogene product (65,66,69).
Immunohistochemical localisation of c-met in frozen liver biopsy material has 
shown that in diseased liver of various aetiologies, the level of expression of HGF 
receptor appears to be reduced. An explanation for this finding may be receptor 
internalisation following binding to ligand (61), i.e. down regulation of the 
receptor in response to increased availability of ligand. There is some evidence 
for down regulation of c-met following binding of HGF by hepatocytes in vitro 
(190). These changes may be related to the role of HGF in liver disease.
Evidence supporting this proposal includes the finding that HGF receptor 
numbers are reduced in liver following partial hepatectomy (61,63) and carbon 
tetrachloride induced hepatitis (61). Interestingly, the numbers of HGF receptors 
remain unchanged in uninjured organs following partial hepatectomy. Similarly, if 
unilateral nephrectomy is performed, rapid down regulation of HGF receptors is 
noted in the remaining kidney without evidence of change in other organs (63). 
This has led to the suggestion of two types of HGF receptor, functional and non 
functional, both of which may bind HGF, but only one of which may be activated 
by such binding (63).
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Figure 8.1 Human liver (normal) stained with monoclonal antibody 
DO-24
Acetone fixed, frozen liver tissue Primary antibody DO-24 culture supernatant 
Detection by alkaline phosphatase-anti-alkaline phosphatase method 
Haematoxylin counterstain
Hepatocyte membranes are stained, consistent with the presence of membrane 
bound HGF receptor.

Figure 8.2 Human liver from a patient with cirrhosis stained with 
monoclonal antibody DO-24
Acetone fixed, frozen liver tissue. Primary antibody; DO-24 culture supernatant
Detection by alkaline phosphatase-anti-alkaline phosphatase method.
Haematoxylin counterstain.
Hepatocyte membrane staining is present, although less intense than that seen in 
histologically normal tissue.

Figure 8.3 Human liver from a patient with hepatocellular carcinoma 
stained with monoclonal antibody DO-24
Acetone fixed, frozen liver tissue Primary antibody, D O -24 culture supernatant
Detection by alkaline phosphatase-anti-alkaline phosphatase method
Haematoxylin counterstain.
No hepatocyte membrane staining is demonstrated.

However, there is also evidence of increased hepatic expression of c-met gene 
during liver regeneration in rats following carbon tetrachloride treatment (190). 
Similarly, studies using epithelial cell lines in vitro have demonstrated low levels 
of expression of c-met in confluent cell cultures, with high levels of expression in 
cells cultured at low density. Moreover, it has recently been shown that HGF 
itself may induce expression of c-met (192).
Reasons for this apparent disparity between HGF receptor gene expression and 
expression of HGF receptor may relate to the rate at which HGF receptor is 
internalised i.e. rapid generation of further mRNA in order to replace internalised 
receptor protein at the plasma membrane of the cell.
Unfortunately, the staining produced with this antibody was of low intensity 
with considerable background signal and limited availability of the antibody 
precluded large scale study of c-met expression. The original report of c-met 
localisation using DO-24 described the use of a fluorescein labelled secondary 
antibody. This may allow clearer definition of membranous staining than the 
alkaline phosphatase-anti-alkaline phosphatase method, since the exquisite 
sensitivity of the immunofluorescence of the technique allows identification of 
very small quantities of antigen within a tissue section. Unfortunately, in immuno­
fluorescence, the signal is viewed against a dark background in which little 
histological detail is discernible. The alkaline phosphatase method was chosen 
since in this work I was attempting to relate the staining pattern of c-met to the 
histological findings in each biopsy.
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CHAPTER 9. Hepatocyte Growth Factor In vivo Inhibition Studies
132
9. INTRODUCTION
9.1 Cytokine and Growth Factor Inhibition
Considerable evidence has accumulated in favour of the hypothesis that HGF is a 
mediator of hepatic regeneration following injury (Chapter 1 section 1.7.6). 
However, the hypothesis has not been clearly tested. A number of agents are 
implicated in the hepatic regenerative response. Examples in which the activity of 
each agent is neutralised include tumour necrosis factor alpha (inhibition by 
neutralising antibody) (193), catecholamines (oq adrenergic receptor blockade by 
prazosin) (138) and oestrogen (inhibition by tamoxifen) (142).
In a similar fashion, the biological effects of other cytokines have been 
investigated by experiments in which inhibition is induced by administration of 
neutralising antibody (194,195). To help define the significance of the 
contribution made by HGF to the hepatic regenerative response I sought to inhibit 
the effect of HGF in vivo by administration of neutralising antibodies to HGF.
In this study two test antibodies were used, a monoclonal (D9), raised against 
a synthetic 11 aminoacid peptide based on rat HGF (see page 141) and a rabbit 
polyclonal antibody raised against a synthetic 14 kDa protein based on rat HGF 
(38986, as described in Chapter 4) with appropriate control antibodies. Prior to 
undertaking HGF inhibition studies in vivo I attempted to assess antibody 
suitability using in vitro HGF inhibition with primary isolated rat hepatocytes in 
culture. Isolated hepatocytes were cultured in the presence or absence of HGF 
which had been preincubated with test antibody or control. DNA synthesis was 
assessed by incorporation into DNA of tritiated thymidine. Unfortunately, as a 
result of technical difficulties the assay described here involved only one antibody 
and could not be successfully repeated in the time remaining for the project.
In the in vivo study the antibodies were administered before and after partial 
hepatectomy and the animals killed at 24 and 72 hours following surgery. One 
hour prior to death bromodeoxy-uridine (BrdU) was administered. Liver
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regeneration was assessed by histology and DNA synthesis determined by BrdU 
u p t a k e  by liver cells.
9.2 Materials and Methods 
Materials - see page 141.
Rabbit polyclonal antiserum to HGF peptide rHGF(3121 and normal preimmune 
rabbit serum 951 see Chapter 5, section 5.4. In each case, antibody was purified 
from culture supernatant or serum by caprylic acid/saturated ammonium sulphate, 
dialysed against PBS and filter sterilised.
9.2.1 Methods - In vitro HGF inhibition study
9.2.1.1 Hepatocyte isolation
Hepatocytes were isolated from an adult male Wistar rat (350g) using the 
collagenase perfusion method of Seglen (196). Animals were maintained in 12:12 
light/dark cycle and given laboratory and water ad libitum. All solutions, 
glassware and tubing were sterilised prior to use in the perfusion. The rat was 
anesthetised (4% halothane, 800ml/min nitrous oxide, 800ml/min oxygen) and 
laparotomy performed. The portal vein was cannulated and the superior and 
inferior vena cava divided. Calcium free buffer was used to perfuse the liver (via 
portal vein cannula) for at least 12 minutes.
The pump was switched to collagenase buffer and this was recycled allowing 
reperfusion of the liver for 12-15 minutes until the liver softened. The liver was 
removed from the animal and transferred to warm washing buffer wherein the 
liver capsule was removed and cells released with scissors. The cell suspension 
was filtered through sterile gauze and then cells washed by pelleting by microfiige 
(Microcentaur: Fisons Scientific Equipment) at 500rpm for two minutes and 
resuspended in 30ml PBS. This step was repeated and the final cell pellet 
resuspended in Williams medium E supplemented with 10'9 M insulin, 109 M 
dexamethasone, 2mM glutamine, 50 units/ml penicillin, 50pg/ml streptomycin and 
5 /o fetal calf serum. Cell numbers were determined in a haemocytometer and
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viability was calculated by trypan blue (0.05%) exclusion. Cell viability was 
greater than 80%.
9.2.1.2 Hepatocyte culture 
The isolated hepatocytes were diluted with medium to give appropriate cell 
numbers for culture. The cells were plated at 6 x 104 cells per well on Costar 24 
well culture plates. The cells were incubated at 37°C in a humidified atmosphere 
of 95% air/5% carbon dioxide for a period of 20 hours. At this stage the medium 
was changed to Williams medium E containing additives as above but without 
fetal calf serum. To this medium had been added combinations of HGF and 
antibody as described below. Three wells were used for each combination.
HGF Antibody Antibody Dilution
1) Medium - -
2) Medium lOng/ml -
3) Medium lOng/ml D9 1/50
4) Medium lOng/ml D9 1/100
5) Medium lOng/ml D9 1/500
6) Medium lOng/ml Control 1/50
7) Medium lOng/ml Control 1/100
8) Medium lOng/ml Control 1/500
The hepatocytes were cultured for a further 24 hours, then DNA synthesis was 
determined by pulse labelling cells with [^H] thymidine (2.5pCi/well) for a further 
6 hours in the presence or absence of 1 OmM hydroxyurea. The cells were washed 
once with cold PBS and solubilised with 500pl PBS containing 2% 
(volume/volume) triton X-100. After scraping the cells from the wells, they were 
transferred to 1,5ml Eppendorf tubes on ice. 500pl ice cold trichloroacetic acid 
(TCA) was added to each tube and the cells centrifuged at 13,000rpm 
( Microcentaur ’ centrifuge) for 2 minutes at 4°C. The samples were washed 
twice with 200pl of 5% trichloroacetic acid and the final pellets resuspended in 
200pl 1.5M tris base at 4°C. These samples were placed in glass scintillation vials
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containing 5mls of scintillant (Ecocint) and 2mls of water and counted in a liquid 
scintillation counter (Packard Tri-Carb (B) 300C, Canberra Packard, Pangboume, 
Berkshire, UK). The difference between the values for [3H] thymidine present in 
acid precipitable material from cells incubated with and without hydroxyurea was 
taken to represent DNA synthesis. All results are expressed as the mean value of 
triplicate wells.
9.2.2 Methods - In vivo HGF Inhibition Study
9.2.2.1 Purification of monoclonal antibodies from culture supernatant
0.1M acetic acid was added to 20ml of culture supernatant to lower pH to 4.5. 
Neat caprylic acid was then added to a final concentration of 5% 
(volume/volume) and the solution mixed by vortexing for 5 minutes. Suspension 
centrifuged at 13,000rpm (‘Microcentaur’ centrifuge) for 7 minutes, pellets 
discarded and supernatant retained. An equal volume of saturated ammonium 
sulphate was added in aliquots and the solution mixed at room temperature for 2 
hours. Solution centrifuged (‘Microcentaur’) at 13,000rpm for 3 minutes. A 
floating fatty layer formed on the surface of the solution, this was retained and 
dissolved in PBS and dialysed against several changes of PBS at 4°C overnight. 
After dialysis the solution was removed, filter sterilised and the protein content 
estimated by absorption of ultraviolet light at 280nm. Aliquots stored at -70°C 
until use.
9.2.2.2 Purification of polyclonal IgG from serum
Procedure as for monoclonal antibody until saturated ammonium sulphate step. 
After mixing with saturated ammonium sulphate for 2 hours at room temperature 
the solution was centrifuged at 13,000rpm (‘Microcentaur’ centrifuge) for 3 
minutes. The pellet formed was reconstituted with PBS and the supernatant 
discarded. Solution containing pelleted material dialysed against PBS sterilised, 
protein content estimated then sterilised and stored as for monoclonal IgG.
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9.2.2.3 In vivo inhibition
36 adult male Lewis rats (n=36, mean weight 250g) were housed with a 12:12 
hour light/dark cycle and permitted ad libitum consumption of water and a 
standard rat pellet diet. After a one week equilibration period, the animals were 
separated into 6 groups of 6 animals identified as "A" to "F". Twelve hours prior 
to partial hepatectomy, groups A & E and groups B & F were injected intra- 
peritoneally with purified D9 and 3A1 antibodies respectively (dose 1.52mg/kg 
body weight). Similarly, rats in group "C" were injected intra-peritoneally with 
polyclonal antibody 38986 (dose 5.85mg/kg body weight) and those in group "D" 
received antibody 951 (dose 5.85mg/kg body weight). The animals underwent a 
70% partial hepatectomy (4) under halothane anaesthesia in mid-morning. Each 
group received further intraperitoneal injections of antibody (D9 & 3A1; dose 
1.52mg/kg body weight, 38986 & 951; dose 5.85mg/kg body weight) at 12, 36 
and 60 hours post hepatectomy as appropriate. At 24 hours post hepatectomy 
groups C, D, E and F were killed by cervical dislocation. Groups A and B were 
killed at 72 hours post hepatectomy (see Table 9.1). One hour prior to death, 
bromodeoxyuridine (dose 50mg/kg body weight) was administered by 
intraperitoneal injection. Aliquots of liver tissue were placed in tissue fixative 
(mercuric chloride, buffered formalin, glutaraldehyde) and remaining liver tissues 
snap frozen in liquid nitrogen.
9.2.2.4 Bromodeoxyuridine (BrdU) immunocytochemistry
Liver tissue fixed in buffered formalin was routinely processed, paraffin 
embedded and 5 (im sections cut onto glass slides coated with 3- 
aminopropyltriethoxysilane. Sections were dewaxed to water and incubated in 
methanol and hydrogen peroxide (0.5%) at room temperature for 15 minutes to 
inactivate endogenous peroxidase. The sections were exposed to 0.1% porcine 
trypsin pH 7.8, followed by 2M HC1 for 30 minutes at 37°C to denature DNA.
After incubation with 20% (volume/volume) normal rabbit serum in Tris 
buffered saline pH 7.6 at room temperature for 10 minutes primary antibody (B44
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mouse anti-BrdU, diluted 1/40 in Tris Buffered saline containing 4% 
(volume/volume) normal rabbit serum) was added and sections incubated 
overnight at 4 C.
A secondary peroxidase-conjugated rabbit anti mouse immunoglobulin diluted 
1/20 in Tris buffered saline containing 4% normal rabbit serum, was applied and 
incubated for 30 minutes at room temperature.
Labelled cells were detected using 3,3’-diaminobenzidine (DAB) substrate 
(0.1%) in presence of hydrogen peroxide (0.02%).
Sections were counterstained with Mayer’s haematoxylin and mounted in 
DPX. One thousand nuclei were counted for each animal, 250 nuclei per field at 
x200 magnification using an El 1A 19mm eyepiece graticule (Graticules Ltd, 
Towbridge, Kent, UK). Four fields were examined per slide, two centred on a 
portal tract and two centred on a hepatic vein.
9.2.2.5 HGF mRNA detection - In situ hybridisation
See Chapter 7, section 7.6.3 for methods.
9.3 Results
9.3.1 In vitro HGF Inhibition
Counts for tritiated thymidine were low but the stimulatory effect of human 
recombinant HGF was evident (ten-fold increase in DNA synthesis). Incubation 
with monoclonal antibody D9 inhibited this effect in a dose dependent manner 
(see Table 9.2). After 24 hours in culture, the characteristic hepatocyte 
morphology was clearly visible. Following administration of test antibodies a 
toxic effect was observed on the cells incubated with control antibody a66.
These cells assumed granular, degenerate appearance and demonstrated very low 
levels of DNA synthesis at all antibody concentrations.
9*3.2 In vivo HGF Inhibition
Thirty four of the thirty six rats tolerated antibody administration, anaesthesia 
and partial hepatectomy without ill effect. One animal, no. 11, died under
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Table 9.2 DNA synthesis by isolated rat hepatocytes in culture - effect of 
human recombinant HGF, monoclonal antibody D9 and 
control antibody
Culture of hepatocytes with lOng/ml human recombinant HGF led to a ten-fold 
increase in tritiated thymidine incorporation (DNA synthesis). Antibody D9 
inhibited this effect in a dose dependent manner. Wells containing control 
antibody demonstrated very low levels of DNA synthesis at all concentrations.
[3H] thymidine incorporation (cpm)
No HGF, No antibody 48
HGF (lOng/ml), No antibody 479
HGF (lOng/ml), D9 at 1/50 206
HGF (lOng/ml), D9 at 1/100 277
HGF (lOng/ml), D9 at 1/500 478
HGF (lOng/ml), control at 1/50 41
HGF (lOng/ml), control at 1/100 25
HGF (lOng/ml), control at 1/500 12
anaesthesia (anaesthetic death) and one animal, no. 35, died in the immediate post 
operative period.
No gross difference was evident between each group on examination of 
harvested liver. Histology of liver tissue confirmed marked proliferative activity 
in all groups. No direct toxic effects were seen in any group. Liver tissue from 
all animals showed considerable DNA synthesis.
The proportion of BrdU positive hepatocyte nuclei in partially henatectomised 
rats (see Tables 9.3,9.4.9.5)
The overall proportion of BrdU positive cells (perivenular and periportal) 
showed highly significant variation between groups (p<0.001), all of the 
significance being attributable to the use of two different time intervals. The 
overall proportion of BrdU positive cells showed no significant differences among 
groups 3 to 6 (p=0.345 by one-way analysis of variance), or between groups 1 
and 2 (p=0.546 by t-test).
The periportal to perivenular ratio of BrdU positive cells differed significantly 
from unity (p= 1.3 7x1 O'5, single-sample t-test), but did not differ significantly 
among groups (Figures 9.1, 9.2, 9.3, 9.4, 9.5, 9.6).
Evidence of HGF gene expression in the liver was identified by HGF mRNA in 
situ hybridisation using pRBC-1 digoxigenin labelled riboprobe (Fig 9.7).
9.4 Discussion
9.4.1 In vitro HGF Inhibition Study
Low counts for tritiated thymidine were noted, this could be due to using a 
larger volume of medium per well, leading to dilution of tritiated thymidine prior 
to uptake. In addition, the hepatocytes were cultured on plastic without collagen 
coating of wells. Although cell adhesion had been satisfactory, it is known that 
coating growth surfaces with collagen leads to enhanced cell attachment and 
growth (197).
Subsequent attempts to culture rat hepatocytes included the use of wells coated 
with rat tail collagen type I.
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Figure 9.1 DNA synthesis, demonstrated by BrdU uptake in liver tissue 
from rat No 2, killed 72 hours after partial hepatectomy 
(monoclonal antibody D9 administered intraperitoneally)
Formalin fixed, paraffin embedded liver tissue. Section stained with murine 
monoclonal anti-BrdU antibody. Secondary antibody; peroxidase-conjugated 
rabbit anti-mouse immunoglobulin. Substrate; diaminobenzidine tetrachloride 
(DAB) solution. Haematoxylin counter stain.
Scattered BrdU positive nuclei are present.
Top (a) x500 
Bottom (b) xl200

Figure 9.2 DNA synthesis, demonstrated by BrdU uptake, in liver tissue 
from rat No 10, killed 72 hours after partial hepatectomy 
(monoclonal control antibody 3A1 adminstered intra- 
peritoneally)
Formalin fixed, paraffin embedded liver tissue. Section stained with murine 
monoclonal anti-BrdU antibody. Secondary antibody; peroxidase-conjugated 
rabbit anti-mouse immunoglobulin Substrate; diaminobenzidine tetrachloride 
(DAB) solution. Haematoxylin counter stain 
Scattered BrdU positive nuclei are present

Figure 9.3 DNA synthesis, demonstrated by Brdll uptake, in liver tissue 
from rat No IS, killed 24 hours after partial hepatectomy 
(polyclonal antibody 38986 administered intraperitoneally)
Formalin fixed, paraffin embedded liver tissue. Section stained with murine 
monoclonal anti-BrdU antibody Secondary antibody; peroxidase-conjugated 
rabbit anti-mouse immunoglobulin. Substrate; diaminobenzidine tetrachloride 
(DAB) solution. Haematoxylin counter stain
A greater proportion of nuclei are stained positively for BrdU in this section 
compared to Figure 9.2.

Figure 9.4 DNA synthesis, demonstrated by BrdU uptake, in liver tissue 
from rat No 22, killed 24 hours after partial hepatectomy 
(polyclonal control antibody 9SI administered intra- 
peritoneally)
Formalin fixed, paraffin embedded liver tissue. Section stained with murine 
monoclonal anti-BrdU antibody. Secondary antibody; peroxidase-conjugated 
rabbit anti-mouse immunoglobulin. Substrate; diaminobenzidine tetrachloride 
(DAB) solution. Haematoxylin counter stain.
A large proportion of nuclei are stained positively for BrdU. A greater proportion 
of periportal nuclei demonstrate BrdU uptake than perivenular.
Top (a) xl200 
Bottom (b) x500

Figure 9.5 DNA synthesis, demonstrated by BrdU uptake in liver tissue 
from rat No 27, killed 24 hours after partial hepatectomy 
(monoclonal antibody D9 administered intraperitoneally)
Formalin fixed, paraffin embedded liver tissue. Section stained with murine 
monoclonal anti-BrdU antibody. Secondary antibody; peroxidase-conjugated 
rabbit anti-mouse immunoglobulin. Substrate; diaminobenzidine tetrachloride 
(DAB) solution. Haematoxylin counter stain.
BrdU positive nuclei are present diffusely the hepatic acinus, but are more 
abundant in the periportal region.

Figure 9.6 DNA synthesis, demonstrated by BrdU uptake, in liver tissue 
from rat No 34, killed 24 hours after partial hepatectomy 
(monoclonal control antibody 3A1 administered intra­
peritoneally)
Formalin fixed, paraffin embedded liver tissue. Section stained with murine 
monoclonal anti-BrdU antibody. Secondary antibody; peroxidase-conjugated 
rabbit anti-mouse immunoglobulin. Substrate; diaminobenzidine tetrachloride 
(DAB) solution. Haematoxylin counter stain.
A large proportion of nuclei demonstrate BrdU uptake. A greater proportion of 
periportal than perivenular nuclei are stained positively for BrdU.

Figure 9.7 Expression of HGF mRNA in liver tissue from rat No 13, 
killed 24 hours after partial hepatectomy
Glutaraldehyde fixed, paraffin embedded liver tissue. In situ hybridisation using 
pRBC-1 probe, alkaline phosphatase conjugated anti-digoxigenin antiserum and 
NBT/BCIP substrate. Positive staining is present in cells corresponding to Ito 
cells.

The control antibody a66 is likely to have been an inappropriate choice for this 
study. Although the antibody is a murine monoclonal of the same class as D9 and 
is present in the form of culture supernatant, this antibody may cross react with 
rat hepatocytes. This may result in a direct toxic effect on the affected cells. 
Human recombinant HGF was used in this study since rat recombinant HGF was 
initially unavailable.
Several attempts were made to repeat these experiments, but as a result of 
technical difficulties these studies could not be completed. In one case collagen in 
a dilute acetic acid solution was used to coat the wells of the culture plates. 
Inadequate washing of the plates is the likely cause of a direct toxic effect on the 
hepatocytes. Two other attempts were marred by bacterial contamination of the 
cell cultures.
9.4.2 In vivo Inhibition
The aim of this study was to establish clearly the significance of HGF in the 
hepatic regenerative response following injury. The procedures of antibody 
administration, anaesthesia and partial hepatectomy were tolerated well by the 
animals with the exception of the two deaths described.
Liver tissue from all groups showed evidence of considerable DNA synthesis, 
demonstrated by BrdU uptake. A highly significant difference was seen between 
animals killed 24 hours after partial hepatectomy and those killed after 72 hours. 
Much greater levels of DNA synthesis were evident in animals killed at 24 hours, 
consistent with the phenomenon described in which the peak of DNA synthesis 
occurs at 24 hours (see Chapter 1, section 1.4.1). The demonstration that a 
greater proportion of periportal then perivenular nuclei were BrdU positive is also 
consistent with the known distribution of initial waves of DNA synthesis within
the hepatic acinus (22).
No difference was seen between groups of animals given anti-HGF antibody
(monoclonal or polyclonal) compared to animals given control antibody.
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Possible reasons for a failure to demonstrate a difference between the groups 
may include -
(1) Use of antibodies which may not be capable of neutralising HGF in vivo.
(2) Antibodies may have been given in insufficient quantity, or the route of 
administration (intraperitoneal) may have hindered antibody access.
(3) Antibodies may neutralise circulating HGF without effect on HGF provided 
locally within the liver.
(4) Antibodies are neutralising HGF but HGF is not required for the initial waves 
of DNA synthesis within the liver.
On the basis of the methods used and results obtained, no further conclusion 
may be reached with regard to the role of HGF in DNA synthesis following partial 
hepatectomy.
Other approaches were considered including -
(1) administration of the naturally occurring HGF antagonist HGF/NK2 (56,57).
(2) administration of antisense oligonucleotides to inhibit translation of HGF from 
mRNA. However, neither of the two groups who have produced HGF/NK2 are 
currently able to synthesise sufficient quantities of protein for such experiments. 
Antisense oligonucleotides could not be used since targetting to the appropriate 
cells is currently not possible.
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MATERIALS 
Animals
Young adult male New Zealand white rabbits (Hyline Rabbits Ltd, Statham, 
Cheshire, UK).
B ALB/C mice were supplied by Glasgow University Department of 
Biochemistry.
Adult male Wistar rats (350g body weight) were supplied by Glasgow 
University Department of Pharmacology.
Antibodies - monoclonal
D9, culture supernatant, to an 11 amino acid synthetic peptide based on rat 
HGF a  chain. Supplied by Professor A D Burt, Royal Victoria Infirmary, 
Newcastle-upon-Tyne, UK.
A312-1, purified antibody to human recombinant HGF, IgG subclass 2a. The 
antibody reacts with human recombinant HGF but not with rat HGF or other 
growth factors (TGFa/p, EGF, plasmin, insulin, tPA, acidic or basic FGF). 
Supplied by Professor Toshikazu Nakamura, Osaka University School of
Medicine, Osaka, Japan.
B25, B43 and A312-2, purified IgG subclass 2a, to human recombinant HGF, 
supplied by Dr P Godowski and Dr Filip Roos, Genentech Inc, California, USA. 
Murine monoclonal antibody IgG subclass 2a CD72 to human B type lymphocytes
(The Binding Site Ltd, Birmingham, UK).
DO-24 culture supernatant, to extracellular domain of c-met, characterised and
supplied by Dr Maria Pratt, University of Turin, Turin, Italy.
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Murine monoclonal IgG antibody 341, culture supernatant, to sheep unnary
antigen, supplied by Miss Andrea Brown, Glasgow University Department of 
Biochemistry.
Monoclonal a66, culture supernatant, antibody to human hepatocyte antigen. 
Supplied by Dr K Hillan, Glasgow University Department of Pathology, Western 
Infirmary, Glasgow.
Murine monoclonal clone B44 anti-BrdU antibody (Becton Dickinson, Cowley, 
Oxford, UK).
Antibodies - polyclonal
Rabbit polyclonal antiserum, Lot No 201, to full length human recombinant 
HGF. The antiserum reacts with human recombinant HGF (a and P chains) but 
does not react with rat HGF. Characterised and supplied by Professor Toshikazu 
Nakamura, Osaka University School of Medicine, Osaka, Japan.
Alkaline phosphatase conjugated affinity purified swine anti-rabbit immuno­
globulins, alkaline phosphatase conjugated affinity purified rabbit anti-mouse 
immunoglobulins, rabbit polyclonal affinity purified antibodies to murine immuno­
globulins, murine monoclonal alkaline phosphatase-anti-alkaline phosphatase 
soluble complexes, peroxidase conjugated affinity purified swine anti-rabbit 
immunoglobulins and peroxidase conjugated rabbit anti-mouse immunoglobulins
(Dakopatts, Denmark).
Peroxidase conjugated gamma chain specific goat antibodies to mouse 
immunoglobulins (Sigma Chemical Co Ltd, Poole, Dorset, UK).
Biotinylated sheep antibodies to rabbit immunoglobulins (The Binding Site Ltd,
Birmingham, UK).
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Sheep alkaline phosphatase conjugated antibodies to digoxigenin (Boehringer 
Mannheim Biochemica, Lewes, East Sussex, UK).
Cell Culture Reagents
DH5 and BL21 (DE3), Escherichia coli were supplied by the MRC Virology 
Institute, Western Infirmary, Glasgow.
SP20 plasmacytoma cells supplied by Glasgow University Department of 
Biochemistry.
2-YT broth, ampicillin, RPMI 1640 with L-glutamine, penicillin, streptomycin, 
William’s medium E, glutamine and fetal calf serum (Gibco BRL, Paisley, UK).
Collagenase (Boehringer Mannheim Biochemica, Lewes, East Sussex, UK).
Isopropyl-P-D-thiogalactopyranoside (IPTG), hypoxanthine, thymidine, 
aminopterin, 2-mercaptoethanol, fetal calf serum, insulin, dexamethasone and 
hydoxyurea (Sigma Chemical Co Ltd, Poole, Dorset, UK).
Polyethylene glycol (PEG) 1500 (BDH Ltd, Warwick, UK).
Chemicals
Sodium dodecyl sulphate, acrylamide, N,N’-methylenebisacrylamide, 
ammonium persulphate, N,N,N’,N’-tetramethyl-ethylenediamine (TEMED), 
glycine, isobutanol, glycerol, 2-mercaptoethanol, coomassie brilliant blue, 
glutathione, sodium thioglycolate, amido black, nitro blue tetrazolium (NBT), 5- 
bromo-4 -chloro-3 -indolylphosphate (BCIP), Freunds complete adjuvant, Freunds 
incomplete adjuvant, orthophenylenediamine (1,2-benzenediamine), 
trichloroacetic acid and bromodeoxyuridine (Sigma Chemical Co Ltd, Poole,
Dorset, UK).
Bromophenol blue and triton X-100 (BDH Chemicals Ltd, Poole, Dorset, UK).
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Acetic acid, caprylic acid and ammonium sulphate (BDH Laboratory Supplies, 
Merck Ltd, Leicestershire, UK).
Digoxigenin-II-UTP and all enzymes used for in situ hybridisation (Boehringer 
Mannheim Biochemica, Lewes, East Sussex, UK).
Glu-plasminogen (Enzyme Laboratories (Europe), Sketty, Swansea, UK). 
Horseradish peroxidase-avidin D (HRP) conjugate (Vector Laboratories, 
Peterborough, UK).
Tritiated thymidine (Amersham, Aylesbury, UK).
‘Marvel’ powdered milk (Premier Beverages, Adbaston, Stafford, UK). 
Chromatography Reagents
Glutathione sepharose 4B, heparin agarose (Pharmacia Biotech Ltd, Herts,
UK).
Hydroxylapatite (Bio-Rad Laboratories Ltd, Herts, UK).
CNBr-activated sepharose 4B (Pharmacia LKB, Biotechnology AB, Uppsala, 
Sweden).
Molecular weight markers (SDS-PAGE)
‘Electron’ MW range 14,300-71,500 Da (BDH Chemicals Ltd, Poole, Dorset,
UK).
Prestained molecular weight markers MW range 38,800-116,000 and unstained 
MW range 29,000-205,000 Da (Sigma Chemical Co Ltd, Poole, Dorset, UK).
‘Rainbow’ coloured prestained molecular weight markers MW range 14,300- 
200,000 Da (Amersham, Buckinghamshire, UK).
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Plasmids
pGEX-2T 266 plasmid containing an 800 base pair cDNA fragment coding for 
a 26.7kDa peptide based on human HGFa-chain formed as a fusion with 
glutathione-s-transferase; pET-121 plasmid containing a 365 base pair cDNA 
fragment coding for a 14kDa peptide based on rat HGFP-chain: These plasmids 
were prepared by Dr K Hillan and Dr C Preston, MRC Virology Institute,
Western Infirmary, Glasgow. pGEX-2T (Pharmacia Biotech Ltd, Herts, UK); 
pET-8C (supplied by Dr C Preston).
pRBC-1 containing a 1.4kbase EcoRI rat HGF cDNA fragment coding for the 
3’ portion of the a-subunit, the p-subunit and a portion of the 3’ untranslated 
region (supplied by Professor T Nakamura, Osaka University School of Medicine, 
Osaka, Japan).
hHGFa266. The PCR amplified cDNA fragment of 796 base pairs coding for 
part of the human a-subunit, generated as described in Chapter 2, was cloned into 
the BamHI site of the pGEM II2f plasmid (Promega, Southampton, UK).
‘Polymorph prep’ (Nycomed A.S. (UK) Ltd, Birmingham, UK) contains 
sodium metrizoate 13.8% (weight/volume) and dextran 500 8 .0^ 
(weight/volume).
Recombinant HGF
Human recombinant HGF - full length recombinant human HGF supplied by Dr 
P Godowski, Genentech Inc, California, USA. Full length recombinant rat HGF 
supplied by Professor T Nakamura, Osaka University School of Medicine, Osaka,
Japan.
Scintillation fluid
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Ecocint A scintillation fluid (National Diagnostics, Mannville, New Jersey 
08835, USA).
Tissue fixatives
Glutaraldehyde, buffered formalin and mercuric chloride were provided by 
Glasgow University Department of Pathology, Western Infirmary, Glasgow. 
Equipment, plasticware and disposables 
Chromatography columns, length 42cm, diameter 3.3cm and length 40cm, 
diameter 2.2cm (Pharmacia Biotech Ltd, Herts, UK).
BioRad Mini-Protean II SDS-PAGE and blotting equipment (BioRad 
Laboratories, Hertfordshire, UK).
Large scale (20cm x 2cm) SDS-PAGE equipment (Scotlab, Coatbridge, UK). 
‘Atomix’ MSE blender, Fisons Instruments, Crawley, Sussex, UK. 
Conductivity meter CDM3 (Radiometer Copenhagen, Denmark).
Beckman DU-64 spectrophotometer, Beckman RIIC Ltd, Glenrothes, UK. 
Jenway 3061 pH meter (Scotlab, Coatbridge, UK).
Petri dish, 5cm culture plates (Sterilin Ltd, Hounslow, Middlesex, UK).
Tissue culture 96-well plates ‘Costar’ (Northumbria Biologicals Ltd,
Cramlington, UK).
Tissue culture 24-well plates (Costar UK Ltd, High Wycombe,
Buckinghamshire, UK)
Dynatech microtitre/ELISA plates (Dynatech Laboratories, Chantilly, Virginia,
USA).
Dialysis tubing, Visking (Medicell International Ltd, London, UK).
“Problott” transfer membrane (Applied Biosystems)
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PVDF (Polyvinylidene difluoride) membrane (Millipore Corporation, Bedford, 
MA 01730, USA).
Hybond C extra-mtrocellular membrane (Amersham International pic, 
Buckinghamshire, UK).
Human tissue and serum
Placenta Fresh normal term placentas were obtained with the assistance of Dr 
John Kingdom, Glasow Royal Maternity Hospital.
Serum and liver biopsies
Serum from healthy volunteers and patients with various liver diseases was 
collected prospectively, with fresh frozen liver biopsies from August 1991 to June 
1993. Full ethical approval was obtained from the appropriate local Ethical 
Committee prior to the collection of serum and liver biopsies (see Appendix 5). 
Healthy Controls
Volunteers were recruited from staff in the University Department of 
Pathology, Western Infirmary, Glasgow. A number of volunteers were recruited 
from among patients of the University Department of Surgery, Western Infirmary 
following admission to surgical wards for minor elective surgical procedures e.g. 
groin hernia repair, varicose vein surgery.
Serum was obtained from 33 normal healthy controls, 11 male, 22 female, 
Mean age 43.0 years, Median 41.0, Range 55.0.
Disease Controls
A second control group was included, comprising patients admitted to the 
Coronary Care Unit of the Western Infirmary, Glasgow following an acute 
myocardial infarction confirmed by serial electrocardiographs and cardiac enzyme
measurements.
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Serum was obtained from 11 patients with acute myocardial infarction, 7 male, 
4 female. Mean age 52.0 years, median 58.0, range 36.0.
Patients with Liver Disease
Serum was obtained from patients with liver disease attending outpatient 
Gastroenterology and Hepatology Clinics or following admission to medical or 
surgical wards at the following Glasgow hospitals: Southern General Hospital, 
Gartnavel General Hospital, Western Infirmary and Stobhill Hospital.
Additional, retrospective sera were obtained from patients with acute viral 
hepatitis from the Regional Virus Laboratory, Ruchill Hospital, Glasgow.
Venous blood was obtained by venepuncture from patients and volunteers, 
allowed to clot at room temperature and serum obtained by centrifugation at 
lOOOrpm for 3 minutes and stored at -70°C until use.
Wherever possible, blood was obtained at the time of routine venepuncture. In 
those cases where separate venepuncture was required informed consent was 
obtained from each patient and the General Practitioner informed by letter of the 
patient's involvement in the study.
Serum was obtained from 221 patients with liver disease, 121 male, 100 
female. Mean age 52.0 years, median 55.0, range 83.0. Table 6.2 illustrates the 
various conditions included.
Liver Biopsies
Liver biopsies were obtained at the time of diagnostic liver biopsy performed 
on patients admitted to the above hospitals. At the time of biopsy, a 3-5mm 
length of tissue was taken, immersed in Tissue Tek' OCT compound (Miles Inc 
Diagnostics Division, Elkhart, USA), then immediately snap frozen in liquid 
nitrogen. Biopsies were stored in liquid nitrogen. In addition, formalin fixed, 
paraffin embedded tissue from each case was available from the pathology
department of each hospital.
149
Normal human liver tissue; fresh frozen normal human cadaver (organ donor) 
liver was supplied by Dr K Hillan, Department of Pathology, Western Infirmary, 
Glasgow.
Medical Records
In each case of liver disease medical records were obtained and examined. 
Information thus obtained was used to compile a database using the Paradox 3.5 
program at the Western Infirmary PC cluster. In addition to standard biographical 
data, each record included clinical history and examination findings together with 
the results of investigations.
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Appendix 1
SDS-PAGE gels
Stacking gel; 4%, 0.125M Tris, pH 6.8
Reagent Volume
dH20 6.1 ml
0.5M Tris Hcl, pH 6.8 2.5 ml
10% SDS (weight/volume) 100 pi
30% Acrylamide/0.8% N' N'-bis-methylene acrylamide 1.3 ml
10% ammonium persulphate 50 pi
TEMED (N' N' N' N-tetramethylenediamine) 10 pi
Stacking gel (protein sequencing) 5%, 0 .125M Tris, pH 8.8 
Reagent 
dH20
0.5M Tris Hcl, pH 8.8 
10% SDS
30% Acrylamide/0.8% bis-acrylamide 
10% ammonium persulphate 
TEMED
Resolving gels
Reagent 15% 12.5% 12% 10% 7.5%
dH20 2.3 ml 3.15 ml 3.35 ml 4 ml 4.85 ml
1.5M Tris Hcl, pH 8.8 2.5 ml 2.5 ml 2.5 ml 2.5 ml 2.5 ml
10% SDS 100 pi 100 pi 100 pi 100 pi 100 pi
30% Acrylamide/0.8% bis- 
acrylamide
5 ml 4.2 ml 4 ml 3.3 ml 2.5 ml
10% ammonium persulphate 100 pi 50 pi 50 pi 50 pi 50 pi
TEMED 5 pi 5 pi 5 pi 5 pi 5 pi
5.7 ml 
2.5 ml 
100 pi 
1.65 ml 
50 pi 
10 pi
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Appendix 2
SDS-PAGE and Western blotting buffers
Electrophoresis buffer
25mM Tris 
250mM glycine 
0.1% SDS
Upper electrophoresis buffer (protein sequencing, 4x)
12 pg Tris base and 0.8 g SDS in 150 ml dH20, titrated to pH 6.8 with 6N HC1,
dH20  added to a final volume of 200 ml.
Lower electrophoresis buffer (protein sequencing, 4x)
36.34 g Tris base and 0.8 g SDS in 150 ml dH20 , titrated to pH 8.8 with 6N HC1,
dH20  added to a final volume of 200 ml.
Pre-run electrophoresis: Glutathione solution, lOmM (350 |il) added to 70 ml 
upper electrophoresis buffer.
Sample loading buffer: (non reducing)
dH20  4 ml
0.5M Tris-HCl, pH 6.8 1 ml
Glycerol BOO jil
10% SDS 1.6 ml
0.05% bromophenol blue 200 jil
For reducing conditions, 50 (il p-mercaptoethanol added to 1 ml loading buffer. 
Samples diluted with an equal volume of loading buffer and heated at 95°C for 4 
mins prior to use.
Western Blot Transfer buffer: 2.52g NaHC03
0.954gNa2CO3
600ml Ethanol made up to 3L with dH20
CAPS Transfer buffer (blot transfer buffer for protein sequencing): 
lOmM 3-[cyclohexylamino]-l-propansulphonic acid, 10% (volume/volume) 
methanol; pH 11.0
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Appendix 3
Staining solutions/chromogens
Coomassie Blue stain solution
500 ml 100% methanol 
100 ml glacial acetic acid 
400 ml dH20
2.5 g Coomassie brilliant blue
Coomassie Blue destain solution
500 ml 100% methanol 
100 ml glacial acetic acid 
400 ml dH20
Amido Black stain solution
Amido Black 0.1% solution in 45% methanol and 10% acetic acid
Amido Black destain solution
2% acetic acid in 90% methanol
NBT/BCIP: Nitro-Blue-Tetrazolium/S-Bromo-4-chloro-3-Indolyl Phosphate
Stock solutions:
NBT: 70% Dimethylformamide containing 7.5% nitroblue tetrazolium
BCIP: 100% Dimethylformamide containing 5% 5-bromo-4-chloro-3-indolyl 
phosphate
NBT/BCIP: 100 mM Tris, pH 9.5, containing 0.44% Stock solution NBT and 
0.33% stock solution of BCIP
Fast Red: 20 mM naphthol AB-TR, 10 mM Fast Red TR, 15mM Levamisole in 
veronal acetate buffer pH 9.2
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Appendix 4
ELISA solutions and buffers
Coating buffer 0.1M NaHC03
8.4 g NaHC03 dissolved in 1 Litre dH20
Phosphate Buffered Saline (PBS) x 20 stock solution
320 g NaCl, 48.4 g K2HP04 and 13.6 g kH2P 04 dissolved in 1.5 Litre dH20  
(boiling),
made up to 2 Litres with dH20
Blocking solution: PBS containing 3% (weight/volume) Bovine Serum Albumin 
Washing solution: PBS containing 0.025% (volume/volume) Tween 20 
Sample dilent: PBS containing 0.5% (volume/volume) Tween 20 and 0.5% 
(weight/volume) Bovine Serum Albumin.
Orthophenylenediamine substrate solution
Twenty-five millilitres 0.2M citrate adjusted to pH 5.0 with Potassium hydroxide 
made up to 50ml with dH20  orthophenylenediamine (100 mg) dissolved in 
solution and 25pl of 31% H20 2 added immediately prior to use.
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Appendix 5
Approval for these studies was obtained from the appropriate local Ethical 
Committee.
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Appendix 6 
In-situ hybridisation solutions/bufTers
Pre hybridisation buffer 
2 x SSC/50% formamide
volume 
5 pi
1.25 ml 
1 ml 
5 ml 
0.25 ml 
0.5 g 
0.25 ml
2.25 ml
10ml
Digoxigenin buffer 1 
12.7 g Tris Hcl 
2.36 g Tris base 
8.77 g NaCl
makes 1 Litre, pH to 7.5 at 20°C
Digoxigenin buffer 3 
12.6 g Tris base 
5.84 g NaCl 
10.16 g MgCl26H20
Tris base diluted in950 ml H2O and pH adjusted to 9.5 after addition of 
salts, pH checked (9.5) and volume made up to 1 Litre
hybridization buffer 
2M Tris pH 7 
lOOx Denhardts 
20 x SSC 
Formamide 
20% SDS
50% Dextransulphate 
Salmon sperm DNA (10 mg/ml) 
denatured and sonicated 
DEPC treated H20
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Appendix 7
Rat Hepatocyte Isolation Buffers
Calcium free buffer (x 10)
41.5 g NaCl
2.5 g  KC1
12.0 g  H EPES
dissolved in 500 ml dH20  pH adjusted to 7.4
Collagenase buffer (x 10)
9.75 g NaCl
1.25 g Kcl
6.0 g HEPES
dissolved in 250 ml dH20  pH adjusted to 7.4
Collagenase (60 mg) added to 120 ml collagenase buffer prior to use
Washing buffer (x 10)
16.3 g NaCl 
l.Og Kcl 
4.8 g HEPES
dissolved in 200 ml dH20  pH adjusted to 7.4, then 2.45 ml 
1M CaCl2 solution added
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